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I.
A·

INTRODUCTION

The problem
This investigation involves an examination in rats, of the effects on the

duration of drug-induced sleep or hypnosis

~esulting

from the pretreatment

with pharmacological agents that affect one or more neuroamine systems.

The

primary index of the duration of sleep used is the loss and recovery of the
righting reflex.

The excitatory and depressant activity of monoamines in the

CNS have been revealed by studies involving their direct application, systemic
injection and pharmacological alteration or, inferentially, from studies
demonstrating diurnal or circadian fluctuations

(~infra).

In as much as

Friedman and Walker (1969), among others, have shown that the duration of pentobarbital hypnosis varies with the time of day, and that levels of monoamines
in several CNS areas also follow a circadian pattern

(~infra),

it was of

interest to extend these studies and examine the effects that pretreatment
with drugs influencing the monoamine systems might have on CNS monoamine levels
and sleep duration.

Such an approach seeks to determine a possible interrela-

tionship between central amines and drug-induced sleep.

Because the exact

mechanism of sleep produced by hypnotics is unclear, experiments were designed
to examine the nature of the involvement of monoamines in the phenomenom.
Furthermore, the efficacy of the modulating drugs used for these pretreatments
has not heretofore been examined on a 24-hour basis.
The circadian pattern for hypnotic sleep duration is inversely related
to metabolizing enzyme

activity(~~).

1

Nair and Casper (1969) sug-

2

gested that there might be a central component for the control of the enzyme
activity, and in turn, the duration of hypnosis.

By utilizing appropriate

dosages of the pretreatment drugs that significantly alter amine levels (according to published reports), the effect of changes in the levels of CNS
monoamines on the duration of action of hypnotics might be demonstrated.

The

presence or absence of specific monoamines, as well as their relative levels
might serve to augment or limit the hypnotic effect.

Daily fluctuations of

these amines could change the sensitivity of the CNS and its possible regulation of drug metabolizing systems, thereby resulting in an altered effect of
the hypnotic.
B.

Terminology.
The present study examines periodic alterations in 1) the duration of

drug-induced sleep and 2) central monoamine
tionships.

le~els,

and possible interrela-

The review of the literature sunnnarizes studies on states of normal

sleep and the effects of drugs on normal sleep.

Furthermore, it examines

the

nature of the formation of specific monoamines, their effects on sleep and the
pharmacology of drugs utilized to induce sleep.

The stages of normal sleep

and drugs which affect these stages are discussed.

It is understood that

drug-induced sleep differs markedly from normal sleep.

Briefly, the stages

of sleep can be classified as paradoxical sleep (PS or REM, rapid eye movement)
or slow wave sleep (SWS or non-REM, NREM).

The monoamines to be considered in

these phenomena include; norepinephrine (NE), dopamine(DA), epinephrine (Epi),
serotonin (SH'l'), histamine (H) and acetylcholine (ACh).
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The term "circadian", coined by Halberg, is derived from the Latin,

--

circa diem, which means "about one day".

It refers to rhythms that have a

frequency of about one cycle per day, or a period of 20-28 hours.

The term

"diurnal" has been used by some workers to describe rhythms that have been
measured on a 24-hour basis, although it also has a secondary meaning of
"daily", as opposed to nocturnal, or nightly.

Wurtman (1967) criticized the

ambiguous use of the term "circadian", which he suggested should be restricted
to free-running rhythms.

The problem arises in studies in which the animal must

be sacrificed to determine the aspect under study and can only be measured
once (eg. toxicity, brain amines, etc.) as opposed to rhythms which can be
continuously measured (eg. temperature, urine or blood contents, etc.).

In

this study the terms circadian, 24-hour, diurnal or daily rhythms are used
interchangeably.

To establish whether or not rhythms are free-running requires

examination for several cycles, as well as their insensitivity to exogenous
cues.
Halberg also proposed terms to refer to non-circadian rhythms.

Ultradian

rhythms have a frequency greater than one cycle per day, or a period between
one and 19. 9 hours.

Infradian refers to a rhythm with a frequency of less than

one cycle per day, or a period greater than 28.5 hours.

Exogenous rhythms are

those which can be altered by changes in environmental parameters, while
endogenous rhythms (free-running) appear to be under internal control, as they
persist under an unchanging environment, such as constant light or constant
darkness.
C.

Practical considerations
The present study concerns itself only with the effects on drug-induced
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sleep and not with the effects of drugs on normal sleep.

Effects of these

drugs on normal sleep and drug-induced sleep are cited with regard to possible
relationships to the results of this study.
In studies of circadian rhythms of physiological and pharmacological
phenomena, an investigator concerns himself with the problem of frequency of
sampling.

Some investigators are content to show differences between the

and dark periods, while others take measurements every hour.

As in previous

studies from this laboratory, data is obtained every six hours (0600, 1200,
1800 and 2400 hours), giving two points in the light and two in the dark.
Ordinarily this is sufficient to show differences between light and dark
phases and demonstrate the basic 24-hour pattern.

Pretreatment and sacrifice

times are bracketed around these test times, so that the average time occurs
at the six-intervals.

II.
A.

REVIEW OF THE LITERATURE

Parameters affecting biological rhythms.
The importance of biological rhythms in physiological and pharmaco-

logical phenomena is becoming better appreciated.

Biological rhythms (growth,

motor activity, feeding, etc.) of plants and submammalian species (protozoa,
coelenterates, mollusks, insects and birds) have been demonstrated (cf.
Bunning, 1967; van Mayersbach, 1967; Walker, 1969).

This review however, will

be confined to studies of rhythms in mannnals, primarily mice and rats.

It

will consider parameters affecting biological rhythms and studies demonstrating
physiological and pharmacological rhythms.
1.

Sex
Sex hormones (vide infra) alter the ongoing biorhythms and result in

differences in male and female rhythms.

Slonaker (1912) demonstrated that

motor activity increases progressively and is maximal at the peak of estrus.
Colvin~

al. (1968) attributed variations in the sleep-wakefulness (S-W)

cycle to the superimposition of the estrous cycle.

EEG monitoring of chroni-

cally-implanted female rats revealed that the pre-estrus rat has PS in the
afternoon, followed by an alert pattern in the evening.

The day of vaginal

cornification is marked by a higher percentage of PS, after a night in which
the animal is alert and PS is absent.

The hormonal changes of proestrus

appears to increase alertness, which is compensated for on the following
night.
Dray et al. (1965) reported a diurnal rhythm of testosterone levels
in man, which peaked at 0800-0900 hours and reached a trough at midnight.

5
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This variation appeared to be due to a decrease in its production, rather than
an alteration in metabolism.
circadian rhythm.)
plasmas~crone

(Women had too little testosterone to detect a

Baird and Guevera (1969) found no differences in the mean

or estridiol content of six non-pregnant women and five men,

sampled at 0800 or 1700 hours.

However, Tulchinsky and Korenman (1970) re-

ported that plasma estrone levels in women and men were three times as high
at 0800-0900 hours than at 2400 or 0400 hours.

The differences between cir-

culating sex hormones in male and female influence the basic biorhythm, as
well as the response to drugs (vide infra).
2.

Species
The differences between species has been examined most extensively in

rodents, which are nocturnal.
differs among species.

The ability to adapt to altered photoperiods

Phase-shifting leads to a resynchronization of the

biorhythm in two days in spiders (Aschoff, 1963), while about three weeks are
needed for mice and rats to readapt (Hanin et al., 1970).
3.

Age

Differences in physiological and pharmacological response of the
irmnature and adult animal have been reported.

These include the development

of liver metabolizing enzymes, brain biogenic amines (vide infra) and the S-W
cycle.

The newborn of most higher species start with very short S-W cycles

which merge, then prolong into the 24-hour adult pattern (cf. Ellington, 1972).
Enzyme development influences metabolism of drugs and/or endogenous substances.

The changes in sleep cycle and brain amines are probably inter-

related, both reflecting the maturation of the CNS.

Shaywitz

~al.

(1971)

were unable to correlate growth hormone and sleep state in newborns, although
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levels were elevated for the first 2-3 days after birth and became normal by
day 4 (cf. Mills, 1966).

sws

In the adult, growth hormone release is related to

(vide infra).
4.

Population
Quay~

the CNS.

al. (1969) examined the effect of isolation on the anatomy of

Isolated rats have greater body and pineal weights and a higher

ratio of pineal to brain weight, than do grouped animals.

Grouped animals

exhibited higher mean cerebral cortical weight than isolated rats.

The ratio

of cortical acetylcholinesterase to cholinesterase decreased in grouped rats,
when more than two rats were maintained per cage.

There were no differences

in pineal SHT levels or pineal HIOMT activity between grouped and isolated
rats.

Amphetamine toxicity in aggregated mice has been shown by several in-

vestigators to be greater than for isolated mice.

Walker (1972) reported that

amphetamine was most toxic during the dark (active) phase for isolated or
aggregated mice.
5.

Illumination
The influence of light on biorhythms can be considered with regard to

photoperiod (relative duration of light-dark periods), intensity and spectrum
of the light source.

This includes not only circadian periods, but longer

periods, such as monthly (lunar) and seasonal (solar).

The physiological

transducer for these effects involves the eye-pineal axis (cf. pineal gland,
under SHT section) and possible extraretinal receptors, which respond to
•
direct penetration of light through the skull (Lisk and Kannwischer, 1964).
Biorhythms are most easily synchronized by light-dark photoperiods,
usually of a 12:12 or 14:10 hours relationship (cf. Aschoff, 1969).

The exact
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ratio requirement of light and dark is probably species specific.

A number of

studies have examined the time required for animals to adapt to 1) a specific
photoperiod, 2) reversal of the photoperiod and 3) constant light, constant
darkness or a new photoperiod.

Some rhythms are resistant to photoperiod

changes and require days or weeks to readapt fully.

Others do not readapt,

i.e. free run, and are not controlled by light, but by some other environmental factor or the rhythm might fade out.
difficulties involved in such experiments.

Von Mayersbach (1967) points to
He was never able to duplicate

values 24 hours apart, indicating that certain cycles might be greater or
lesser than 24 hours or that in the process of removing animals those to be
used subsequently are disturbed.
Reiter (1969) reported that the levels of light found in most artificially-lit animal rooms (10-150 footcandles) are sufficient to have an inhibitory action on the pineal, and probably affect other systems.

Harker (1964)

stated that light intensity has relatively little effect on period length, but
changes in light intensity determine phase setting.
Marshall and Bowden (1936) demonstrated the effects of wavelength of
light on the timing of the sexual cycle of the ferret.
0

in animals exposed to ultraviolet light (3650 A).

Estrus begins earlier

Infrared light has no effecL

Luce-Clausen and Brown (1939) showed a delayed onset of estrus in rats maintained in darkness but a normal onset for animals exposed to visible or
infrared illumination.

Spaulding et al. (1969) studied the effects of spec-

tral components of light on motor activity in mice.

The lowest activity

occurred in mice exposed to blue or green light, or daylight; intermediate
activity occurred under yellow, while the highest activity was in red light
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or darkness.

Wurtman and Weisel (1969) found that rats maintained under Vita-

Lite, which closely (93%) approximate the daylight spectrum, have larger
gonads and smaller spleens than those under conventional cool-white fluorescent lights.

Cool-white lights are deficient in the near-UV wavelengths

and have greater amounts of the yellow and orange wavelengths.
6.

Temperature
The effects of ambient temperature on biorhythms appear to be minimal

within a 2-6°C. range from normal environmental temperature, to which the
mannnalian thennoregulatory system can adjust.
between heat production and heat loss.

Body temperature is a balance

Heat production is high during the

day in man, due to muscular activity, but even subjects at rest and fasting
exhibit a diurnal temperature rhythm.

Halberg (1959) found that artificial

alterations of body temperature have no effect on the activity rhythm (cf.
Sweeney and Hastings, 1960).
7.

Barometric eressure
Harker (1958) described barometric pressure as a weak synchronizer,

i.e. although it is incapable of controlling a biorhythm, it might have an

.

influence on an existing rhythm.

Hayden and Lindberg (1969) entrained body

temperature rhythm in mice by fluctuations in ambient barometric pressure,
under constant ambient temperature and darkness.
8.

Feeding habits
Feeding may be involved as a phasing factor of other biorhythms but

it is difficult to devise methods of testing its role.

If food is present

only at one time during the day, animals will feed then, but if present continually rodents will eat during the dark phase.

Honova et al. (1968) showed
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a rhythm ·of rat liver tyrosine transaminase, which they stated might be controlled by the feeding pattern in rats and man.

--

Studies of diurnal fluctua-

tions of plasma amino acids (Wurtman et al., 1967b, 1968b), of course, must
~

consider the effect of dietary intake and its amino acid content.
9.

Miscellany
Other factors which might subtly influence ongoing circadian rhythms

include sound, odors, lunar or seasonal variations, magnetism and electrical
fields.

Sound can interrupt sleep and activity rhythms, depending upon in-

tensity and duration.

Halberg et al. (1954) reported that the activity of

normal mice affected blind mice.

After exposure of rats to the pungent odor

of isonitrile for six hours, Miline et al. (1963) noted atrophic alterations
of pineal parenchymal cells (which might also be due to a direct effect).
Taste, smell and hearing rhythms in man (Henkin et al., 1963; Henkin, 1968),
are influenced by adrenal hormones.
The influence of the moon and sun on living things is an old observation that is coming under scientific scrutiny.

Rhythms related to the lunar

cycle have been demonstrated for lower aquatic species (cf. Harker, 1964:
Bunning, 1967).

Brown~

al. (1970) have demonstrated that living systems are

able to distinguish among strengths and directions of magnetic, electrostatic
and ganuna radiation.

Radiation is probably involved in the seasonal varia-

tions (well-appreciated for plants) and cycles of long duration such as the
eleven-year sunspot cycles (Brown~ al., 1958).

Wever (1971) showed that a

10.0 Hz alternating electrical field can affect human circadian rhythms
(activity and rectal temperature).
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B·

Physiological parameters
1.

Motor activity
Circadian rhythms in motor activity with a peak in the dark have

been demonstrated in the mouse
1970).

Holmquest~

(Saelens~

al., 1968) and the rat (Quay,

al. (1966) studied the relationship between motor

activity and body weight and the adrenals, in rats.

After 40 days of random

illumination, the activity rhythms were lost without affecting the steady rise
of body weight or endocrine organ weight.

Quay (1970) reported that normal

and pinealectomized rats could reverse their activity rhythms after photoperiod reversal.

Curtis (1937) demonstrated diurnal activity rhythms for

sheep and pigs, which was maximal during the day.

Lindsley et al. (1964)

initiated a circadian activity rhythm in young monkeys that had been maintained in darkness for three years.

This rhythm required 3-5 weeks to

stabilize after the initiation of the standard photoperiod.

Winget et al.

(1969) found a correlation between diurnal motor activity and body temperature
in the monkey.

RUther et al. (1967) reported that rats under constant light

were less active and rats under constant dark were more active, than rats
maintained under a normal light-dark photoperiod.
2.

Body temperature
Many studies have shown that the diurnal pattern of body tempera-

ture fluctuates in phase with the activity rhythm (Brahmachary, 1967;
Friedman and Walker, 1968; cf. Kleitman, 1963).

Julku et al. (1970) showed

that mice exposed to a cold environment had better thermoregulatory ability
at 1600 hours than at 0500 hours.

Smith (1969) studied human rectal

•_ciur(~r'.1-
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ture and thermoregulation (as measured by core-periphery heat conductance) and
found that they generally peaked in the light phase.
3.

Blood composition
Halberg et al. (1954) reported circadian variation of eosinophils

in rats.

Even blind mice exhibit a circadian rhythm in eosinophils, lympho-

cytes and other white cells, as well as adrenal cortical hormones (Haus et al.,
1967).

After adrenalectomy or under constant light, the rhythms disappeared.

pauly and Scheving (1965) showed similar rhythms for neutorphils, eosinophils
and lymphocytes, with peaks at the onset of inactivity, when the light period
began.

Under continuous darkness, the rhythms persisted but became dissociated

with continuous light.

In pregnant women, total counts of leukocytes, seg-

mented neutrophils and stab neutorphils was maximum during the day and fell to
a minimum in the early morning, while eosinophils and lymphocytes showed a
reverse pattern (Luce, 1970).

Diurnal rhythms for circulating eosinophils

have also been demonstrated for the monkey (Migeon et al., 1955) and man
(Donato and Strumia, 1952;

Halberg~~.,

1951).

Scheving and Pauly (1967)

demonstrated that the diurnal rhythm for blood clotting time in rats was
longest at 0130 hours.

Scheving

~al.

(1968c) also found diurnal rhythm in

.the levels of several rat blood proteins, such as mucoproteins, albumin and
several globulins (including gamma-globulin), which peak at the end of the
phase.

Buckell and Elliott (1959) reported a diurnal pattern of plasma fibri-

nolytic activity.

In humans, blood pH rises over the day, then decreases

during the night, with the onset of sleep (Cullen and Earle, 1929).
Bonilla and Stringham (1968) were unable to demonstrate a diurnal rhythm
for serum ca+I- in mice, but this might be due to stress or interruption of the

,
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rhythm, since each animal was sampled four times during the day by orbital
venous plexus puncture.

Bahorsky and Bernardis (1967) observed that normal

rats had a diurnal rhythm in serum Na+ and K+ levels, peaking in the early
dark phase, but found no rhythm in serum phosphorus or urea nitrogen.

Fasted

rats maintained the serum Na+ rhythm, but lost the serum K+ rhythm.
4.

Urinary excretion
Norn (1929) demonstrated a circadian rhythm for urinary Na+, K+

and Cl

in man, which peaked during the day and troughed at night.

(1966) examined electrolyte excretion in normal and fasted subjects.

Min et al.
In

normal subjects, with an evenly spaced diet and minimum activity, a diurnal
rhythm for Mg+I- and ca+I- excretion was observed, which peaked in the early
morning.

The pattern for phosphorus excretion was reversed.

cretion peaked in the late morning.

Na+ and K+ ex-

The electrolyte patterns observed in

fasting, obese patients were almost identical to those of normals, except the
K+ and phosphorus rhythms were absent.

Fiorica~

patterns for human urinary Mg+I- and Ca+!- excretion.

al. (1968) found similar
During and following

exercise their excretion was decreased, suggesting that the activity cycle
might cause their rhythm.

Cohn~

al. (1970) reported that rats fed ad

libitum exhibit diurnal rhythms in the rates of food consumption and urinary
excretion of Na+, K+, c1-, inorganic phosphorus and creatinine, with peak
values during the dark.

If the rats are fed 1/24 of their daily food allotment

hourly, the excretion rhythms are either extinguished or markedly decreased,
suggesting that the food or feeding might be a synchronizer.

Acid and annnonium

excretion is high at night and decreases in the morning, and is not dependent
on whether the subject is fed or fasting or the night is spent awake and
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recumbent, or active (cf. Mills, 1966).
5,

Hormones in blood and urine
The rate of urine flow is the result of several potentially in-

dependent influences , of which the rate of liberation of posterior pituitary
antidiuretic hormone (ADH) and the total solute excretion are probably the
most important.

Zsoter and Sebok (1955) reported a diurnal pattern for human

serum ADH levels, which peaks during the night, and helps to explain the decreased urinary output while asleep.
Venning et al. (1956) reported that human urinary aldosterone excretion was greater during the day than the night.

The phenomena was not affected

by changes in sodium intake but was abolished if subjects remained horizontal
(Muller et al., 1958).

However, plasma aldosterone has a circadian pattern,

even in subjects continuously horizontal (Michelakis and Horton, 1970).

An

identical pattern for human plasma renin has been shown (Gordon et al., 1966),
suggesting that the aldosterone rhythm might be driven by renin secretion.
Circadian variation in the urine and plasma levels of 17-hydroxycorticosteroids (170HCS) have been demonstrated in humans and many animal
species (cf. Nichols and Tyler, 1967; Krieger, 1970).

In humans, plasma

170HCS levels peak in the early morning, just prior to awakening, while in
the rat, the peak occurs in the early evening.
hormone (ACTH) exhibits a similar rhythm.

Plasma adrenocorticotrophic

Urinary 170HCS excretion follows a

similar circadian pattern, but the cycle lags about two hours behind plasma
170HCS.

170HCS rhythms, in man and rodents, can be reversed within eight days

by reversal of the photoperiod.

A child has no diurnal 170HCS cycle but

develops one between 3-13 years of age.

The infant monkey, however, exhibits
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a circadian 170HCS pattern in the first week of life

(Bowman~

al., 1970).

The plasma 170HCS rhythm is absent in Cushing's disease (Doe et al., 1960), in
which pituitary ACTH formation is increased.

The response of humans to ACTH

administration is decreased at night, suggesting a rhythm for adrenal sensitivity (Perkoff et al., 1959).

The control of the 170HCS rhythm might be due

to changes in corticotrophin-releasing factor (CRF) or the sensitivity of
anterior pituitary neurosecretory cells to CRF-induced ACTH release (Clayton
~al.,

1963).

Krieger~

al. (1968) demonstrated that pretreatment of

c~ts

with atropine and thiamylal just prior to the normal rise of plasma 170HCS,
blocks the rise.

Krieger and Rizzo (1969) found that any alteration of CNS

SHT levels blocked the daily rise of plasma 170HCS, but alteration of central
NE with depletors or blockers had no effect on the rhythm.
Hellman~

diurnal pattern.

al. (1969) reported that human cortisol content exhibited a
It was not smooth, but exhibited a series of steep peaks,

due to about eight episodic bursts of cortisol per day.

A circadian rhythm

for mouse serum and adrenal gland corticosterone peaked at 1600 hours and
troughed at 0400 hours (Reinberg and Halberg, 1971).

In serum and in the

adrenal, the greatest corticosterone response to saline occurred 4-8 hours
before the normal circadian corticosterone peak, while the greatest response
to ACTH was found eight hours after the peak.

Ungar and Halberg (1962) and

Andrews (1971) reported an in vitro circadian response of mouse and hamster
adrenals to ACTH.

Hodges and Mitchley (1970) found that circadian and stress-

induced changes in plasma corticosterone levels in rats were abolished by
betamethasone in the drinking water.
paired.

Adrenal sensitivity to ACTH was unim-

The normal plasma corticosterone rhythm returned within one day of
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drug withdrawal, but the stress response was normal only after three days.
suprachiasmatic nuclear lesions and a caudal frontal cut abolished the adrenal
corticosterone rhythm, while blinding shifted the rhythm (Moore and Eichler,
1972).
DeGroot (1967) found that the ovaries of prolactin-treated (pseudopregnant) rats contained the lowest ascorbate levels and highest progesterone
concentrations at 1600 hours.

The latter response is thought to be due to

luteotropic hormone (LR) release, since hypophysectomy prevented the progesterone rise.

Serum prolactin of lactating cows exhibits a circadian fluctua-

tion, although individual patterns show sporadic release (Koprowski et al.,
1972).

Clark and Zarrow (1967) found a diurnal rhythm in ovarian cholesterol

content in the mature, cycling rat, which appears to be under the control of a
daily release of LR.

Rats maintained in constant light showed an earlier onset

of this diurnal ovarian cholesterol pattern, while the pattern was absent in
androgenized (sterilized) animals (Zarrow

~al.,

1969).

Pronounced rhythms

of plasma immunoreactive FSH in both sexes have been reported (cf. Curtis,
1972).

They peak at 0400-0900 hours.
Auerbach (1963) found a diurnal pattern in plasma protein bound iodine

(PBI) in humans, which was maximum at 1230 hours and minimum at 0730 hours.
Bushler

~al.

(1968) reported similar results and also found PBI in phase with

plasma thyroxine (T4), hematocrit, plasma proteins and plasma thyroid binding
globulin (TBG).

The patterns were reversed by reversing the sleep schedule,

but not by dexamethasone treatment or rescheduling meals.

The rate of dis-

appearance of thyroid hormone from blood is cyclic in humans, calves and rats,
being maximum at the time of their greatest activity (cf. Curtis, 1972).
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Diurnal variation has been reported in plasma PBI of rabbits, of thyroid

131

1

content in cats and monkeys after tracer doses of 131 r, plasma thyroid stimulating hormone (TSH) in humans and rats and rat pituitary TSH (cf. Curtis,
1972).
Von

Euler~

al. (1955) reported a diurnal variation for free and con-

jugated urinary catecholamines in humans.

Minumum excretion rates of free Epi

and NE were at night, while the maximlllll rates, about three times the minimum,
occurred at 0800-1100 hours.

Catecholamine excretion is affected by emotion,

exertion, and posture, but its rhytl:un persists, with reduced amplitude, during
bed rest, sleep deprivation or constant darkness (cf. Curtis, 1972).
~al.

Scheving

(1968b) reported that rat adrenal epinephrine fluctuates daily, with

maximum concentrations occurring during the light phase.
Fasting diabetics have a diurnal pattern for blood sugar, which peaks
at about 0800 hours.

Since a diurnal pattern of inununoreactive insulin (IR!)

has not been demonstrated in fasting diabetics, the blood glucose pattern
might be due to insulin resistance, which leaves the glucose-mobilizing
effects of the ACTH-cortisol cycle unopposed (Faiman and Moorhouse; 1967).
In normal subjects, plasma IR.I exhibits peaks associated with meals and falls
during the night, so it is uncertain if there is a circadian pattern.
Plasma growth hormone peaks at almost any time of day, but the largest
and most consistent peaks occur at the onset of the first period of SWS
(vide infra) •
6.

Rhythms in constituents of carbohydrate, lipid and protein

metabolism.
Circadian variations in blood glucose have been demonstrated in
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the rat (Pauly and Scheving, 1967; Friedman and Walker, 1969), mouse (Dziekanouska and Andrzej, 1961), chicken (Twiest and Smith, 1970) and cow (Allcroft,
1933).

Maximum levels occur during the period of maximum activity.

Friedman

and Walker (1969 ) found a biphasic pattern for blood glucose, with peaks at
the end of the light and dark periods.

Bahorsky and Bernardis (1967) obtained

similar results in rats, and that were abolished by fasting. Normal subjects
exhibit diurnal variation in the glucose tolerance test, while hyperglycemic
patients do not (Jarrett and Keen, 1969).
Agren !:.!, al. (1931) reported a circadian pattern for liver glycogen in
the rat and rabbit.
~al.

These rhythms were abolished by adrenalectomy.

Halberg

(1960) found a similar liver glycogen rhythm in the mouse, which

persisted after food deprivation, even to the point of death of the animal.
Sollberger (1964) reported circadian variations in liver glycogen levels in
several species, which generally peaked during the period of greatest motor
activity.

Fuller and Diller (1970) found that the hepatic liver glycogen

rhythm in rats fed ad libitum peaks at 0500-0800 hours.

In rats fed a single

meal from 0800-1200 hours, hepatic glycogen levels exhibited a prolonged peak
from 1200-2000 hours.

They also found that the circadian pattern for plasma

free fatty acids was inversely related to liver glycogen content.
Feigen et al. (1968) demonstrated in humans, that blood amino acids
levels (except citrulline) exhibit a diurnal rhythm, which peak between 12002000 hours and trough between 0400-0800 hours.

Increases and decreases in

total protein content of an isocaloric diet or exercise had no effect on the
pattern.

Reversal of the S-W cycle resulted in a rapid reversal in the amino

acid pattern.

Wurtman et al. (1968b)obtained similar results.

Coburn et al.
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(1968) reported a circadian rhythm for plasma tyrosine in rats, but not for
plasma phenylalanine, which was controlled by food intake.

A circadian

rhythm for plasma tyrosine occurred in human phenylketonuric subjects (who
lack phenylalanine hydroxylase), suggesting that dietary absorption or liver
metabolism might be controlling the rhythm.

Tewksbury and Lohrenz (1970)

found that urinary amino acid levels exhibit a rhythm similar to those of
whole blood, suggesting that the basic amino acid rhythm is normally present
and is augmented by food intake.
7.

Enzyme systems
Wurtman and Axelrod (1967) reported that liver tyrosine trans-

aminase (TT; EC 2.6.1.5) in rats peaked shortly after the onset of darkness
and was low during the day.

Adrenalectomy, hypophysectomy, thyroidectomy,

pancreatectomy, constant darkness or fasting did not alter the pattern.
Transection of the spinal cord suppressed the rhythm at peak levels, while
constant light decreased levels.

Black and Axelrod (1968) showed that the

enzyme activity was reduced by increasing NE, in vitro and in vivo, while
depleting NE increased enzyme activity.

Honova et al. (1968) reported that

in the rat, the enzyme rhythm appeared within 48 hours after birth, but was
180° out of phase with the adult pattern, which develops 21-23 days after
birth.

Brain TT activity does not fluctuate, indicating that separate control

mechanisms exist for central and peripheral TT activity (cf. Fuller, 1970).
Radzialowski and Bousquet (1968) demonstrated a circadian pattern in
rats, for hexobarbital oxidase (HBO), aminopyrine N-demethylase, £-nitroanisole O-demethylase, 4-dimethylaminoazobenzene reductase (4DAB) activities,
all peaking at 0200 hours.

Adrenalectomy abolished all but the 4DAB pattern.
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The peak of diurnal rat plasma corticosterone levels occurs at the time of
minimal enzyme activities (1400 hours).

Exogenous corticosterone abolished

the diurnal aminopyrine and £-nitroanisol enzyme activities, suggesting that
the adrenal might be involved in regulation of hepatic drug-metabolizing
enzymes.

Jori~

al. (1971) found a similar circadian pattern for the liver

enzymes metabolizing hexobarbital, imipramine, £-nitroanisol and aminopyrine,
which could be reversed by photoperiod reversal.

Nair and Casper (1969)

found a circadian rhythm for HBO and 0-demethylase activities in the rat
liver, which were maximal midway through the dark phase.

The daily pattern

for HBO activity correlated inversely with the circadian pattern of RB
sleeping time; ie., sleep was longest when HBO activity was minimal.

Con-

tinuous light or darkness abolished the enzyme rhythm, although the activity
was significantly higher in animals subjected to constant dark.

Chedid and

Nair (1972) demonstrated electron microscopically a circadian pattern for
the relative amounts of hepatic endoplasmic reticulum in the rat.

Roberts et

al. (1970) reported a circadian variation for HBO activity, but not for PB
sleep duration or brain, liver and serum concentration of.PB and its metabolites.
Diurnal fluctuations occur in the activities of hepatic steroid hydro-

--

xylases (Colas et al., 1969) and tryptophan pyrrolase (Rapport et al., 1966)

--

.

Phillips and Berry (1970) noted a circadian pattern in mouse liver phosphoenolpyruvate from pyruvate).

Gielen et al (1970) found a circadian pattern

for cholesterol-7-alpha hydroxylase activity (involved in the biosynthesis of
bile acids), which is controlled by the adrenocortical system.

p
•
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Mouse kidney transamidase activity is circadian (Van Pilsum and Halberg,
1964).
8.

CNS amines
a.

Serotonin (5HT)
Scheving

~

.!!.·

(1968a), who measured 5HT levels every hour, found

a circadian rhythm for whole rat brain, which peaked during the light phase.
Dixit and Buckley (1967) reported a similar pattern for rat brain 5HT, during
normal and reversed photoperiods.

Peak 5HT occurs at the time of lowest

corticosterone (2300 hours, mid-light phase) and 6 hours before the corticosterone peak.

Scapagnini

~al.

(1971) noted that 5HT levels in the rat hippo-

campus and arnygdala followed a circadian pattern peaking at 2000 hours and
troughing at 0400 hours.

The plasma corticosterone pattern is similar, with

a peak at 2000 hours and a trough at 0800 hours.

Friedman and Walker (1968,

1969) found that rat caudate nucleus (CN) and rnidbrain (MB) 5HT followed a
circadian pattern, with a peak at 1800 hours and a minimum between 2400-0600
hours.

They related the 5HT levels to the sleep-wakefulness cycle.

Reis

~al.,

(1968) indicated that 5HT in the inferior colliculus and the red

nucleus-medial tegmenturn of the cat was greater at 1900 hours than 0700 hours.
Hery et al. (1972) obtained similar results for rat cortex, hypothalamus and
brain stern 5HT.

5HT synthesis decreased significantly in the brain stern in

the dark (2100 hours) as compared with the light phase (1500 hours) and was
dependant on the initial tryptophan (TP) levels, not the rate of conversion
of TP to 5HT.

They further indicated that although 5HT synthesis was maximal

during the light

period(fo~ation

of 5HT from TP), its release was maximal

during the dark (formation of 5-hydroxyindole acetic acid from 5HT).

Okada

(1971) studied the maturation of the circadian rhythm of rat whole brain SHT.

•
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The pattern appeared at days 35-37, preceding the onset of the adult S-W
pattern, which matures on days 49-52.

Asano (1971) obtained similar results.

R~ther et al. (1967) reported that whole brain 5HT levels of rats maintained

under constant light or constant dark were elevated over that of rats under a
normal light-dark photoperiod.
b.

Norepinephrine (NE)
Scheving

~al.

(1968a) found an ultradian pattern for NE levels

in the whole brain of the rat while Friedman and Walker (1968, 1969) reported
a circadian pattern for rat CN and MB NE, which was maximal at the end of the
dark phase.

Reis~

al. (1968) demonstrated a diurnal cycle in NE levels of

the cat cervical cord, pons, substantia nigralateral tegmentum, anterior
hypothalamus, tuber cinereum and the pineal.

Generally, NE content was maxi-

mal at the middle or end of the light period.

The pattern for the anterior

hypothalamus and pineal peaked in the dark phase.

Constant light abolished

the pattern in the pineal but not in the cervical cord or anterior hypothalamus.

Reis and Wurtman (1968) demonstrated a circadian alteration in the

NE concentrations in parts of the cat hypothalamus and cervical spinal cord.
They did not find diurnal fluctuations in other brain areas, but they measured
levels only at the onset of the light and dark periods.

Reis and Gutnick

(1970) demonstrated a circadian pattern for cat cervical and sacral-coccygeal
spinal cord NE concentrations, peaking at 1900 hours, while that of the
thoracic cord exhibited a biphasic pattern.

Manshardt and Wurtman (1968)

reported a circadian rhythm (peaking during the dark period) for hypothalamic
NE, but not for striatum or midbrain.

Walker et al. (1971) found that NE

levels in the hypothalamus and caudate nucleus were greater at 0300 hours than
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at 1500 hours.

Asano (1971) indicated that the adult circadian pattern for

whole brain NE does not appear until days 35-37, after birth.

The NE levels

peaked in the dark, similar to the pattern for brain parts (vide supra).
A.ncill

~al.

(1970) examined whole rat brain NE, DA and 5HT concentrations

but found a circadian pattern only for 5HT levels, which was maximal at 1200
hours (mid-light period) and minimal at 2400 hours.
c.

Dopamine (DA)
Scheving et al. (1968a) reported an ultradian pattern for whole

brain DA of rats.

Piepho and Friedman (1968) found a ctrcad:im pattern for rat

CN DA, and inverse pattern for caudate homovanillic acid, a degradative product of DA.
d.

Achetylcholine (ACh)
Friedman and Walker (1972) reported circadian patterns for rat

CN and MB, and mouse whole brain ACh.

Peak ACh levels occurred at 2400

hours in the rat, 0600 hours in the mouse while the trough was at 1200 hours
in the rat MB and 1800 hours in the rat CN and mouse brain.

Hanin et al.

(1970) also found a circadian pattern for whole rat brain ACh, which peaked
at 1400 hours.

The pattern was found in grouped rats only and emerged after

18 days in controlled environmental conditions.
e.

Miscellany
Friedman and Walker (1968, 1969) demonstrated a circadian rhythm

for CN and MB histamine, which peaked at 0600 hours in the normal and in the
caudate nucleus of the adrenalectomized rat.
found circadian patterns for hindbrain and
significantly higher during the dark phase.

Piepho and Friedman (1971)

s~inal

cord glycine, which were
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c.

Circadian rhythms in drug response
1.

CNS depressants
Davis (1962) demonstrated in mice that sleep duration (loss of the

righting reflex) produced by a constant dose of PB (60 mg/kg) varied over the
day, peaking during the light period and troughing during the dark period.
Grouped mice showed a longer sleeping time during the day than did isolated
mice.

Pauly and Scheving (1964) found that the maximum toxicity of PB

(75-90 mg/kg, IP) in rats occurred during the dark phase, while the doses
were least toxic toward the end of the light period.

Emlen and Kem (1963)

reported that the rate of recovery from PB anesthesia was more rapid during
the active (dark) than the inactive (light) phase.

Lindsay and Kullman (1966)

demonstrated in mice that PB toxicity was least during the dark period.
Scheving

~al.

(1968d) found a circadian pattern in rats for PB sleep

duration, which was longest at 2000 hours and shortest at 0900 hours.

Fried-

man and Walker (1969) also reported that sleep duration in rats due to PB
(50 mg/kg, IP) exhibited a circadian pattern.

The duration was longest during

the light phase (1800 hours), and shortest during the dark period (0600-2400
hours).
Nair and Casper (1969) found in rats that hexobarbital (RB; 150 mg/kg,
IP) sleeping time was significantly greater at 1400 hours than at 0200 hours.
Haus and Halberg (1959) noted that the percentage of deaths due to ethanol
was greater at 1600-2000 hours, than for the rest of the day.

Marte and

Halberg (1961) found that the maximum toxicity of chlordiazepoxide in mice
occurred at 2400 hours.
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2.

CNS stimulants
Scheving !:.!:. al. (1968e) showed that amphetamine toxicity in rats was

greater in the dark than in the light phase.

The pattern was relatively un-

altered by blinding but abolished by constant light.

Walker (1972) found

similar results in toxicity for isolated or aggregated mice, although the
latter were more sensitive to the lethal effects.

Ancill et al. (1970) found

that amphetamine (10 mg/kg, IP) produced no alteration in the circadian locomotor cycle of the rat, while lower doses (1.25 and 2.5 mg/kg, IP) significantly altered the pattern, in a dose-dependant fashion.
activity were much greater between 0800-2000 hours.

The increases in

While control locomotor

a:tntity doos not increase until the dark period, the low doses of amphetamine
increased motor activity prior to the onset of the dark period.
Pauly and Scheving (1964) reported that the onset time for rats to
undergo continuous tremors from tremorine (100 and 64 mg/kg, SC) depended on
the time of administration.

The maximal latency to tremor occurred during the

light phase (0200 hours) and the minimum occurred during the dark (2100 hours),
for the two doses tested.

Webb and Russell (1966) found that seizure component

times due to the convulsant, hexafluorodiethyl ether, followed a circadian
pattern.

Seizure times and the percentage of animals affected were greater at

1000 hours (light) than at 2100 hours (dark).

Lutsch and Morris (1967)

demonstrated that in mice, lidocaine produced convulsions in a significantly
higher percentage of animals at 2100 hours (dark) than at 1500 hours (light).
Halberg et al. (1955) reported a circadian periodicity in the incidence of mortality and audiogenic seizures in mice, which were maximum at 2000
hours (early dark period).

Schreiber and Schlesinger (1971) showed that
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audiogenic seizure susceptibility in mice was greater during the night than
the day.

Day-night differences in susceptibility appear at 22 days of age and

persist until 30 days of age, reaching a maximum difference at 26 days of age.
several species of mice tested on day 27, exhibited a circadian pattern in
audiogenic seizure severity scores.

Schreiber and Schlesinger (1972) found

that reversing the photoperiod reversed the seizure susceptibility pattern.
Increased susceptibility to audiogenic seizures was directly related to lower
levels of NE and SHT in the brain.

Piepho (1972) demonstrated in vehicle-

treated mice that the extensor latency time of minimal electroshock seizure
(MES) is shorter during the dark phase, while there were no circadian differences in the MES threshold.

Peak toxicity of the convulsants, allylglycine

and strychnine in mice occurred during the light phase, corresponding to minimal brain GABA and glycine concentrations.

The anti-convulsant activities of

acetazolamide, diphenylhydantoin and phenobarbital do not differ in effectiveness from day to night.

However, meprobamate was more effective in protecting

mice from seizures during the light phase.
3.

Allergic response
Reinberg and Sidi (1966) demonstrated a circadian pattern in the

allergic response of humans on a standardized routine, in terms of the area of
erythema and wheal after intradermal histamine.
at the onset of the sleeping (dark) period.

The maximum response occurred

The protective response of the

antihistamine, periactine, was more rapid and of shorter duration when administered at 1900 hours than at 0700 hours.

Reinberg (1967) described

several related studies testing the intradermal allergic response to histamine
and compound 48/80 and urinary 17 OHCS and 17-ketosteroids.

The peak response

...--~~~ ~
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occurred at about 2300 hours, at the time of minimum urinary corticosteroid
excretion.
DeVries

~al.

(1962) reported a circadian pattern in the hyper-

activity of the bronchial tree to histamine in patients with asthma and
bronchitis, which was most sensitive during the night.

Reinberg (1967) in-

dicated that asthma attacks correlated with times when adrenal steroid release
(urinary 170HCS and 17-ketosteroids) and potassium excretion were low.
4.

Drugs altering monoamine levels
Saelens et al. (1968) reported that in mice pargyline increased motor

activity in the dark phase, while
effect.

alpha-methyl-~-tryosine

had an opposite

Black et al. (1969) found that reserpine produced a dose-dependant

depletion of whole rat brain NE, which was maximal during the dark period.
Walker et al. (1971) demonstrated that reserpine depleted hypothalamic and
caudate NE to the same extent in the day or night, although NE concentrations
in controls was greater during the dark.

DL-DOPA with pargyline increased NE

concentrations in these areas, which were greater during the day than the
night.

Scapagnini et al. (1971) found that although the SHT levels in the

hippocampus, amygdala and hypothalamus were greater in the dark than the light
period, £-chlorophenylalanine depleted their SHT content to about the same extent in the light and dark periods.

Zigmond and Wurtman (1970) showed that

the accumrnulation of rat brain 3H-catecholamines after JR-tyrosine administration was significantly higher in the light period than the dark period.
Reis et al. (1969) studied the NE-depleting action of morphine in several
brain regions of the cat.

They found a significant correlation between NE

depletion of an area and the presence of a daily NE rhythm in the area.
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Friedman and Walker (1972) described the circadian fluctuations in
the toxicity of several cholinomimetics.

ACh (IV and IP), neostigmine,

pilocarpine and oxotremorine are most toxic during the dark period.
atropine (IP) pattern is inverted.

The

IV scopolamine and atropine methyl nitrate

also show maximum toxicity during the light period.
Wurtman

~al.

(1970) determined that rat brain S-adenosylmethionine

concentrations were maximal in the dark and minimal during the light period.
5.

Analgetics
Reinberg et al. (1967) found that human urinary salicylate excretion

was circadian.

The duration of salicylate excretion was longest when the drug

was given at 1900 hours.

Lutsch and Morris (1971) reported a circadian

pattern for analgesia in mice exposed to a constant dose of morphine.
maximum at 0300 hours.

It was

Reversal of the photoperiod reversed the analgesia

response pattern.
6.

Miscellany
Scheving

period.

~al.

(1972) measured SHT in rat spleen over a 24-hour

A circadian pattern for SHT concentration was maximum at 2400-0700

hours, in several experiments.

Carlstrom and Laurel! (1968) studied the

effect of nicotinic acid on the diurnal variation of plasma FFA.

Mean plasma

FFA concentration was elevated, in an ultradian pattern; plasma triglycerides
and cholesterol were reduced.

p
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D.

CNS Amines
1.

Serotonin (5HT)
a.

Metabolism
Serotonin or 5-hydroxytryptamine (5HT), an indolealkylamine, was

first isolated by Page (1954) from blood platelets and from intestinal mucos.a
by Erspamer (1954).

Rapport et al. (1948) isolated a vasoconstrictor from

serum which they named serotonin and which had identical properties to synthetic 5HT.

5HT is found in animals (eg. mammals to coelentrates) and plants

(eg. bananas, nuts, etc.) (cf. Garattini and Valzelli, 1965; Erspamer, 1966).
Large amounts are found in the gastrointestinal tract associated with the
enterochromaffin cell system and blood platelets.
The presence of 5HT in the CNS was demonstrated by Twarog and Page
(1953) and Page (1954).

Distribution in the manunalian brain is uneven:

in

the hypothalamus, septal area and midbrain concentrations are relatively high,
while in the cortex, cerebellum and white matter they are low (Bogdanski et al.
1957).

Giarman and Day (1959) found the bovine pineal is rich in 5HT.

Sub-

sequent studies in such species as the rat, monkey, etc. demonstrated that
5HT is higher in the pineal gland than in any other mammalian organ examined
(eg. in rat 57-73 µgm/gm;owman, 1963).
5HT is synthesized from an essential amino acid, tryptophan (TP) in
two steps (cf. Figure 1

).

The first step is the hydroxylation of TP to

5-hydroxytryptophan (5HTP) and the second is the decarboxylation of 5HTP to 5HT.
The first reaction, catalyzed by the enzyme, tryptophan-5-hydroxylase (TPH;
EC 1.99.1.4), is the rate-limiting step in 5HT synthesis.

Following its

synthesis, 5HTP is almost immediately decarboxylated to 5HT by the enzyme
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5HTP decarboxylase

(5HTPD;EC 4.1.1.18).

detectable in the brain or plasma.

This intermediate is not normally

The enzyme is not specific, since it is

capable of decarboxylating other L-aromatic amino acids, including the NE
precursor DOPA.

Therefore, the designation L-aromatic amino acid decarboxy-

lase (AAAiDC) is a better term for the enzyme.
brain and periphery.

Both enzymes are found in the

Brain 5HT can be synthesized from plasma TP taken into

the brain by an active process.
The cellular distribution of SHT in the CNS was determined by histochemical fluorescence techniques, which delineate intraneuronal SHT (Falck
et al., 1962).

With this technique serotonergic pathways in the CNS, which

are especially prominent in the raphe nuclei of the brain stem were traced
(Hillarp et al., 1966).

Ascending SHT-containing fibers go to the dience-

phalon and telencephalon from the rostral raph~ nuclei, while pathways from
the caudal portion descend to the lumbar and sacral cord.

Pujol et al.

/

.

(1971) demonstrated in cats, that lesions of the raphe system decrease diencephalon and telencephalon SHT and produce insomnia proportional to the extent
of destruction of SHT-containing cell bodies in the raphe system.
SHT is stored in the CNS in free (active, mobile) and bound (inactive,
reserve) forms.

The bound form is stored as a complex with ATP in synaptic

vesicles in nerve endings.

Such nerve endings and vesicles can be isolated

by ultra-centrifugation techniques and visualized by transmission electron
microscopy and electron microscopic autoradiographic methods.
Degradation of SHT is primarily via oxidative deamination by monoamine oxidase (MAO;EC 1.4.3.4), an enzyme found in the brain and most tissues.
MAO is widely distributed and localized intracellularly within the mito-
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chondrial membrane.

It is present in nerve cells, but not glia, and located

in the mitochondria around the storage granules found in nerve endings.

It

deaminates a number of amines to unstable aldehydes which are subsequently
transformed to corresponding alcohols or acids by reduction or oxidation,
respectively.

MAO deaminates compounds in which the amine group is attached

to the terminal carbon.

MAO forms the unstable 5-hydroxyindoleacetaldehyde

(SHIAc) from SHT, which is oxidized primarily to 5-hydroxyindoleacetic acid
(SHIAA), although a small amount is reduced to the alcohol, 5-Hydroxytryptophol (SHTPL).
destruction.

MAO inhibitors increase 5HT tissue levels by blocking its
Several metabolites of 5HT, such as melatonin, 5HTPL, and 5-

methoxytryptamine (SMT) are physiologically active (vide infra for further
discussion).
b.

Physiological Effects
1)

Serotonin
There is little doubt that 5HT is a neurotransmitter in the

CNS, if the traditional criteria used to establish putative transmitters are
applied to SHT.

These include CNS localization of 5HT itself, its synthetic

and degradative enzymes, release of 5HT after electrical stimulation and
effects of microiontophoretic 5HT similar to normal physiological responses
(Werman, 1966).
The neurophysiological effects of SHT on the CNS have been extensively
studied.
responses.

Marrazzi and Hart (1956) found that 5HT depressed transcallosal
Krnjevic and Phillis (1963) found that SHT depressed cortical

activity induced by both glutamate and peripheral stimulation.

Intracarotid

administration of 5HT in cats produced an initial arousal pattern, followed
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by a prolonged hypersynchrony (sleep-like) (Koella and Czicman, 1966).
After midpontine transection of the brain stem, cauterization of the area
postrema or application of 5HT-blocking agents to the fourth ventricle, 5HT
produced only arousal.

They concluded that 5HT acts upon receptor sites in

the area postrema and this stimulating effect is transmitted to cell bodies
in the solitary tract nucleus (Moruzzi, 1960).

Bronzino !:.!:. al. (1972)

demonstrated a similar EEG synchronization effect of 5HT applied to the area
postrema.

Bradley and Wolstencraft (1965) found that application of SHT to

single neurons of the pons and medulla had variable effects:

40% of the

neurons examined were excited by 5HT, while 49% were inhibited.

When stimu-

lation is induced via the optic tract, 5HT depresses the lateral geniculate
body (LGB), but is without effect with antidromic stimulation or after
application of excitant amino acids (Curtis and Davis, 1962; 1963).

5HT

also has depressant actions on the hypothalamus (Bloom et al., 1963),
olfactory bulb (Bloom et al., 1964), hippocampus (Biscoe and Straughan, 1965)
and spinal cord (Phillis et al., 1968).
2)

Metabolites
The actions of metabolites of 5HT and other indoleamines

(IA) must be considered.

Part of the interest generated in these substances

is derived from a number of IA compounds which have psycho-pharmacological
activity, such as LSD, DMT (N,N-dimethyltryptamine), DET (N,N-diethyltryptamine), bufotenine (5-hydroxy-N,N-dimethyltryptamine) and psilocybine (4phosphoryloxy-N,N-dimethyltryptamine).

Attempts have been made to relate

schizophrenia and other psychiatric disorders to aberrant metabolism of IA
which might cause the synthesis of these compounds in humans.

Woolley and
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shaw (1954) hypothesized that the hallucinogenic effect of LSD was based on
5HT antagonism but this theory has since been refuted by demonstrating that
bromo-LSD, which is a potent 5HT antagonist, has no hallucinogenic activity.
A number of active hallucinogens (vide supra) are formed by the methylation
of 5HT and tryptamine on the terminal amino position (N-methylation).
Axelrod (1962) isolated a N-methylating enzyme system in rabbit and human
lungs and found it absent in mice, rats and cats.

Morgan and Mandell (1969)

reported the presence of this enzyme in brains of chicks and rats.
Melatonin (M, 5-methoxy-N-acetyltryptamine), is formed from 5HT
(for a detailed discussion, vide infra).

Mcisaac (1961) postulated (under

unspecified conditions) a disorder of M metabolism, whereby the M side chain
closes, forming 10-rnethoxyharmalan, which has hallucinogenic properties.
Szara (1961) reported that 6-hydroxy derivatives of DMr and DET are the active
forms of these compounds and hallucinogenic activity is correlated with
urinary 6-hydroxy derivatives (Szara and Hearst, 1962).

An enzyme is found

in the liver (Jepson et al., 1962) which degrades M by 6-hydroxylation.
Hydroxy indole O-methyl transferase (HIOMr), the enzyme which rnethylates the
5-hydroxy group of N-acetyl 5HT to form M, is also able to methylate other IA
such as 5HT, 5HIAA and 5HTPL, to form 5-methoxytryptarnine (SMT), 5-methoxyindoleacetic acid and 5-methoxytryptophol (SMTPL), respectively.

Arutyunyan

et al. (1964) reported sleep induction and other central actions of 5Mr
(mexarnine).
young chicks.

Taborsky (1971) found 5HT, 5HTPL and SMTPL produced sleep in
The action of 5HTPL was greatly potentiated by pyrazole but

not by iproniazid or disulfiram.

Iproniazid decreased 5HT sleep.

investigators have demonstrated sleep-inducing properties for 5HTPL

Other
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(Feldstein, 1971), and 5-hydroxyindolacetaldehyde (5HIAc; Sabelli and
Giardina, 1970), the immediate oxidative product of 5HT by MAO (see Fig. 1

).

Ethanol alters the metabolism of 5HIAc by shifting product formation away from
SHIAA towards 5HTPL (Feldstein et al., 1967).
Hoffer and Osmond (1967) have advanced a theory for schizophrenia
which involves the transformation of Epi (adrenaline) to adrenochrome by an
oxidative ring closure, to form an indole-like compound.
3)

Effect of Precursors
The role of 5HT in the CNS has been studied by using depletors,

inhibitors of synthesis and precursors.

The innnediate precursor of 5HT, 5HTP,

has been used to increase central 5HT, since 5HT does not cross the blood
brain barrier (BBB).
~al.,

5HTP injections in cats, dogs and rabbits (Bogdanski

1958; Monnier and Tissot, 1958; Costa et al., 1960; Tabushi and

Himwich, 1970) produce a high voltage, slow wave EEG and sedation.

After a

latency of 15-20 minutes, doses of 30-50 mg/kg (IP or IV) of DL-5HTP (or 1525 mg/kg of L-5HTP) induce a state resembling SWS, which lasts for 5-6 hours,
without PS.

In rats, small doses of 5HTP reduce spontaneous activity (Joyce

and Mrosovsky, 1964) and can cause tremor and agitation (Udenfriend

~ ~.,

1957) although 5HT itself has a sedative effect (Pierre and Cahn, 1955).
Similar effects are seen in mice.

In rabbits, small doses of 5HT and 5HTP

induce sedation, while large doses result in excitation.

Ledebur and Tissot

(1965) injected 5HTP directly into the mediolateral part of the caudal brain
stem, inducing SWS, while injections in the dorsolateral pontine tegmentum
induced cortical desynchronization.

Tabushi and Himwich (1970) found that a

low dose of 5HTP (50 mg/kg, IV) delayed the onset of PS, while higher doses

p
36

(100-200 mg/kg) markedly increased SWS.

The anti-SHT agent, methysergide

(1 mg/kg), increased the alert stage and decreased both SWS and PS.
et al.
--

(197la) have shown different effects of SHTP in htnnans.

Wyatt

PS increased

while SWS decreased slightly, apparently compensating for the increased PS.
These results differ from those obtained in cats (Jouvet, 1967b)in which SHT
was implicated in SWS.
Increasing the dietary intake of TP increases the level of brain SHT
(Green~

al., 1962), while animals on a TP-deficient diet have reduced SHT

levels (Gal and Drewes, 1962).

Brain SHT is derived by hydroxylation of TP,

occurring mainly, if not wholly in the brain.

Weber and Horita (1965) demon-

strated that the increase in cerebral SHT in rats after IP TP was unaffected
by evisceration and that perfusion of cerebral hemispheres with a TP solution
resulted in elevated SHT levels on the perfused side only.

Moir and Eccleston

(1968) studied changes in concentrations of 5-hydroxyindoles (SHI) in whole
rat brain and various regions of dog brain after TP and 5HTP injections and
concluded that intracerebral TP hydroxylation is the primary factor controlling cerebral SHT formation.

These and other investigators (Garattini

and Valzelli, 1965) questioned the use of SHTP to increase central 5HT because
it is also decarboxylated in parts of the brain where SHT is not normally
present.
TP levels in human plasma (Wurtman et al., 1968b) and certain rat
tissues (Wurtman et al., 1968c) undergo diurnal variation.

Although SHT con-

centrations in the rat brain and pineal gland also vary with time of day
(vide supra), a relationship between these and the rhythms of plasma or tissue
TP content is still conjectural.
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In normal humans TP reduces sleep latency and slightly increases sleep
length and increases total sleep time.

In insomniacs it reduces sleep latency

and the number of awakenings (Hartman, 1967;

--

Hartman~

al., 197lb). Oswald

et al. (1966) found an increased onset of PS sleep with TP in humans.
4)

Blockade of Synthesis or Storage of SHT.
a)

~-Chlorophenylalanine

(pCPA)

Koe and Weissman (1966) reported that pCPA depletes SHT in
brain, peripheral tissues and blood, in rats and dogs.

Brain SHT and SHIAA

content are reduced to very low levels, while brain NE and DA decreased only
slightly.

pCPA reduces the normal increase in SHI compounds after TP loading,

inhibits liver TP hydroxylase and suppresses the TP- and phenylalanine-hydroxylating activity of livers from animals treated with it.
others have since substantiated (Jequier

~al.,

They concluded and

1967) that pCPA acts by in-

hibiting TPH, the rate limiting step in SHT synthesis.

Bloom and Giarman

(1970) observed that pCPA (316 mg/kg, IP) decreases rat pineal SHT content
more than 90% within a day without affecting NE content.
trations return to normal levels 4-6 days after treatment.

Pineal SHT concenGranular vesicle

opacity of pineal nerve endings observed by the electron microscope is also
lost one day after pCPA treatment and recovers with a time-course similar to
tissue SHT recovery.
Tenen (1967) found that depleting doses of pCPA in rats had no effect
on circular activity cage locomotion but depressed jiggle cage activity.
Volicer (1969) examined the effects of pCPA in mice and rats and found
spontaneous activity decreased only in rats.

,.-----------------------.

">
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The involvement of SIIT in SWS prompted Delorme et
the effects of pCPA on sleep in cats.

~-

(1966a) to study

They observed it produced a state of

insomnia or permanent wakefulness, with inhibition of PS and SWS.

This pattern

of disruption of sleep by pCPA in cats resembles the time-course of SIIT depletion seen in rats (latency of 16 hours and duration of about 3 days).
Mouret~

al. (1967, 1968) obtained similar results in chronically-implanted

rats and cats with doses of pCPA which almost completely deplete central SIIT.
The loss and recovery of sleep correlated with the time-course of central SIIT
change in rats similarly treated.

The loss of sleep in pCPA-treated cats

(440 mg/kg) was inunediately suppressed by 5IITP (40 mg/kg) and restored to
normal for 10-12 hours.

Koella

~al.

(1968) obtained equivalent results with

pCPA and 5IITP treatment in chronically-implanted cats.

Torda (1967) reported

substantially the same results with chronically-recorded, pCPA-treated rats,
and in sleep-deprived rats in which she measured SIIT content (75 hours after
injection).

Whole brain SIIT from animals deprived of sleep (for 15 hours)

was slightly elevated from controls, indicating that pCPA reduction of brain
5IIT is a direct and not a secondary effect produced by sleep-deprivation.
Pujol et al. (1971) extensively examined the metabolism of 5HT with
respect to the insomnia produced by pCPA and lesions of the raphe system, in
chronically-recorded cats.

After a 12-hour latency, a single dose of pCPA

(500 mg/kg) eliminated PS and SWS, which was maximal 36-40 hours after injection
and which recovered after 4 or 5 days without any sleep rebound.

Lesions of

the raphe system produced permanent arousal, with no PS and very little SWS,
which correlated with the completeness of the lesion.

•

Cortical 5IIT and
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SHIAA were greatly decreased; formation of 3H-51IT from 3H-TP decreased, but
3n-TP uptake and synthesis of

3
H-51ITP were unaffected.

5HTP injections in

cats with raphe lesions did not abolish the arousal pattern.
Cremeta and Koe (1966) found that no complaints of insomnia were
reported by normal humans given up to 3 gm/day (about 40 mg/kg) of pCPA.
b)

Reserpine (R)
R depletes tissue 51IT (and other amines) from their

storage sites, probably by interfering with the intracellular binding
(Pletscher et al., 1956).

R causes almost complete depletion of amine sotres,

which, depending on the dose used, recover to normal levels in about a week.
There are some differences in the mechanism of depletion of the amines since
maintaining R-treated animals at 4°C. depletes CAs but not 51IT.

The animals

are not sedated but become so after returning to room temperature, when
central 5IIT decreases (Garattini and Valzelli, 1958; Sulser and Brodie, 1960).
In addition to the actions of R on binding, it also blocks uptake of endogenous and exogenous amines into nerve endings
and in vitro.

(Brodie~

al., 1960) in vivo

The sedative effects of R last only several days compared to

the longer time-course of brain amine depletion (Haggendahl and Lindquist,
1964).

Reserpinized animals have been given the amine precursors SIITP and

DOPA, in an attempt to ascertain whether SHT or NE depletion accounts for the
sedation.

5HT increases the sedation, although large doses cause excitation.

On the other hand, when DOPA was injected the R signs were reversed, suggesting that the depletion of CAs was responsible for the depression (Monnier

"

and Tissot, 1958; Jouvet, 1968).
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In the cat, a single dose of R (0.5 mg/kg) suppressed SWS for 12-14
hours and PS for 22-24 hours, the latter returning to control only 5-6 days
later.

A selective and prolonged period of PGO (ponto-geniculate-occipital)

spiking (30-50/minute) appears within several hours of injection and lasts
for 50-60 hours (Matsumoto and Jouvet, 1964; Jouvet, 1967a). This PGO
activity is identical to PGO activity during PS.

Recordings were made at

the same level of the pons, mesencephalon, lateral geniculate and occipital
cortex and accompanied by lateral eye movements and twitches of the eyes and
ears.

However, the appearance of the cat is quite different from sleep and

there is no decrease of the neck muscle tone.

Hoffman and Domino (1969)

compared the effects of R on the sleep cycle in cats and humans.
(0.01-0.16 mg/kg, IM) decreases SWS in cat and man.

Low doses

In the cat PS decreases

for 48 hours without any rebound, while in man a fall in PS occurred on the
first night with a rebound increase on the subsequent 2-3 nights.

Coulter

et al. (1971) examined the EEG sleep patterns of 20 subjects following
single and repeated oral doses (1.0 mg) of R.

Both treatments produced an

increase in PS and a decrease in SWS.
5HTP (30-50 mg/kg, IV) injected 2-3 hours after R inunediately
suppresses the PGO activity and induces EEG and behavioral sleep for 4-6
hours, after which the characteristic fast cortical activity and PGO spiking
of R reappear.

Similar dosages of DOPA increase the PGO activity 50-80/

minute for 4-6 hours.

After a 20-30 minute latency, brief periods of SWS

occur which are always followed by behavioral and EEG PS, demonstrating an
almost normal pattern, which returns to the R pattern after 5-6 hours

•

(Jouvet, 1968).
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c)

MAO Inhibition
MAO inhibitors (MAOis) which act upon both IAs and CAs

by inhibiting their catabolism and thereby increasing their central concentration have actions on the sleep-wakefulness cycle.

Inhibitors such as

iproniazid, pargyline and nialamide have a specific and selective suppressive
effect on PS, while increasing SWS, probably as a secondary response.

After

a single injection of nialamide (10 mg/kg), PS is suppressed for 90-100
hours; it recovers after one week.
deprived of PS (Jouvet, 1968).

PS suppression occurs even in animals

Recovery of PS after MAOis occurs without

the rebound of PS seen after PS deprivation.

Chronic administration of

phenylisopropylhydrazine (1-4 mg/kg), which inhibits brain MAO without impairing liver MAO, can produce PS suppression for several weeks (Delorme,
1966).

These studies also demonstrated a correlation between

t~

loss of PS

by nialamide and the disappearance of the histochemical MAO stain in the
pontine tegmentum at the level of the locus coeruleus, where lesions
selectively suppress PS.
Wyatt

~al.

PS suppression.

(1969) administered MAOis to humans and found marked

Akindele

~al.

(1970) studied the actions of the MAOI,

phenelzine and nialamide on human sleep.

After 5-22 days of phenelzine

(60-90 mg daily) PS was abolished, coinciding with the time of mood improvement.

No effect of nialamide (75 mg/day for 17 days or 500 mg once, IM)

on PS were noted.
c.
•

The Pineal Gland
As a result of recent, extensive study, the mannnalian pineal can

no longer be considered a vestigal organ (Wurtman et al., 1968a).

The gland
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(weighing 1.0 mg or less in rodents) is unusually rich in such biogenic
amines as NE, H, 5HT and other IAs, as well as the enzymes which metabolize
these compounds.

Although the pineal gland develops embryologically from the

roof of the diencephalon (Kelly, 1962), it maintains no direct neural connections with the brain.

It is on the "peripheral" side of the BBB and

possesses peripheral innervation (vide infra).
for several reasons.
organ.

The pineal is of interest

The 5HT synthesis and content is higher than any other

Two enzymes, which acetylate, then methylate SHT are unique to the

pineal and form melatonin, which has marked physiological and pharmacological effects.

The concentrations of these compounds and enzymes are subject

to alterations by environmental stimuli such as light, and physiological
factors.

Some pineal biochemical reactions can be regulated by the auto-

nomic nervous system.
1)

Melatonin (M)
a)

Localization
Probably the most important biochemical discovery made

in recent decades concerning the pineal gland was the isolation and identification of its characteristic indole, M.

McCord and Allen (1917) demon-

strated that bovine pineal extracts contained a substance which lightens
amphibian skin.

Beginning in 1947, Lerner and coworkers set out to isolate

and characterize the active principle of the extracts, using over 250,000
bovine pineal glands.

Through a series of elegant experiments

(Lerner~~.,

1959, 1960) the active substance was found to be 5-methoxy-N-acetyltrypta-

..

mine or M (see Figure 1) .

,
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M is synthesized only in the pineal, although small amounts have been
found in peripheral nerves.

It is formed in a two-step process in which SHT

is N-acetylated (Weissbach et al., 1960) and then is methoxylated on CShydroxy group (Axelrod and Weissbach, 1961).

Acetyl SHT methyl transferase

(EC 2.1.1.4), the enzyme catalyzing the first reaction is widely distributed
in mammalian tissues, however, the second enzyme, which transfers a methyl
group from S-adenosylmethionine to N-acetyl-SHT (HIOMT) is found in the
pineal and thus determines the selective localization of M synthesis (Axelrod
et al., 1961).

Spectral characteristics for pineal gland, retinal and

Harderian gland HIOMT have been described recently (Cardinali et al., 1972).
Although N-acetyl-SHT is the best substrate for HIOMT, it is not the only
one.

The enzyme can also methylate other indolamines such as SHT, SHIAA and

SHTPL, forming small amounts of SMT, SMIAA and SMTPL, respectively (Axelrod
and Weissbach, 1961; Mcisaac

et~.,

1965).

M is degraded mainly in the liver, by hydroxylation at the sixth
carbon (about 80/ of M) and excreted in the urine in the conjugated forms
0

as the 0-sulfate and 0-glucuronide.
6-hydroxy indole.
1962).

This enzyme is specific in forming a

Thus it plays no role in SHT synthesis

(Jepson~

al.,

In addition, traces of injected M appear in the urine unchanged and

as SMIAA (Kopin et al., 1960; Wurtman et al., 1964c).
The disappearance of injected M (acetyl-3H) from blood and its tissue
distribution have been studied in mice and rats (Kopin et al., 1960) and
cats (Wurtman et~., 1964c).

3H-M appears to be taken up by all tissues,

including the brain, indicating that unlike SHT, its access to the CNS is
not hindered by the BBB.

In the cat, one hour after injection it is
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concentrated in the pineal, parts of the eye and ovaries (Wurtman
1968).

~al.

,

Other endocrine tissues and peripheral nerves selectively take up

3a-M to a small degree, while adipose tissue has the smallest uptake, indicating that the uptake in such organs as ovary, pineal and adrenal gland is
unrelated to their relatively high lipid contents.

Anton-Tay and Wurtman

(1969) have shown that 3H-M injected into the blood or the lateral cerebral
ventricles is selectively concentrated in the hypothalamus and midbrain.
M has been shown by several investigators to have pronounced effects
on the reproductive system of rodents and birds (Wurtman
~al.,

1969; Reiter and Franchini, 1969).

~al.,

1968a;Tait

Relatively low doses decrease rat

ovarian weight, retard vaginal opening, increase pituitary LR content and
depress the proportion of daily vaginal smears showing estrus phases (Chu et
al., 1964; Mcisaac et al., 1964).
Baschieri et al.

(196~)

Male gonadal growth is similarly reduced.

found that daily injections of M (l.O mg/kg) de-

creased thyroid cell height and 1311 uptake
b)

Pharmacological Effects
Marczynski et al. (1964) examined the effects of M im-

plants on the EEG of unrestrained cats.

Small amounts of crystalline M

(15-30 µgm) were administered by cannulae directly into the preoptic region
of the hypothalamus, nucleus centralis or brain stem reticular formation
(RF) and the animals observed for behavioral and EEG effects.

Implants in

the preoptic region had the most pronounced actions, which appeared after
15-30 minutes and lasted 2-3 hours.

The EEG exhibited cortical synchroni-

zation with an increase in amplitude and slowing of subcortical activity,
while at the same time the animals went to sleep.

Implants in the nucleus
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centralis medialis led to qualitatively similar EEG activity and behavior,
however brain stem implants produced no consistent changes.

Administration

of pineal extracts or M decreases the spontaneous motor activity in the rat
(Reiss~

al., 1963b; Wong and Whiteside, 1968).

Arutyunyan et al. (1964) examined the pharmacological properties of
M.

Subcutaneous injection of M (25 mg/kg) produced a slight behavioral

depression in cats lasting 1-1.5 hours.
mice were without effect.

Similar doses (25-50 mg/kg, IV) in

Doses of M (10-20 mg/kg, IV) in cats and rabbits

resulted in slow, high-amplitude waves in the EEG of cortical and subcortical
structures 5-10 minutes after injection, which lasted 1-2 hours.

M (20 mg/kg,

SC) significantly prolonged the hypnotic effects of HB (60 mg/kg, IP) and
chloral hydrate (200 mg/kg, IP) in mice.

This effect might be due, in part,

to the ability of M (50-100 mg/kg, SC) to reduce body temperature 2-3°C.
the rabbit, M (25 mg/kg) had no hypothermic action (Barchas
In similar experiments, Barchas

~ ~·

~al.,

In

1967).

(1967) found M (25 mg/kg, IP) in-

creased HB (100 mg/kg, IP) sleeping time in mice 50 per cent.
Martini (1970) examined the effect of M on PB sleep.

Fraschini and

They injected M into

the lateral cerebral ventricles of rats immediately after PB (30 mg/kg, IP).
M (30-120 µgm) potentiated PB sleep in a dose-dependent fashion (about a 1445% increase).

These results seem specific for M, since comparable intra-

ventricular doses of SHT with PB produced small decreases in sleeping time.
M (2.S mg/kg, IV or IP) in 4-day old chicks (which have an incomplete BBB)
immediately caused the animals to assume a roosting posture for about 45
minutes (Barchas

~al.,

1967).

A dose of M (10 mg/kg) did not alter blood

pressure in cats or the contractile force of the heart or the EEG in dogs.

,.

II

,.

1'1

,ii
'•1'
111

46

I!
!,I

Hishikawa et al. (1969) found in young chickens that M (10-60 mg/kg, IP)
had a powerful sedative and hypnotic effect which appeared within 1-2 minutes
and lasted for 30-60 minutes.

M-induced sleep was characterized by a slow,

high voltage EEG, similar to normal SWS.

Pinealectomized rats show increased

motor activity and an activated EEG (Reiss et al., 1963a; Nir
Recently

Anton-Tay~

~al.,

1969a).

al. (1971) gave human volunteers IV doses of M (0.25-

1.25 mg/kg in ethanol).

Initially the EEG was "deactivated", followed in

15-20 minutes by sleep lasting about 45 minutes.

Similar results occurred

in several epileptics but not in Parkinson patients who experienced minimal
sleep effects but did improve in their condition.
Anton-Tay~

al. (1968) administered M (about 1.0 mg/kg, IP) to

female rats and measured 5HT and NE in the MB, hypothalamus and cerebral
cortex over a 3 hour period.

Cortical 5HT decreased 14% 20 minutes after M

and was still depressed after 60 minutes, while its concentration in the MB
and hypothalamus increased significantly.

After 3 hours the cortical and

hypothalamic 5HT concentration had returned to normal, but that in the MB
continued to increase.

A weakness in experimental design is the use of "zero-

time" controls instead of vehicle-treated animals (diluted ethanol) sacrificed at specific times after injection, thereby obscuring possible (and
probably) amine changes due to ethanol (Feldstein, 1971) and effects due to
circadian rhythms.

In preliminary experiments with rats sacrificed one hour

after 0.5 mg of M (total dose), whole brain 5HT was elevated significantly
while NE content was unchanged.

In mice, M (30 mg/kg, IP) given every 3

hours for 18 hours caused no change in gross behavior or NE content of the
brain or heart.

'I
',
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Klein et al. (1970) and Berg and Klein (1971) have studied several
aspects of M synthesis using cultured rat pineals.

Treatment of cultures

with NE or dibutyryl adenosine 3', 5 1 -monophosphate (DAMP) caused a 6-10fold increase of N-acetyltransferase activity and subsequent M formation.
They concluded that N-acetyltransferase, which forms N-acetyl 5HT, is elevated by NE through a cyclic AMP mechanism dependent on protein synthesis,
since cycloheximide and actinomycin D block the augmented formation of
labeled M from labeled TP.

Wurtman et al. (1971) examined these effects of

NE and found they could be blocked by the

~-adrenergic

blocking drug propran-

olol but not the a-adrenergic blocker, phenoxybenzamine.

Neither altered

the response to DAMP.
2)

Anatomy
The work of Rowan (1925) which demonstrated that gonadal

function in the junco finch involved regulation by environmental lighting
gave the first hint of the importance of light on physiological systems.
His observations indicated that the endocrine system was not closed, but
could be influenced greatly by environmental stimuli.

Fiske et al. (1960,

1962) showed that pineal weight and synthetic activity in rats kept in constant light decreased 25%, while constant darkness had no effect (compared
with animals maintained under diurnal lighting conditions).

Axelrod et al.

(1965) has shown that pineal weight varies over a 24-hour period, and is
lowest at the end of th!light period.

Pineal extracts depress gonadal weight

and function (Wurtman et al., 1959), while pinealectomy or constant light
increase ovarian weight (Wurtman et al., 1961).

Injections of M reduced

gonadal weight and function in animals maintained in normal lighting.

These

,

'
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results suggested that the pineal contained a factor which inhibited gonadal
function in the rat, whose synthesis or release was probably related to environmental lighting.
The rat pineal gland is rich in such biogenic amines as SH.T (Quay,
1963), histamine (Machado et al., 1965), DA and NE(Pellergrino de Iraldi and
Zieber, 1966).

Quay (1963) has shown that the concentration of pineal SH.T

is not constant but exhibits a characteristic diurnal variation when animals
are maintained under diurnal lighting conditions (usually 12 or 14 hours
light, 12 or 10 hours dark).

It is highest during the day and falls during

the night, in these nocturnal animals.
pattern for pineal 5HIAA.

Quay (1965) demonstrated the same

Rats placed in continuous darkness for one week

retained their pineal 5HT rhythm (Snyder et al., 1964, 1965), although this
might not have been sufficient time to abolish the 5HT rhythm.

Blinded

animals retain a similar pattern of pineal 5HT under normal illumination,
constant light or constant dark.

This rhythm is extinguished in 5 days when

normal animals are placed in constant light.
M, synthesized from pineal 5HT and in vitro M-forming activity have
similar diurnal patterns although peaks and troughs do not correspond to that
of pineal 5HT (Quay, 1965).

Wurtman et al. (1963b) reported that continuous

light decreased HIOMT activity relative to that of animals kept in darkness.
If the nerves entering or leaving the superior cervical ganglion (SCG) were
cut, pineal HIOMT activity was no longer alterable by continuous light or
darkness (Wurtman et al., 1964a,b).

Axelrod et al. (1965) observed in rats

kept under diurnal lighting, a diurnal pattern of pineal HIOMT activity,
which was greatest at midnight.

Animals kept in darkness showed a marked
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rise in HIOMT activity, which could be prevented by puromycin and partially
blocked by actinomycin D, agents which interfere with DNA-directed protein
synthesis.
Kappers (1960) demonstrated that the pineal is richly innervated by
post-ganglionic sympathetic axons, which have their cell bodies in the SCG.
In the rat, these provide the only innervation to the pineal.

Axons origi-

nating in the retinal ganglion cells travel via the optic nerve to the optic
chiasm, where they separate into several components (Hayhow

~al.,

1960).

The largest and most important nerve bundle contributes crossed and uncrossed
fibers to the primary optic tract (POT) which transmit to the occipital cortex where images are perceived.

The superior and inferior fasciculi of the

accessory optic system leave the optic chiasm.

The superior fasciculus

terminates in three nuclei within the MB tegmemtum, while the inferior fasciculus enters the lateral hypothalamus, running with fibers of the median
forebrain bundle (MFB) before terminating in the nucleus of Bochenek in the
rostral midbrain tegmentum.

Retinohypothalamic fibers have been described

which leave the chiasm dorsally and terminate in the adjacent medial hypothalamus in some species (Krieg, 1932), although other studies have questioned
their existence (Hayhow et al., 1960).
Studies by Moore and Axelrod and coworkers have elegantly determined
the pathways by which light influences pineal function, with regard to M and
HIOMT activity.

Rats with bilateral lesions of the MFB (where it passes

through the lateral hypothalamus) or sham-operated animals were placed in
continual light or darkness for 30 days

(Axelrod~

al., 1966).

HIOMT

activity and pineal weight in sham-operated animals kept in darkness was five

r
I

so
times greater than in animals kept in light, while animals with lesions
showed no differences between the light and dark-treated animals.
cedures were performed in rats:

Four pro-

1) both eyes were enucleated; 2) one eye was

enucleated and the MFB on the ipsilateral side transected (interrupting the
photic input to both inferior accessory optic tracts, IAOT); 3) bilateral
lesions were placed in the optic tract at the LGB (producing a functionally
blind rat with an input to IAOT intact); 4) both IADT and primary optic tracts
were severed (only retinohypothalamic fibers maintained intact in order to
determine if they mediate pineal function), (Moore et al., 1967).

Animals

prepared as outlined above were kept under continual light or dark for 30 days,
then their pineals were assayed for HIOMT activity.

In enucleated rats or

animals in which the IAOT had been interrupted, light and dark had no effect
on M synthesis but the characteristic changes in HIOMT activity did occur in
animals with only POT lesions, implicating the IAOT in these effects.

Wartman

et al. (1969) demonstrated that although cholinergic innervation is not important in the pineal response to light, the facilitation of HIOMT activity
in darkness is mediated by the parasympathetic system.

The results of these

experiments indicate that impulses produced in the eye by light travel in the
optic nerve, are transmitted through the IAOT., reaching the nucleus of
Bochenek in the MB.

From there they descend through the spinal cord, where,

at the upper thoracic cord, preganglionic sympathetic fibers enter the SCG.
Postganglionic sympathetic fibers (nervi conarii) transmit the impulse to
their termination in the pineal gland.
A possible mechanism by which pineal IAs might exert their actions
centrally has been suggested by several workers (Koella, 1969a; Fraschini and
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Martini, 1970).

Since Mis not found in the general circulation, it and other

IAS may exert their effects by being transported through the cerebral spinal
fluid (CSF), in a direct, internal circulation of the brain (Sheridan et al.,
1969).

They have demonstrated such transport in the hamster.

In the experi-

ments of Fraschini and Martini (1970) intraventricular injections of M potentiated PB sleep.

Koella (1969b) hypothesized that because of the high con-

centration in the pineal of SHT, M and some other active IAs, these substances
could

11

leak" via the recessus pinealis, into the posterior part of the third

ventricle, then flowing with the CSF into the fourth ventricle where they can
exert a hypersynchronizing action on the area postrema, nucleus tractus
solitarii and upper brain stem, areas which have been shown to be sensitive
to such hypersynchronizing actions of IAs.
3)

Other Pineal Amines
Pineal NE is present in relatively high concentrations in the

rat (Pellegrino de Iraldi and Zieher, 1966; Wurtman and Axelrod, 1966).

At

the end of the light (sleep) period NE was three times that at the end of the
dark (awake) period.

The increase in pineal NE at the onset of the dark

period is in phase with the rapid increase in M formation (Quay, 1965) and
occurs when pineal 5HT is falling sharply (Quay, 1963).

Thus the work of

Klein and coworkers suggest that the stimulation of N-acetyltransferase and
subsequent M production, by NE might occur physiologically.

The NE rhythm

is abolished by blinding or maintaining rats in constant light or constant
darkness after as little as one day (Wurtman

~~.,

1967a).

This further

suggests that the NE rhythm, like the HIOMT but not the 5HT rhythm is exogenous and dependent on environmental light input to the pineal.

Sectioning
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the preganglionic fibers to the SCG (Pellegrino de Iraldi and Zieher, 1966)
or unilateral MFB transection and contralateral enucleation (Wurtman et al.,
1967a) also abolish the pineal NE rhythm, to a constant, intermediate level.
Other rhythms in the pineal include greater incorporation of circulating 32 p during the dark than light (Roth, 1965) and increase content of
ethanol soluble lipids during the day than the night (Quay, 1961).

r
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2.

Cathecholamines
a.

Metabolism
The CAs NE, Epi and DA are 3,4-dihydroxy derivatives of phenyle-

thylamine (see Figure 2 ).

Elliot (1905) first postulated that an Epi-like

substance might be released from sympathetic nerves and thus be responsible
for chemical transmission at synapses.

The presence of an adrenergic "sym-

pathin" in extracts of manunalian brain was first described by von Euler (1946).
Von Euler (1948) finally established that NE is the sympathetic transmitter
by chemically isolating NE in splenic nerves.

Holtz (1950) confirmed this

finding in brain and spinal cord and demonstrated that NE content was much
greater than that of Epi.

Until 1954 it was generally suspected that brain

NE was located mainly in blood vessels.

Vogt (1954) measured CAs by bioassay

and first demonstrated their relatively high concentration in specific anatomical areas, in cat and dog brain.
similar in other species.

The distribution pattern is generally

In man, rat, cat and monkey, the highest con-

centrations are in the hypothalamus and range from 1-3 µgm/gm.
centrations in other areas can be ranked as follows:

The con-

MB and pons, medulla

oblongata and striatum followed by a group of structures with very low concentrations, such as the hippocampus, cerebral cortex, cerebellum and spinal
cord.

In the corpus striatum, particularly the CN, where the NE concentration

is relatively low, DA is found in very high concentrations (3-8 µgm/gm).
Since 1962, the highly specific and sensitive histochemical fluorescence microscopy technique has permitted the direct visualization of the
biogenic amines, NE, DA, Epi and SHT, at the cellular level.

The use of

these methods confirmed that NE present in peripheral manunalian tissues and
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specific CNS areas is localized almost exclusively in sympathetic or adrenergic nerves (Carlsson.!:,£ al., 1962).

In the presence of formaldehyde gas the

amines are converted to fluorescent isoquinoline derivatives which are green
in the case of the NE and DA products and yellow for the 5HT derivative.

In

many areas of the brain fine nerve fibers with extensive terminal arborizations or variscosities containing CAs or 5HT have been demonstrated.

Using

these techniques and selective stereotaxic placement of lesions in the CNS,
Heller and Moore (1965) and Ungerstedt (1971) described NE, DA or 5HT pathways
in the brain.

More recently, the use of density-gradient centrifugation and

autoradiographic localization of 3H-NE and electron microscopy have combined
to reveal that NE is localized largely within specific storage particles or
synaptic vesicles contained in adrenergic nerve endings.
Gross mesencephalic and specific hypothalmic lesions produce a fall in
CA and 5HT concentrations and fluorescence in the brain.

After it was shown

that thoracic cord section decreases spinal cord NE (Magnusson and Rosengren,
1963), several NE-containing bulbospinal systems were described (Dahlstrom
and Fuxe, 1965).

They are localized in the medulla and send axon processes

into the spinal cord.

Ascending systems containing NE neurons originate in

the lower brain stem (medulla, pons and MB) and extend to the hypothalamic,
preoptic area, limbic system and cortex.

Lesions in the MFB of the lateral

hypothalamus and in the dorsomedial brain stem tegmentum significantly decreased whole brain NE and 5HT, while lesions in the ventrolateral tegmer_tum
decreased NE only (Heller and Moore, 1965).
Lesions have been used to demonstrate a nigro-striatal system of DAcontaining neurons which originate within the substantia nigra and project

l
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to the striatum.

Other DA neurons are located in the MB and project rostrally,

primarily to the olfactory tubercle.

The only monoaminergic cell bodies

located above the MB, with the exception of a DA cell group in the retina, is
small set of neurons localized near the median eminence, which is thought to
be of importance in neuroendocrine regulation.

Areas where there is the

greatest number of nerve endings (not cell bodies) contain the highest NE
concentration.
b.

Biosynthesis
As first suggested by Blaschko in 1939, the synthesis of CAs

begins with tyrosine.

Tyrosine is transported into the brain and central

adrenergic neurons by specific active transport mechanisms.

Once within the

neuron it is hydroxylated by the cytoplasmic enzyme, tyrosine hydroxylase
(TH; EC 1.14.3.a) to dihydroxyphenylalanine (DOPA; see Figure

2 ).

Direct

demonstration of enzymatic hydroxylation of tyrosine was only achieved
recently (Nagatsu et al., 1964).

They found that TH is easily saturated by

substrate and is therefore the rate limiting step in the biosynthesis of CAs.
Several CAs also inhibit TH, suggesting that this inhibition is involved in
the regulation of CAs synthesis.
tyrosine or

DL~-tyrosine

to DA.)

(TH does not hydroxylate tyramine, D-£Alpha methyl-£-tyrosine (AMPT), a com-

petitive inhibitor of TH is converted to a-methyl DOPA, depleting tissue CAs
but not SHT (Spector et al., 1965; Anden

~al.,

1966).

DOPA is decarboxylated within the cytoplasm to form DA which is taken
up into storage granules by an active process.

The decarboxylating enzyme

is sometimes known as DOPA decarboxylase although it is the same non-specific
L-aromatic amino acid decarboxylase (AAADC) that forms SHT from SHTP.

The
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wide distribution and high activity of this enzyme in many tissues has made
it difficult to achieve sufficient enzyme inhibition to decrease CA levels.
In DA-neurons there is no further synthesis, while in NE-neurons the DA is
hydrozylated, within storage granules by
14.2.1).

dopamine~-hydroxylase

(DH; E C 1.

The enzyme also catalyzes the conversion of several other phenyle-

thylamines other than DA, to their

~-hydroxylated

products (Kaufman and

Friedman, 1965), as long as they contain an aromatic ring with a 2- or 3carbon side chain terminating in an amino group.

The potent inhibitor of DH,

disulfiram, decreases brain and heart NE content, probably by complexing with
copper ions of the enzyme.
In chromaffin tissue, such as the adrenal medulla and certain areas of
the brain, the cytoplasmic enzyme, phenylethanolamine-N-methyltransferase
(PNMT; EC 2.1.1) methylates NE to form Epi (Wurtman and Axelrod, 1966).
Presumably the NE passes from the storage granules for .this step and newly
formed Epi is taken back into storage granules.

PNMT is strongly inhibited

by its substrate NE and product Epi at concentrations (of Epi) normally
present in the adrenal medulla.
c.

Degradation
Armstrong et al. (1957) first reported that a 3-0-methylated

4-hydroxylated catechol acid, 3-methoxy-4-hydroxymandelic acid ("vanillilmandelic acid, VMA") is a urinary metabolite of both NE and Epi (see Figure 2
Subsequently the 0-methylated amines normetanephrine (NM) and metanephrine
(MET) were also found in the urine.
involved two enzymes:
ferase (COMT).

Metabolic degradation of CAs primarily

monoamine oxidase (MAO) and catechol-0-methyltrans-

Since both act on a wide variety of amine substrates and each

).
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is active on the products of the other, a spectrum of CA metabolites can be
identified in urine.
N-methylation and
lethylamines to MAO.

~-hydroxylation

decrease the susceptibility of pheny-

The relative proportion of oxidized to reduced products

in the deaminating steps varies among species and under different conditions.
DA is a better substrate for MAO than Epi or NE, so large amounts of the
deaminated metabolites of DA (dihydroxyphenylacetic acid, DOPAC and homovanillic acid, HVA) are excreted in the urine.
d.

MAO Inhibition
Inhibition of MAO elevates tissue levels of biogenic amines such

as NE, DA and SHT (Spector, 1963) and decreases the excretion of deaminated
metabolites of amines, such as VMA, 3-methoxy-4-hydroxyphenylglycol and HVA,
while the excretion of NM, octopamine and tyramine increases (Sjoerdsma,
1966).

Although MAO inhibition does not prolong the physiological effects

of NE, MAO is important in regulating the intracellular level of amines by
metabolizing any amines which leak into the axoplasm from storage granules.
The second pathway for CA metabolism is the 0-methylation of the
catechol ring by COMT (E C 2.1.16), which requires S-adenosylmethionine
a methyl donor.

as

NE and Epi are metabolized to the corresponding 3-0 methy-

lamines NM and MET (see Figure 2 ).

It is localized extraneuronally,

primarily in the liver and kidney, as well as in brain tissue (highest in
the area postrema and lowest in the cerebellar cortex) and within the red
blood cell, and is responsible for inactivating CAs released into the circulation or in tissues lacking abundant adrenergic innervation.

The 0-methyl-

ated metabolites can be conjugated, often with a sulfate or deaminated by MAO
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to form 0-methylated glycols or acids.

COMT is inhibited by dichloromer-

curibenzoate, suggesting it has a sulfhydryl group at the active site.
Polyphenols such as pyrogallol inhibit COMT in vitro but are less effective
in vivo.

~

------

MAO and COMT act upon CAs to produce physiologically inactive metabolic products, but neither enzyme plays a primary role in terminating the
physiological actions of CAs.

The rapid inactivation of CAs is due to up-

take back into the presynaptic nerve endings.

This is an active and specific

uptake mechanism, which can be blocked by cocaine and antidepressant drugs,
such as imipramine and some sympathomimetics.
e.

Pharmacological Effects of CAs in the CNS
Bass (1914) produced sleep when he applied Epi under the dura or

into the brains of dogs.

Leimdorfer (1948) demonstrated that intracisternal

Epi injections produced drowsiness in cats.

Epi and NE injected into the

lateral ventricle of chronically-implanted cats produced a state resembling
light anesthesia (Feldberg and Sherwood, 1954).
Other pharmacological investigations of the role of CAs in central
phenomena utilized systemic injections of amines (see Rothballer, 1959;
Jouvet, 1972a, b).

In moderate doses, NE and Epi produce cortical activa-

tion paralleling the increase in peripheral sympathetic tone.

The principle

site of action appeared to be in the upper pons and lower mesencephalon,
since lesions in these areas abolish the activating effect of NE.

Weil-

Malherbe et al (1959) demonstrated that NE and Epi did not pass the BBB.
Key and Marley (1962) compared the effects of injected (IV or IP) sympathomimetics in young chicks, which have an incomplete BBB and older birds,
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with chronically implanted electrodes.

Amines such as NE, Epi and DA pro-

duced behavioral sleep with cortical slowing, while in adults these same
drugs induced arousal.

Mandell and Spooner (1968) summarize over twenty

studies on the behavioral effects of NE and Epi administered so as to cross
the BBB (intracisternally, intraventricularly or IV in animals with immature
BBB).

In a variety of species (mice, rat, chick, cat, dog and man) the

predominent effect was sedation and/or somnolence.

Torda (1968) found that

microinjections of NE into the preoptic area of the reticular activating
system (RAS) during deep sleep significantly shortened the latency and
duration of PS and the latency of arousal.
arousal almost immediately.

NE given during PS resulted in

Cordeau et al. (1971) found Epi and NE (50 µg-

3 mg) introduced in the third ventricle or cisterna magna of cats produced
wakefulness and/or excitation.
Both NE and DA appear to play roles in sleep.

Since they do not

penetrate the BBB, precursors (such as DOPA) are used to elevate their
central concentration.

Precursors or inhibitors of synthesis alter the CNS

content of both amines produce differing effects due to their dissimilar
localization and central

effects(~

infra).

Peripheral injection of DOPA greatly increases CNS DA concentration
and to a lesser extent central NE (Chambers et al., 1971).

Accompanying the

increase in brain CA content is a marked increase in EEG and behavioral
alerting in chicks and young chickens (Key and Marley, 1962; Spooner and
Winters, 1965) and in rabbits and cats (Monnier and Tissot, 1958; Jouvet,
1967a).

Ledebur and Tissot (1965) injected DOPA directly into the caudal

brain stem or in the dorsolateral pontine tegmentum, inducing a fast
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cortical activity in the rabbit.

DOPA, DA (both IP) and amphetamine (SC}

produced alert EEG patterns in implanted chicks even though the blood
pressure responses are similar to the rise produced by NE, which is behaviorally depressant (Spooner and Winters, 1967).

Jouvet (1967b)reported

that in cats DOPA (30-50 mg/kg) caused an increase in waking, with almost
total disappearance of SWS and PS for 6 hours.

On the other hand, dihy-

droxyphenylserine, the direct precursor of NE, (Blaschko et al., 1950)
increases both SWS and PS in the rat (Havlicek, 1967).

Wyatt~

al. (1970a)

showed that in htnnans, L-DOPA led to a significant decrease in the duration
of PS sleep.

Gunne et al. (1971) tested L-DOPA in six patients with narco-

lepsy but did not find it superior to amphetamine in its waking action.
f.

Inhibition of Synthesis
Disulfiram blocks CA synthesis by inhibiting DH (Moore, 1969).

Wise and Stein (1969) administered disulfiram to rats in a self-stimulation
bar-pressing paradigm and found that animals stopped pressing the bar and
appeared sedated.
AMPT, a relatively specific inhibitor of CA synthesis, inhibits TH
(Weissman and Koe, 1965), producing a fall in NE and DA content in rat brain
(Dominic and Moore, 1969).

Torda (1968) administered AMPT to rats (80 mg/kg,

3 times, 6 hours apart, IP or by surgical implant) and found no EEG changes
for the first 3 hours, but after 18 hours NE was reduced to almost zeroJ SWS
increased and PS and wakefulness shortened.

In AMPT-pretreated

animal~.

microinjections of NE into the preoptic area or RAS "temporarily reversed
the EEG changes", shortening SWS and lengthening PS.

Hartmann~ al. (197la)
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reported that in the rat oral AMPI' (50-100 mg/kg) increased PS while AMPl'
(75 mg/kg, IP) decreased PS, corresponding to the time of maximum decrease
in brain NE.

In the cat, King and Jewett (1971) found AMPI' (3-400 mg/kg,

IP) increased PS and brain NE was depressed.

Jouvet (1972a)administered AMPI'

(150-200 mg/kg, IP) to cats with lesions in the raphe system, when behavioral
and EEG waking was almost permanent (2-6 days after lesioning).

Behavioral

sedation and cortical synchronization began 4-6 hours after AMPI' lasted 24
hours and then returned to behavioral and EEG insomnia.

Weitzman et al.

(1969) found that in the monkey, AMPI' significantly decreased PS and behavioral waking with a proportionate increase in SWS.

Wyatt et al. (197lb)

administered AMPT to five patients, resulting in an elevation in total PS
(a lengthening of REM episodes instead of a greater frequency of episodes).
Various effects of AMPT on sleep include increased duration of PS both
lengthened SWS and PS in the cat (King and Jewett, 1969), increased duration
of SWS in the rat (Branchey and Kissin, 1970) or no apparent effects in rats
(Marantz and Rechtschaffen, 1967).
Several investigators have studied the effects on sleep of alphamethyl DOPA, which blocks the decarboxylation of both SH.TP

and DOPA, thus

decreasing 5H.T and DA transiently and NE for several days.

Dusan-Peyrethon

et al. (1968) found methylDOPA (100-200 mg/kg) in cats, caused a profound
decrease in PS (for 10-22 hours) and a relative increase in SWS.

In humans,

Baekeland and Lundwall (1971) administered alpha-methylDOPA (250 mg, 3 times
daily and 500 mg at bedtime) and found an increase in PS and a decrease in
stage 4 sleep.

63

3.

Histamine
Histamine (H,

~-imidazolylethylamine;

Fig. 3) was first synthesized

in 1907 and isolated by Barger and Dale (1910), long before its biological
significance was known.

Dale and Laidlaw (1910) investigated the pharmacology

of Hand recognized its effects to be similar to those of many tissue extracts.
They further noticed that the immediate response of sensitized animals to an
otherwise innocuous protein was the same as H poisoning.

It was not until

1927 that Best, Dale, Dudley and Thorpe isolated H from liver and lung samples.
Lewis (1927) and coworkers established that H was liberated from cells of the
skin in allergic responses.

For further discussion of some of the peripheral

actions of H, see Kahlson and Rosengren (1968) and Goodman and Gilman (1970).
a.

Localization.
H has probably attracted less attention than most other biogenic

amines in the nervous system because investigations on H have been hampered
by problems with interfering substances in tissue determination methods and
the lack of specific inhibitors of s)rnthesis or depletors.

These technical

problems have resulted in a great deal of variation in reported tissue H
values from laboratory to laboratory.

The postganglionic sympathetic nerves

are high in H content (60 µg/gm, which is about four times their NE content),
while the spinal cord is lowest (0.1-1 µg/gm).
H levels (von Euler, 1956).
for NE and SIIT.

Other nerves have intermediate

The regional distribution of His similar to that

H is highest in the hypothalamus (twice the concentration of

SHT), intermediate in the MB and lowest in the cortex and white matter.
Taylor~

al. (1972), using an extremely sensitive and specific H assay,

lmidazole-4acetaldehyde
Aldehyde

l

DH

n ( C H2 )2COOH

NVN
lmidazole-4acetic acid
I-methyl H

l

n C H 2CHO
H3CNVN
l-methylimidazole-4-acetaldehyde

1

n C H2 COOH
H3CNVN
l-methylimidazole4-acetic acid
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confirmed these results and showed wide differences in H content of various
brain nuclei.

The posterior lobe and stalk of the hypophysis, area postrema,

choroid plexus and pineal body contain H, although the H in the posterior
hypophysis may be in mast cells.

Mast cells, which contain large amounts of

Hin the periphery, are virtually absent in the CNS (Olsson, 1968).
studies have examined the subcellular localization of brain H.

Several

Michaelson

and Coffman (1967) reported that H is located primarily in the crude mitochondrial pellet, while others demonstrate a greater proportion in the
microsomal pellet (Carlini and Green, 1963; Kataoka and DeRobertis, 1967).
Early fluorometric studies of tissue histamine content were hampered
by the presence of an interfering substance, which has since been identified
as the polyamine, spermidine.

Michaelson (1967) pointed out the overlap of

fluorescence emission curves of H and spermidine.

In the early methods,

spermidine was extracted and yielded a fluorophor with the same fluorescence
characteristics as H, thus giving false high H values.
Tabor and Tabor (1964) and Kremzner

~al.

(1970) reported that the

spermidine concentration is uniformly high in the CNS, although the concentration in white matter is three to four times that in gray matter.
Few studies have examined the pharmacology of spermidine or its
function and effects in the brain.

Friedman and Rodichok (1970) evaluated

the toxicity of IP spermidine on a 24-hour basis.

The

LDso

pattern is

bimodal, with peaks just prior to the onset of the dark and light periods.
Spermidine levels in mouse whole brain, myelencephalon, and liver peak midway through the dark period (Friedman and Rodichok, 1972).

Histamine levels
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in the brain exhibited a similar circadian pattern, corresponding to the motor
activity rhythms of these animals.
b.

Synthesis
His formed from histidine (Rd); see Fig. 3

Hd decarboxylase (RdDC; EC 4.1.1.22).

) by the action of

There is a good, though not exact,

correlation between the distribution of R and Rd.DC activity in the brain
(White, 1959).

In areas where this correlation fails, such as the area

postrema, which is rich in H but poor in RdDC activity, R may be concentrated
from the blood by mast cells.

There has been some controversy as to whether

HdDC was the same non-specific decarboxylase involved in the formation of 5HT
and DA, but recent evidence indicates that there is a distinct R-forming
enzyme

(Schwartz~

al., 1970).

There are two main pathways of R metabolism;

ring N-methylation by imidazole-N-methyl transferase (HMT, EC 2.1.1.8) to
form methyl H, while oxidation of the side chain by histaminase forms imidazoleacetaldehyde and then imidazoleacetic acid by aldehyde dehydrogenase
(see Fig. 3

).

After His formed in the soluble portion by Rd.DC, His

taken up into a particulate form (probably similar to the vesicles storing
other biogenic amines) protecting it from destruction by such enzymes as HMT
which is in the soluble portion.

The activity of HMT is very high in guinea

pig brain but relatively low in rat brain (Brown et al., 1959).

White (1959)

demonstrated in cat brain that methyl H is the major metabolite, indicating
that histaminase activity is absent.

Snyder et al. (1966) found in the rat

that most of intraventricularly-injected H was recovered as imidazoleacetic
acid.

67

c.

Physiological effects
1)

Histamine and related substances
Feldberg and Sherwood (1954), by intraventricular H injection

in cats produced increased respiration, vomiting, muscular weakness as well
as some sedation lasting about one hour.

Sawyer (1955) obtained similar

results in anesthetized rabbits, and concluded that H activates a rhinencephalic mechanism (olfactory bulb, MFB and basal ganglia), which stimulates
the adenohypophysis.
arousal reaction.

In unanesthetized or etherized rabbits, H evoked an

Monnier et al. (1970) reported that a H infusion of the

rabbit third ventricle produced marked electrographic arousal with a decrease
in delta waves.

This effect was not blocked by acetylsalicylic acid, in-

dicating that the effect was not merely pain-mediated, but probably due to a
direct central awakening action, such as on the ascending MB RF and the
hypothalamic and hippocampal systems.

Friedman and Walker (1969) demon-

strated a diurnal fluctuation in CN H in rats, which peaked during the dark
phase, when animals are awake.

Monnier et al. (1970) found a five-fold in-

crease in release of "H-like" substances in the hemodialysate associated with
arousal compared with relaxed animals.
Krnjevic and Phillis (1964) found that the activity of single pyramidal Betz cells of cats was "slightly moderated" by Hd and more rapidly by
H iontophoretically-applied.

However, the same depressing effect was also

achieved with CAs, ephedrine, hydroxytryptamine or GABA.

Small amounts of

H depressed cerebral cortical neuron excitability, as did Rd and imidazoleacetic acid (Phillis 5:! !!_., 1968).

Larger amounts caused both depression

and excitation, the latter possibly due to the metabolite, methyl H.

These

r
f
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effects, as well as the effects of NE, ACh and SHT, were antagonized by antihistamines (mepyramine maleate).

H applied iontophoretically to thalamic

neurons had no effect (Curtis and Davis, 1962), perhaps due to the barbiturate anesthesis used.

However, Bradley (1968) observed depressant effects on

50% of the brain stem reticular neurons examined.

Curtis et al. (1961) found

no effect of H on spinal neurons, possibly because of barbiturate anesthesia.
In cats anesthetized with nitrous oxide and methoxyflurane or anemicallydecerebrated, NE, SHT and H applied extracellularly to spinal neurons increased
membrane polarization, decreased the amplitude of the EPSP and IPSP and
blocked synaptic or antidromic invasion of some motoneurons (Phillis et al.,
1968), effects resembling an inhibitory transmitter.

However, iontophoretic

strychnine and IV pixrotoxin failed to antagonize the actions of these amines.
Sadre and Tiwari (1966) demonstrated that H, like chloropromazine,
potentiated the

hypnotic actions of PB and chloral hydrate in mice.

hypnotic effects of PB in rats (Bovet
et al., 1963;
2)

Monnier~

~al.,

The

1958) and rabbits (Goldstein

al., 1967) were reversed by IV H.

Modification of CNS H content by drugs
Boissier

~al.

(1970) administered low doses of Rd (100 mg/

kg, IP) and found a maximum increase in cerebral H content one hour later.
After 90 minutes no significant changes in the H content of several brain
parts could be demonstrated.

Taylor and Snyder (1972) utilized high doses

of Hd (500 and 1000 mg/kg, IP) and achieved maximum mouse whole brain H
content elevation of 110 and 169%, respectively, one hour after injection.
Multiple Hd injections elevated brain H further.

One hour after Hd (1000

mg/kg, IP), H content in all mouse brain parts examined (except medulla
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oblongata) was significantly increased.
Taylor and Snyder (1971) studied the effects of various HdDC inhibitors on the formation of 3H-histamine from intraventricularly injected
3H-histidine.

Histidine can be decarboxylated to H in mannnalian tissues by

the "specific" HdDC, which is inhibited by a-hydrazinohistidine or NSD 1055
(cf. Snyder, 1972), or by the aromatic amino acid DC, which also decarboxylates DOPA and 5HTP and is inhibited by a-methyl DOPA (Lovenberg £!al.,
1962).

a-hydrazinohistidine and NSD-1055 administered IP significantly

lowered 3H-histamine content in the hypothalamus and thalamus-MB.

a-methyl

DOPA failed to affect 3H-histamine concentration in any brain region.
of the drugs altered brain levels of
of 200-500 mg/kg of

3
H-histidine or endogenous Hd.

a~hydrazinohistidine

activity.

Doses

and NSD-1055 lowered hypothalamic

H by 40% while a-methyl DOPA had no effect.
the effect of these inhibitors and

None

Taylor and Snyder (1972) studied

4~thiazolylmethoxyamine

on in vitro HdDC

All four compounds inhibited HdDC activity significantly, although

the effect of a-methyl DOPA was much less than the others.

Menon et al.

(1971) studied five HdDC inhibitors for their effects on rat brain H, NE, DA
and 5HT content and behavioral activity.

4-Thiazolylmethoxyamine (100 and

300 mg/kg, IP) depletes whole brain H to 10% of control 3 days and 1 day,
respectively, after administration.

One day after a dose of 100 mg/kg, 5HT

content was increased while NE and DA content decreased slightly.

After

three days DA was further decreased, NE slightly elevated and 5HT, approximately normal.

Taylor and Snyder (1972) examined whole mouse brain amine

content one hour after Hd (1000 mg/kg, IP).

5HT was significantly decreased

but NE, DA and acid and neutral indoleamines were unchanged.
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Taylor and Snyder (1971; 1972) tested the effect of a large variety
of drugs on H content of the rat hypothalamus and mouse brain, respectively.
In the former study, resperine, pCPA, chlorpromazine, pargyline, tranylcypromine, atropine, physostigmine, L-DOPA and 6-hydroxydopamine had no effect
on H content.

In the latter study, H content was significantly lowered by

L-3-methylhistidine and reserpine, while dexbrompheniramine and PB elevated
it.

Adam and Hye (1966) examined in the cat the effects of a number of

compounds on H content of several areas of the hypophysis, hypothalamus and
the massa intermedia.

Compound 48/80 lowered H in the posterior hypophysis

and stalk but had no effect in other areas.

Reserpine depleted, while

iproniazid and phenothiazines increased hypothalamic H content.

Green and

Erickson (1964; 1967) demonstrated that chlorpromazine (20 and 40 mg/kg)
elevated, while diphenhydramine (50 mg/kg) significantly lowered rat and
guinea pig brain H respectively.

Boissier

~al.

(1970) examined H content

in several rat brain areas one hour after diphenhydramine (SO mg/kg), but
found no significant alterations from control.
Merritt~

al. (1964) reported sedation in rats and a 63% decrease

in brain NE, 24 hours after 15 mg/kg, IP of decaborane (DB).

Merritt and

Schultz (1966) showed in whole rat brain that this dose of DB depleted DA
levels 60% after 4 hours, with a return to normal 24 hours later.

They

suggested that the decarboxylase system might be inhibited by DB.

Merritt

and Sulkowski (1967) demonstrated in

~

that AA.ADC was rapidly and

completely inhibited by DB (15 mg/kg, IP) within 2 hours and did not begin
to recover until after 72 hours.

Whole rat brain SHT was depleted signifi-

cantly after 4 hours, reaching a maximum at 24 hours, followed by a slow
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recovery.

Medina et al. (1969) reported that DB (15 mg/kg, IP) depleted rat

brain H to a maximum at 24 hours.
than one week to return to control.

H levels recovered slowly, requiring more
They showed that DB inhibited HdDC almost

90% within 2 hours after administration.
~easure

Unfortunately, these authors did not

other biogenic amines, such as NE, DA or SHT, so that their inter-

relationships could be compared.

Schayer and Reilly (1971) found that DB

inhibited brain and stomach HdDC and in vivo H formation in the brain and
skin.
4.

Acetylcholine (ACh) in the CNS
The cholinergic system in the CNS has been the subject of several

recent and thorough reviews (Karczmar, 1969, 1970, 1973; Potter, 1970).
a.

Formation and Localization
ACh is formed from acetyl CoA and choline, by the enzyme choline

acetyltransferase (choline acetylase, ChAc, EC 2.3.1.6).
animals, ChAc is found normally only in nerves.

In multicellular

The placenta of higher

primates, although not innervated, contains considerably more ACh and ChAc
than most nervous tissues (Hebb and Ratkovic, 1962).

The highest ChAc

activity is found in the CN, retina, corneal epithelium and spinal roots
(3-4 mg ACh/gm/hour synthesized).
contain only trace amounts.

Dorsal spinal roots and the cerebellum

Intracellular ChAc is found predominantly in

the crude mitochondrial fraction(from sucrose density, differential centrifugation data) of homogenized mammalian brain.

This fraction contains mito-

chondria, membrane fragments and synaptosomes with enclosed synaptic
vesicles.

Upon further resolution, the enzyme is found to be in the
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cytoplasm and not in the vesicle, therefore it must be concluded that ACh is
made in the cytoplasm and concentrated in the vesicles.

ACh released from

nerve endings acts postsynaptically and its actions are terminated by acetylcholinesterase (AChE or acetylcholine acetyl-hydrolase, ED 3.1.1.7), which
hydrolyzes it to form acetate and choline.

The choline is taken back into

the presynaptic ending by an active process, for the resynthesis of more ACh.
ACh has been established as a transmitter (using the criteria outlined by Werman, 1966; vide supra) only in the motor neuron collaterials of
the Renshaw cells (Eccles, 1969).

It is likely that other synapses in the

CNS are also cholinergic although it is technically very difficult to establish this conclusively.
b.

Pharmacological Effects
ACh injected directly into the carotid artery induces a state of

cortical activation (Bremer and Chatonnet, 1949; Monnier and Romanowski,
1962; Marczynski, 1967).
after IV injection.

Yamamoto and Domino (1967) reported the same effect

In the intact animal, physostigmine, prostigmine and

nicotine increase cortical and behavioral arousal in the intact animal
(Jouvet, 1972b).

Microelectrophoretic studies have shown that some central

neurons are excited and others are depressed by ACh (Curtis and Crawford,
1969).

Areas affected by ACh include CN, ventral basal thalamus, cochlear

nucleus, brain stem and pyramidal cells of the cortex.
Microinjection of ACh with a chemitrode into the bulbar, mesencephalic, pontine or rostral RF produces EEG synchronization and a hypnogenic
action in the cat, that is identical to the EEG and behavioral appearance
of SWS (Courville et al., 1962).

Similar injections of ACh in encephale
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isol~ cats produced EEG synchronization comparable to that in unanesthetized

;;..----

intact cats (without peripheral blood pressure changes), indicating that the
effect is central.

Cordeau et al. (1961) found that the administration of

ACh with physostigmine produced EEG synchronization and behavioral arousal.
ACh alone, applied to all areas of the RF produced EEG synchronization and
sleep.

Yamaguchi!:!. al. (1964) placed crystalline ACh into areas of the RF

rostral to those studied by Cordeau and coworkers, resulting in sleep.

The

effect was more pronounced when ACh was administered in the mesencephalic
RF.

Application of carbachol did not produce sleep.

were catatonic, the EEG was desynchronized.

Although the animals

Hernandez-Peon

~al.

(1963)

also obtained arousal when carbachol was applied to the lateral mesencephalic
RF.

They suggested that the mesencephalic arousing system is activated by

cholinergic influences, as well as adrenergic.

Cho et al. (1962) found that

the potent muscarinic compound, oxotremorine produced flaccid paralysis and
areflexia, associated with deep sleep, when injected into the brain stem RF
of conscious cats and dogs.

These effects could be antagonized by atropine

(IV, Il1 or by central microinjection).

A descending sleep system has been

I

postulated which follows the MB limbic circuit described by Nauta (1958)
(ie. the MFB from the preoptic region through the lateral hypothalamus into
the MB limbic area).

ACh injections into this circuit is followed by sleep,

while lesions or atropine injections made caudally to the ACh injection
suppress its sleep-inducing effect (Velutti and Hernandez-Peon, 1963).

Since

cholinoceptive neurons are present in the cortex, diencephalon, brain stem
and other areas, and some sites respond preferentially to muscarinic or
nicotinic compounds, the exact mechanisms of the EEG activation induced by
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cholinergic agents is uncertain.
Jasper and Tessier (1971) measured the rate of liberation of free ACh
from the surface of prostigmine treated cerebral cortex of freely moving cats
during sleep and arousal.

The rate of release was lowest during SWS and in-

creased during PS and waking, and seemed to be related to the EEG pattern,
rather than the behavior per

~·

Administration of hemicholinium (which

blocks ACh synthesis) into the lateral ventrical of cats, increased SWS, decreased waking and had no effect on PS (Domino and Stawiski, 1971).

A number

of studies have attempted to correlate brain ACh metabolism and the state of
arousal (cf. Jouvet, 1972b).

EEG arousal elicited by midpontine transection,

mesencephalic RF and septal stimulation via peripheral or central sensory
stimulation or by amphetamine is accompanied by an increase in ACh release at
the cortical level and a decrease in bound brain ACh.

Cortical synchroni-

zation from precollicular transection or physiological sleep is accompanied
by a decrease in the cortical release of free ACh and an increase in bound
ACh.

Barbiturate anesthesia further reduces ACh release (Kurokawa et al.,

1963).
Hanin et al. (1970) reported a diurnal variation of whole rat brain
ACh.

Peak concentrations occur at 1400 hours (2 hours into the light phase)

and trough between 2200-0600 hours, primarily in the dark, when rats are
awake.

These results are in line with the data cited above, showing that

arousal is accompanied by a decrease of bound ACh (and a release of cortical
ACh), while the reverse occurs during sleep.

Friedman and Walker (1972)

found that peak ACh levels of the rat MB and CN occurred at 2400 hours, while
whole mouse brain ACh levels peaked at 0600 hours.

Trough values occurred
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at 1200 hours in rat MB and 1800 hours for rat CN and mouse brain.

These

results differ from the Hanin study and Saito (1971), who found that whole
brain ACh content peaks at 6 hours in tie light and troughs throughout the
dark period.

These differences point to the complexity of the system and

the difficulty of demonstrating a clear-cut correlation between ACh levels
and the arousal state.

Additional aspects of circadian variation of

cholinergic function is discussed under the biological rhythms section.
Monnier and Herkert (1972) recently reported that the ACh concentration in hemodialysates of aroused rabbits (via RF stimulation) was
significantly greater than that from sleeping or sleep-resistant donors.
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£.

Sleep-wakefulness Phenomena
1.

Sleep Phenomenology
Berger (1930) discovered the electroencephalogram (EEG) and first

investigated its nature.

Numerous investigators have since studied the

changes occurring in the EEG, when subjects (human and animal) changed from
the alert, wakeful state to drowsiness, light sleep and deep sleep (as
measured by the arousal threshold).

Mauthner (1890) and von Economo (1926,

1929) were probably the first to express the idea that sleep was not passive
but an actively-induced, controlled phenomenon. Hess (1924) argued that sleep
is a vegatative function to be classified with such activities as respiration,
circulation, temperature regulation, etc.

He further stated that sleep was

not simply a state of quiescence but was accompanied by active physiological
processes, under control of the central and autonomic nervous systems.
The studies of Loomis and coworkers (1937, 1938) and Davis and coworkers (1938, 1939) revealed that in the transition from the resting awake
state (with its typical, more or less continous alpha waves

8-12 HZ) to deep

sleep, the human subject goes through typical stages, which they labelled A-E.
Stage A is characterized by an intermittent loss of alpha waves.

In stage B

the alpha pattern disappears completely and is replaced by a fast low voltage,
irregular pattern.

In stage C spindle-shaped bursts of 14 Hz are observed.

Slow (1.5-3 Hz) and finally very slow (0.6-1.5 Hz) delta waves characterize
stages D and E,respectively.

Brazier (1949) observed that during the tran-

Sition from the waking state to sleep, the locus of maximum EEG activity
shifts from the occipitoparietal towards the frontal region.

Some workers

also point out a characteristic pattern, the K-complex and sharp vertex spike,
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transient phenomena appearing in the sleep EEG either spontaneously or in
response to rhythmic sensory stimulation.
Derbyshire

~al.

(1936) and Klaue (1937) observed that states which

clinically appeared to be deep sleep contained occasional cortical EEG
desynchronizations.

Dement and Kleitman (1957) first studied this new kind

of sleep, referred to by Jouvet as paradoxical sleep (PS).

It is characterized

by a low voltage, fast cortical EEG pattern, hardly distinguishable from an
activated pattern.

It is accompanied by the appearance of theta waves (4-6

Hz) in the hippocampus and by spindles of 6-8 Hz in the pontine reticular
formation.

This stage is also known as rapid eye movement (REM) sleep,

desynchronized sleep, dream sleep, activated sleep and rhombencephalic sleep
(by Jouvet, who considered that it is probably organized by structures in the
rhombencephalon).

Subjects awakened during this period often recall dreams,

while they rarely recall dreams when awakened from the other sleep stages.
Certain characteristic phasic events of this sleep stage include, in addition
to the eye movements, muscular twitching, cardiorespiratory irregularities
and bursts of monophasic sharp waves from the pons, lateral geniculate nuclei,
occulomotor nuclei and visual cortices.

These PGO spikes seem to represent

some sort of primary triggering process for the phasic events, especially the
eye movements (Dement, 1970).
Dement and Kleitman (1957) suggested a relatively simplified classification of the various sleep stages, which has been adapted by many workers
in the field.

Stage 1 is characterized by "modified" alpha waves and cor-

responds to late stage A and stage B; stage 2, showing spindling with low
background is about equivalent to C; stage 3 is identified by delta waves
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and spindling; stage 4, containing slow waves only, is comparable to D and E.
They added a stage 1 REM or emerging stage 1 (from stage 2), which contains
rapid eye movements and a low voltage, fast EEG pattern.

Sometimes stages

1-4 are referred to collectively as non-REM (NREM) or slow wave sleep (SWS),
as opposed to REM sleep.

Rechtschaffen and Kales (1968) present precise

definitions of these states in the human, making it possible to classify any
20-30 second epoch into one of the NREM states, REM sleep or wakefulness.
In the older EEG terminology, the delta pattern (0.5-3.5 waves per second)
corresponds to stage 3 and 4; theta (4-7 waves per second) to stage 1 and 2;
alpha (8-13 waves per second) to awake but not visually stimulated and beta
(14-25 waves per second) to arousal.
A characteristic sign of sleep is the low level of muscular activity
probably related to the reduced reactivity of CNS structures involved in the
organization of motor output.

The electrical threshold of the motor cortex

is elevated during sleep in the monkey (Lilly et
(Hughes and Mazurowski, 1958).

~.,

1956) and the cat

Marchiafava and Pompeiano (1964) found the

flexor motor output produced by pyramidal tract stimulation to be reduced
with the onset of SWS and further decreased during low voltage fast sleep.
The complete inactivity of the neck muscles during PS is so characteristic
it is used to verify fast low voltage sleep.

As first observed by Tarchanoff

(1894), spinal reflexes such as the "knee jerk" are reduced and often missing
during sleep.

Giaquinto~

al. (1963) and Gassel et al. (1964) found that

cats with a motor nerve stimulator and monitored for EMP and EEG, spinal
relexes were only slightly affected during SWS, but during PS monosynaptic
reflexes were abolished.
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2.

Sleep Deprivation
Another approach to study sleep-wakefulness phenomena is sleep de-

privation and subsequent biochemical and neurophysiological examination for
induced changes.

There is a physiological need for sleep, since deprivation

can lead to malfunction, permanent damage and death.

Temporary sleep loss

is made up for by increased total sleep, by an increase in the length of the
various stages.

Extensive reviews of this subject have appeared (Wilkinson,

1961; Oswald, 1962; Kleitman, 1963).

Tyler (1955) found sleeplessness in

man (30-75 hours) produced symptoms resembling schizophrenia; i.e., instability, inattention, memory loss and hallucinations.

Rodin et al. (1962)

studied the EEG of human subjects deprived of sleep for as long as 120 hours
and found ''marked evidence of drowsiness" within 24 hours after the start of
the experiment.

Pieron (1913) found dogs deprived of sleep for 500 hours were

hyperirritable but in good condition.

Upon microscopic examination of the

prefrontal cortex of these animals, he found cell shrinkage, vacuolization
of cytoplasm and disappearance of Nissl substance.

The amount of damage was

proportional to the degree of sleep loss and was apparently reversible.

Stern

(1937) found that the blood-CSF barrier of dogs became more permeable after
prolonged sleep deprivation.
a.

PS Deprivation
Jouvet et al. (1964) selectively deprived chronically-implanted

cats of PS by placing them on small platforms surrounded by water.

Animals

that lapsed into PS, with muscle relaxation would fall into the water, and
soon learned to develop SWS without PS.

Although having the normal amount
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of slow sleep at the termination of the PS deprivation, animals were sleepy,
weak·and photophobic.

During recovery, PS periods were prolonged and occurred

at shorter intervals.

The recovery of cats deprived of PS by electrical

stimulation of the reticular formation when they lapsed into PS was studied
by Siegel and Gordon (1965).

They observed PS rebound during the first re-

covery day, in which PS occupied 53% of total sleep, versus only 33% on baseline days.
b.

Neurochemical Alterations After Sleep Deprivation
Pujol

~al.

(1968) reported that in rats, NE turnover is in-

creased during PS and decreased during PS deprivation.

In examining the

effect of pCPA on sleep, Torda (1967) found that 15 hours of PS deprivation
increased brain 5HT slightly but not significantly.

Tsuchiya et al. (1969)

found no change in telencephalon (TE), diencephalon (DE) and mesencephalonpons-medulla (MPM)
deprivation.
5HT decreased.

ACh, NE and 5HT content after 10 hours of total sleep

After 24 hours of deprivation TE ACh increased and DE

NE and

After 96 hours of PS deprivation TE ACh decreased, DE and MPM

NE content decreased but SHT did not change.

Stern et al. (1971) measured NE

and 5HT in the cerebral hemispheres, DE and brain stem of 1) PS-deprived rats
(3, 5, 6 and 8 days, without allowing recovery), 2) after 5 days of control
stress treatment and 3) in normal rats.

Amine levels in the three regions

were unchanged after 3-8 days of PS deprivation.

Pargyline (20 mg/kg, IP,

2.5-3.5 hours before sacrifice) after 5 days of PS deprivation or stress increased NE and 5HT over that of normals, suggesting their increased synthesis.
They concluded that the enhanced amine synthesis after PS deprivation might
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be due to non-specific stress, rather than loss of PS

--

~ ~·

Steinberg

et al. (1969) found that human urinary NE and Epi were elevated significantly
following 24 hours of sleep deprivation.

NM, MET and VMA were not changed

significantly.
Karadzic et al. (1971) examined free amino acids in frontal and
occipital cortex, CN, thalamus, hippocampus and mesencephalic RF in PSdeprived, normals and stressed cats.

Seven of eleven amino acids measured

in the brain changed significantly after deprivation.

Aspartic acid, cys-

teine, lysine, arginine and glycine increased significantly in several areas
and gaba and threonine were altered significantly in 4 out of 6 and 5 out of
6 areas, respectively.

Glutamic acid, serine, tyrosine and histidine were

not altered significantly.
3.

Drugs Acting on Sleep Stages
a.

Reserpine
In cats reserpine suppresses SWS 12-14 hours and PS for 22-24

hours which recovers after 5-6 days.

It selectively triggers PGO activity

(30-50 per minute) for 50-60 hours (Jouvet, 1967b).

The PGO activity is

similar to PGO activity of PS, but without the decrease in neck muscle tone.
5HTP (30-50 mg/kg), 2-3 hours after reserpine totally suppresses the PGO
activity and induces EEG and behavioral SWS for 4-6 hours.

The same dosage

of DOPA after reserpine increases PGO activity and an almost normal level of
PS and SWS is evident for 4-6 hours (Matsumoto and Jouvet, 1964).

This is

part of the evidence for Jouvet's theory (1967 a,b) that serotonergic mechanisms are responsible for SWS and CA mechanisms are involved in PS.

The

reserpine-induced PGO activity is enhanced by eserine, decreased by atropine
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(over 1.0 mg/kg) but totally suppressed by PB, imipramine, alpha-methyl DOPA
and MAOI (Delorme, 1966).
b.

MAO Inhibitors (MAOIS)
MAOis are potent PS suppressors (Jouvet et al., 1965), although

there is some species variation in the response to them.

Pargyline, niala-

mide, iproniazid and phenylisopropylhydrazine are selective PS suppressors.
PS is suppressed for 90-100 hours after nialamide (10 mg/kg) and a stepwise
recovery occurs without any rebound in about a week.

Nialamide can even

suppress PS after 72 hours of operational PS-deprivation.

In man after one

week of MAOI treatment, a progressive and significant reduction of PS
(Wyatt et al., 1969).

occurr~d

Karczmar et al. (1970) have demonstrated a pharmaco-

logical model of PS by giving eserine to reserpinized animals, which could
be abolished by atropine.
c.

a-Methyl-p-tyrosine (AMPT)
AMPT significantly increases PS in rats

Torda, 1968), cats (King and Jewett, 1971) and man
Baeklund and Lundwall, 1971).
it decreased PS in monkeys.

(Hartman~

(Wyatt~

al., 197la)

al., 197la;

On the other hand Weitzman et al. (1969) showed
a-methyl

~-tyrosine

(AMMT) or a-methyl DOPA

reduce PS and increase SWS (Jouvet, 1967b). a-methyl DOPA still reduces PS
after selective PS deprivation (Dusan -Peyrethon ~al., 1968)
d.

g-Chlorophenylalanine (pCPA)
A SHr depletor, pCPA, produces waking

b~havior

(Mouret et al.,

1967; Torda, 1967) and decreased both PS and SWS in cats (Delorme

et~.,
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1 966b; Koella et al., 1968 Karadzic, 1968;

Pujol~

al., 1971).

SIITP (10-SO

mg/kg) restores sleeping patterns to normal (Jouvet, 1968; Pujol et al.,
1971).

£-Chloromethamphetamine (lS-30 mg/kg), which also selectively de-

pletes SHT (Pletsdl:!r

~al.,

1964) induces a constant state of arousal for

16-18 hours, with recovery after 60 hours
e.

(Delorme~

al., 1966a).

Garrnna-butyrolactone
Jouvet et al. (1961) demonstrated the gamma-hydroxybutyrate (GHB)

and gamma-butyrolactone (GBL) at relatively low doses (SO mg/kg) induced both
types of sleep states (vide infra). The induction of PS was not observed in
the rat and was inconsistent in the normal cat (Marcus et al., 1967; Winters
and Spooner, 1966).
(Jouvet, 1972b).

GHB triggers PGO spikes and PS in chronic pontile cats

Matsuzake et al. (1964) demonstrated that the PS-triggering

action of short chain fatty acids was not limited to the C4 butyrate compounds
but was more pronounced with CS and C6 compounds.
pS

The C4 to C6 agents produce

in the decorticated, mesencephalic and pontile cats, but not in cats with

lesions of the pontine tegmentum (Jouvet et al., 1961) or after midpontine
transections (Tokizane, 1966).

After atropine (which suppresses the final

tonic phase of PS), GHB or GBL are still able to induce PS in pontile cats,
while after MAOI (nialamide) which blocks the first phase of PS (PGO activity)
short chain fatty acids are unable to induce PS
4.

(Delorme~

al., 196S).

Localization of "Sleep Centers"
Attempts to delineate a "sleep center" in the CNS have utilized

lesioning and electrical and chemical stimulation, coupled with neurophysiological recording to reveal neuronal pathways and/or nuclei which might be
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involved in the normal sleep-wakefulness cycle.

The effects of various CNS

lesions will first be examined, followed by an analysis of stimulation experiments and finally a discussion of attempts to find humeral sleep-inducing
factors.
a.

Lesion Experiments
Bremer (1936) demonstrated that transection of the spinal cord

....

at the first cervical vertebra (encephale isole preparation) resulted in an
alert animal with a desynchronized EEG.

Animals with a mesencephalic tran-

section at the level of the superior colliculus (cerveau isole) were stuporous and exhibited a synchronized EEG analagous to SWS.

He concluded this

state was due to exclusion of the bulbomesencephalic RF, assuming that in
natural sleep the RF is depressed and normal ascending, activating impulses
are reduced or eliminated.

He further stated that the functional depression

of the RF plays a major or even a primary role in curmnulative "defacilitation"
because of its central position in the arousal sequence.

Ranson (1939),

using lateral hypothalamic lesions, produced sleep in monkeys which lasted
4-8 days.

Sleep of short duration was produced by lesions in the rostral

hypothalamus or at the junction of the hypothalamus and thalamus.

He con-

eluded that sleep is a deviation from the waking state (deactivation) and
that wakefulness is largely dependent upon hypothalamic drives.

If sym-

pathetic discharge from the descending pathways of the posterior hypothalamus
is abolished, these waking drives are eliminated, producing sleep.

Large

bilateral lesions of the posterior hypothalamus in cats produced sleep lasting
several days (Rangstrom: 1947).
sensory stimuli.

Sleeping animals could be aroused by various

His conclusion was that the lesions destroyed a large

l

85

number of cells containing specific hyponogenic substances, which are transported to other brain areas, to produce sleep.

Villablanca (1962) observed

/

that in cerveau insole cats kept alive for 20-60 days the sleep-wakefulness
cycle (as measured by EEG and behavioral indices) was reestablished.

The

SWS during the first 10 postoperative days was attributed to surgical trauma.
This indicated that the waking state could be organized by structures rostral
to the lower MB.

Nauta (1946) found that bilateral transection of the hypo-

thalamus in or near the mammillary bodies or suprachiasmatic region produced sleep, while unilateral or bilateral medial or rostral hypothalamic
lesions did not alter the S-W cycle in the rat.

He concluded that lesions

which interrupt fiber bundles such as the Vicq d'Azyr and MFB interfere with
normal waking capacity.

These fibers are known to connect the mammillary

region with the anterior thalamic nuclei, the lateral hypothalamic area and
septal region.

He postulated an "intensive relay" of impulses from the

posterior hypothalamus ("waking center") through the lateral hypothalamus and
an active sleep center in the anterior hypothalamus.

"Since animals whose

mammillary and suprachiasmatic areas had been transected behaved like animals
with transections at the mammillary level only, he deduced that the sleep
center exerts an inhibitory influence on the waking center and not directly
on the cortex and other major parts of the nervous system.

Nauta suggested

that the impulses from the anterior sleep center are conveyed to the waking
center via the medial forebrain bundle.

The waking center, in turn, exerts

an activating influence upon the lateral hypothalamus and thence upon the
cortex, and inhibitory influence upon a hypothetical center 'L' for 'body
sleep'" (Koella, 1967, p. 102).
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Lesions of the basal forebrain (preoptic region, diagonal band of
Broca) in cats, reduced the time spent in the drowsy state, although the time
asleep was not altered

(Sterman~

al., 1964).

Batini et al. (1958) tran-

sected the rostral brain stern at the pons (rostropontine-pretrigerninal preparation), inducing permanent EEG and behavioral sleep.

From these experi-

ments Moruzzi (1960) concluded that the "entire reticular formation of the
midbrain with the support of the tonic sensory inflow which is likely to
occur through cranial nerves still connected to the cerebrum (I, II, III)
is by itself not adequate for maintaining a state of vigilence.

The phasic

aspect of EEG activation is still present, however, in the cat whose rnidbrain
is connected to the cerebrum; clear-cut EEG arousal is elicited in this
preparation, by olfactory stimuli."

Lesions slightly caudal (rnidpontine

pretigeminal) produce behavioral and EEG arousal.
biturate readily evoke slow waves and spindling.

However low doses of barIn light of this Moruzzi

(1960) states that"there is a region in the rostral part of the pons which
seems to be of critical importance for the maintenance of the EEG patterns
of wakefulness.

Since the classical sensory pathways are out both in the

prepontine and in the rnidpontine preparations, it would follow that the transection does not act by severing fibers from lower levels."
Hemisection of the MB at the superior colliculus or midcollicular
level produced slow waves and spindles in the ipsilateral cortex, which
gradually disappeared within 4-5 days (Cordeau and Mancia, 1959).

As such

patterns also occurred with the lateral sensory paths intact, they concluded that ascending activating influences from the lower brain stern travel
in two distinct paths to supply the two cortices.

Hodes (1963) had

similar
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findings with hemisection or unilateral procaine injections of the cord.
Jouvet et al. (1966) demonstrated in cats that an 80-90% destruction
of the raphe system (the medial SHT-containing neurons of the brain stem,
from the nucleus raphe abscurus to the caudal medulla) resulted in permanent
wakefulness.
reappear.

After 3-4 days very short periods of behavioral and EEG SWS

There was a correlation between the extent of destruction of the

raphe system, the decrease in cerebral SHT and the loss of sleep.
et al.
-

(1968) and Pujol et al. (1971) obtained similar results.

--

Kostowski
Lesions of

the pontine tegmentum selectively abolish PS without significantly impairing
either waking or SWS (Jouvet, 1962).

Histochemical methods show a dense

group of neurons high in NE content located in the area of the locus coeruleus.
Total destruction of the locus coeruleus causes complete PS-suppression
(Jouvet and Delorme, 1965) and produce a significant decrease of NE in the
brain rostral to the lesion (Roussel, 1967).

Control lesions nearby do not

affect sleep.
b.

Stimulation Experiments
Hess (1944, 1949) performed the pioneer studies on electrically-

evoked sleep using point by point stimulation of the entire DE and surrounding
areas of the rat brain.

Following repetitive stimulation via low voltage,

rounded DC pulses, cats exhibited reduced activity and other presomnic signs
(such as eyelids drooping, smaller pupils, lying down and curling up).
Soon after they appeared to be asleep.

He could reverse the sleep effect

with higher voltages and/or higher frequencies of stimulation.

In these

animals the electrode tips were in the thalamus, in the lower two-thirds of
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the massa intermedia, near the midline (medial thalamus).

Electrodes placed

in the surrounding area produced only "partial sleep", with depressed motor
activity.

These findings point to the specificity of the medial thalamic

area as a hypogenic site and the production of sleep at will, rather than
coincidently.

Hess' findings have since been confirmed by Akert and co-

workers (1950, 1952, 1953) who further showed a striking similarity between
the behavioral and EEG patterns after the electrical stimulation.
~al.

Akimoto

(1956) produced behavioral and EEG sleep in the dog with low voltage,

low frequency stimulation of the thalamus.

Monnier and coworkers (1950, 1963)

induced sleep by stimulation of the intralaminar thalamic nuclei of cats and
rabbits.

Low voltage and frequency were necessary, as higher frequencies and

voltages produced arousal.

Jouvet (1962) also reported sleep effects of low

frequency stimulation of the medial thalamic nuclei in cats.

Following low

voltage and low frequency stimulation of the hippocampus of the cat, Parmeggiani (1960, 1962) observed a number of presomnic signs.
~al.

Penaloza-Rojas

(1964) induced a sleep-like state by low frequency stimulation of

various areas of the cerebral cortex.

Sterman and Clemente (1962 a,b)

stimulated the preoptic area (basal forebrain) of freely-moving cats and
observed sleep, which included EEG spindling.
Moruzzi and Magoun (1949) demonstrated that the brain stem RF is
responsible for cortical and behavioral arousal through the ascending reticular activating system (ARAS).

The ARAS is composed of the brain stem core

from the medulla to the rostral part of the mesencephalon, with cortical
projections.

They could reproduce the electrocortical features of natural

wakefulness by stimulation of the ARAS as well as the classical specific
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afferent pathways, in the periphery of the brain stem.

The specific system

(medial and lateral fillets) ascends the stem outside the RF, and in addition
sends collaterals to the RF, which merge diffusely and tend to maintain the
activating tone of the ARAS.

The specific system is relatively-unaffected by

anesthetics, while the nonspecific RF is very sensitive, due to its polysynaptic organization (Larrabee and Posternak, 1952).

Favale

~al.

(1961)

similarly produced sleep in cats by stimulation of various areas of the brain
stem RF, such as the MB tegmentum and some nuclei of the medulla.

Jouvet

(1962) also reported sleep effects after stimulation of the MB RF of cats.
When he stimulated the pontine RF with low voltage stimuli at low frequency he
produced PS (lasting as long as 15 minutes).
arousal.

Strong stimuli usually produced

Caspers and Winkel (1954) produced behavioral and EEG sleep effects

after stimulation of the MB RF in the rat.

Magnes et al. (1961) in cats pro-

duced widespread cortical synchronization by low frequency stimulation near
the nucleus of the solitary tract.
Koella (1967) attempted to synthesize the results of lesion and stimulating experiments, to establish the structure of the sleep-controlling apparatus.

He concluded that all structures which upon stimulation yield sleep or

sleep-like signs constitute the "sleep center".

This heterogeneous structure

is made up of components which qualitatively and quantitatively subserve different functions.

Low rate stimulation of the nucleus of the solitary tract

produces cortical synchronization (Magnes

~al.,

1961), while lesions of this

area increase the effectiveness of arousal stimuli.

The authors interpret these

findings to mean that there is a two-way network connecting the solitary tract
nucleus with the ascending mesencephalic RF, forming a negative feedback
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system which limits phasic arousal.

Koella considers the bulbar synchroniz-

ing structures a sleep-facilitating apparatus, acting via inhibitory influences on the activating or arousal system, in a subordinate capacity.

It

is responsible for short, phasic sleep, rather than long, tonic periods of
sleep.

Similarly, the MB RF is important for short, phasic periods of

awakening.

Reduction of the ascending, activating influence therefore,

results in sleep.

Lesions in this area produce semi-permanent sleep in the

TE and behavioral sleep signs.

Stimulation in this area might activate in-

hibitory pathways, which have been shown to have inputs into the RF from the
lower brain stem, thalamus and cerebral cortex.

Koella considers the basal

forebrain, including the anterior hypothalamus, as another subordinate controlling structure.

Waldvogel (1945) elicited yawning by stimulation of the

area between the anterior commissure and infundibulum.

Parmeggiani (1962)

evoked many presomnic signs in the cat by hippocampal stimulation and occasionally produced light sleep.

The pons seems to control a phase of sleep, but

acts only when slow sleep is already present.

Stimulation of the tegmentum

also produces sleep signs for a short duration.
Koella concludes from various lines of experimental evidence that the
thalamic hypnogenic area qualifies as the "head ganglion" of sleep.

Thalamic

stimulation produces sleep of long duration, preceded by presomnic signs.
type of sleep includes PS episodes seen in normal sleep.

This

After repeated stimu-

lation it becomes progressively easier to reinduce sleep after awakening.

Lower

voltages are needed to produce sleep in the thalamus than in other areas such
as the lower brain stem and hypothalamus.

The recruiting response, best

elicited by low-rate stimulation of the midline thalamus, closely resembles
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to sleep spindles.

The thalamic-induced recruiting response can be recorded

in the MB RF (as well as the cortex), suggesting a thalamo-reticular pathway,
which might also convey inhibitory impulses to the ascending activating
system, as previously mentioned.
c.

Humoral Sleep Factors
1)

Cerebrospinal Fluid (CSF)
Early studies related to an active induction of sleep en-

visioned a humoral factor primarily responsible for the induction of sleep.
Legendre and Pieron (1910, 1911) sleep-deprived dogs for as long as 18 days,
withdrew some of their CSF and injected it into the fourth ventricle of nonfatigued dogs, which promptly showed signs of drowsiness and sleep for 2-6
hours.

Dogs treated with CSF from non-fatigued animals remained alert.

Schnedorf and Ivy (1939) confirmed these basic findings but emphasized that
the central "depressing" effects of the injection was in part due to concomitant elevation of intracranial pressure and to hyperthermia, which usually
followed the intracisternal injection.

They attempted without success to

detect ACh in the CSF.
Pappenheimer et al. (1967) studied the perfusate from sleep-deprived
goats whose ventricular systems were cannulated.

When injected into the

ventricular system of cats and rats, the perfusate induced signs of sleep
(inactivity) lasting up to 18 hours, while there was no change in the activity
of animals receiving CSF from non-sleep-deprived animals.
the recipient animals have been reported.

No EEG studies of

The factor responsible for the

inactivity has not yet been identified, but it has been reported to be dialy-
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zable (moelcular weight under 1000-2000).

Ringle and Herndon (1969) made

some unsuccessful attempts to induce sleep in rats with CSF from sleepdeprived rats.
Drucker-Colin et al. (1970) perfused sleep-deprived cats via pushpull cannulae inserted in the MB RF.

The outgoing perfusate from the cats

during the PS-rebound induced sleep in recipent cats when injected through
the push-pull cannulae inserted in their midbrains.
2)

Plasma
Demole (1927) observed that blood calcium was decreased during

sleep and predicted that brain calcium would increase during sleep.

He in-

jected several microliters containing 0.25-2 mg of CaCl2 into the infundibular
and tuber cinereum region of the hypothalamus, producing sleep after several
hours latency.

Other areas of the hypothalamus and other brain structures

were unresponsive.
these results.

Koella (1967) cites several other studies which confinned

Cloetta et al. (1934) found calcillln to be increased during

sleep, particularly in the infundibular region.

These findings suggest that

a shift of calcium from the blood to certain parts of the brain stem might be
an important hypnogenic factor.

The mechanism of this shift is unknown but

it might be due to an increased permeability of limiting membranes, as indicated by Stern (1937).
Purpura (1956) utilized a cross circulation arrangement in cats and
showed that 30-80 seconds after arousal was produced by reticular stimulation
in the "donor" animal, it occurred in the non-stimulated recipent cat.
order to test for sleep-inducing factors in the blood, Kornnuller

~al.

In
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(1961) and Monnier, Koller and Graber (1963) used the crossed blood circulation technique in cats and rabbits, respectively.

Stimulation of the medio-

central intralaminary thalamus of the donor induces a significant increase in
cortical waves.

Both groups observed that after a delay of less than a

minute the recipient shows a statistically significant increase in cortical
slow activity (usually after the fourth stimulation of the thalamus).

On

the other hand, stimulation of the MB RF, which induces arousal in the donor,
significantly reduces cortical slow waves in the recipient.

These results

suggest that hypnogenic and alerting substances may be transported in the
plasma and can change the state of consciousness of recipient animals.
Monnier and Hosli (1964, 1965) demonstrated that a dialysate of cerebral
blood from rabbits during sleep induced by electrical stimulation of the
thalamus, when injected into recipient rabbits produced EEG evidence of sleep.
Recipients receiving a dialysate from non-stimulated control rabbits had
waking patterns.

They excluded changes in visceral activities (blood pres-

sure, heart rate respiration and body temperature), electrolyte concentration
and pH.

The dialysis techniques indicated that the active substances were of

low molecular weight.

Comparisons between the "sleep dialysate" and other

pharmacological substances indicated that its effects generally resembled
those of chlopromazine and substance P.

Apparently the sleep dialysate

factor obtained from the rabbit is active only after electrically-induced
sleep, since Ringle and Herndon (1968) failed to show any sleep-promoting
effects from the reconstituted plasma dialysates from 72 hours sleep-deprived
rabbits, in recipient rabbits, rats or mice.

The fact that a blood perfusate

can induce sleep only after stimulation of the thalamus, but not when taken
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from sleep-deprived rabbits shows that it is necessary to differentiate between
electrically-induced sleep, normal sleep and the condition produced by prolonged sleep deprivation.

Hypnogenic factors released under these conditions

are not necessarily related to substances which are produced during and induce or facilitate the onset of normal sleep.
£er

~

On the other hand, the thalamus

is not involved in the sleep mechanism, since its total destruction

does not significantly alter the sleep-waking cycle (Angeleri et al., 1969).
Finally, the fact that Siamese twins, sharing the same blood circulation, may
sleep independently (Alckseyeve, 19S8) makes it unlikely that sleep depends
exclusively upon blood-borne factors.
3)

Neurohtnnors
The studies of Koella and Czicman (1966) reported that intra-

carotid SHI produced an initial brief arousal followed by a prolonged phase
of hypersynchrony, presumably acting on the area postrema.

This stimulating

effect is transmitted to the neurons in the solitary tract nucleus, which has
beenruown by Moruzzi (1960) to have hypersynchronizing properties.

pCPA

depletes brain SHI, by inhibiting its synthesis and produces insomnia in the
cat, which develops and recovers following the time course of brain SHI
content (Jouvet, 1969).

SHIP, the SHI precursor, restores sleep to the normal

pattern for 10-12 hours when given at the peak of the pCPA effect.

In

addition, Pujol et al. (1971) and others have shown that lesions of the raphe
system deplete brain SHI and induce permanent arousal.

Matstnnoto and Jouvet

(1964) found that reserpine produced insomnia in the cat; eliminating SWS for
days and PS for 2-4 days.

SHIP restored SWS innnediately without PS while DOPA

restored PS, indicating SHI was involved in SWS, while CAs were necessary for
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pS.

Feldberg and Sherwood (1954) injected NE and Epi into the lateral ventri-

cle of chronically-prepared cats, producing a sleep-like state after 20
minutes that lasted about 3 hours.

Others have demonstrated alerting actions

of NE (Torda, 1968; Cordeau et al., 1971).

The case for NE in sleep pheno-

mena therefore, is less clear than for SHT.
Sharpless and Rothballer (1961) and Soderberg (1962) have shown that
stimulation of the RF may release a blood factor with an activity similar to
vasopressin.

Other studies have shown that stimulation of monoamine bundles

or terminals might release monoamines (McLennan, 1964; Stein and Wise, 1969;
Arbuthnott et al., 1970)

or monoamine metabolites which might be eliminated

either in the blood or CSF, where they could act on other (unknown) brain
areas.

Jouvet (1972b) points out that central "hypnogenic" stimulation or

sleep deprivation might release a greater amount of transmitters or metabolites than physiological sleep.
The daily fluctuations of brain biogenic amines are discussed in
detail under the Biological rhythm section but it is appropriate that these
changes are briefly mentioned here.

In newborn rats, which have not yet

acquired a circadian rhythm of sleep there is no alteration of brain SHT
(Okada, 1971), while in the adult rat, with a well-established sleep cycle,
there is a significant increase in endogenous brain SHT during the day (when
these nocturnal animals sleep) and a decrease during the night (Dixit and
Buckley, 1967; Friedman and Walker, 1968).

The latter investigators found a

reversedpittern for MB and CN NE content, suggesting that this amine might
have a waking role.
Cordeau

~al.

This is supported by the work of Torda (1968) and

(1971).

Jouany

~al.

(1960) have shown that GHB induces sleep which is not

distinguishable from natural sleep.
anesthesia.

At higher doses the effect resembles

Bessman and Fishbein (1963) have shown that GHB occurs in the

rat and human brain, where it is derived from GABA.
Kroll (1933) prepared water extracts from brains of sleeping cats and
rabbits and injected them intraventricularly or intracisternally into waking
cats and rabbits.

The donor animals had been put to "sleep" by intraventri-

cular injection of cacl 2 , by Pernocton (butallylonal) or by electrosleep
(Passing a current longitudinally through the head).

Recipient animals

promptly slept when treated with the brain extracts from "sleeping" animals,
while recipients of extracts from waking donors did not sleep.

Kroll also

demonstrated that brain extracts from hibernating hamsters and porcupines
induced sleep in cats for several days (but not in monkeys).

There were

several uncertainities in these experiments, such as the possibility that the
extracts might contain sufficient Pernocton or CaCl2 to induce sleep or that
the electrical current might produce electronarcosis rather than sleep.
Hunter and Rigal (1966) reported that plasma human growth hormone (HGH)
was elevated during the night.

Quabbe

~al.

(1966) suggested that nocturnal

peaks of HGH might occur preferentially during periods of deeper sleep.
Takahashi

~al

(1968) found that a plasma HGH peak appeared at the onset

of deep EEG sleep and smaller peaks appeared during subsequent deep sleep
phases.

If sleep was delayed or interrupted, the HGH peak also shifted.

Peak

HGH secretion was not correlated with changes in plasma glucose, insulin or
cortisol.

Honda~

al. (1969) obtained similar results and suggested that

secretion is inhibited during PS while SWS increases HGH secretion by
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stimulating the secretion of hypothalamic HGH releasing factor.

Sassin et al.

(1969) supported this conclusion and demonstrated that reversal of the sleepwake cycle was accompanied by a concomitant plasma HGH pattern reversal,
perhaps both due to the same neural mechanism.
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f.

Barbiturates
Barbiturates belong to the general class of hypnotic-sedatives.

These

agents are general depressants, depressing a wide range of cellular functions
in many organ systems.

The type compound, barbituric acid, first synthesized

from urea and malonic acid by von Baeyer, is not a central depressant.

The

derivatives of barbituric acid obtained by replacing the two hydrogens on the

cs

position by alkyl or aryl groups are called barbiturates and frequently

have hypnotic potency.

In 1903, Fischer and von Mering introduced diethyl-

barbituric acid (barbital), to medicinal use.
1.

Distribution
In general, structural changes resulting in increased lipid solu-

bility are associated with a decreased duration of action, a decrease in
latency to onset of activity, more rapid metabolic degradation and often
increased hypnotic potency.

Barbituric acid derivatives with only one sub-

stituent group are without central depressant activity and the dimethyl or
ethylmethyl derivatives are very weak.

Barbiturates with an ethyl group and

a longer chain are more potent than barbital, but when the chain length
exceeds 4 or 5 carbons, activity decreases.
is well stated by Goodman and Gilman (1970):

The present use of barbiturates
II

more than 2500 barbitur-

ates were synthesized, many were carefully studied pharmacologically, and
approximately 50 were marketed for clinical use.

Today, a dozen or so bar-

biturates are widely used; of these, five or six would probably be sufficient
to meet most therapeutic needs."
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A number of factors, both physiochemical and physiological influence
the hypnotic or anesthetic potency of barbiturates.

Some of the former in-

clude water solubility, ionization, distribution between water and lipids,
rate of entry into the brain compared with other tissues, protein binding,
volume of distribution in the body and rates of metabolism and excretion.
There is no impenetrable barrier to barbiturate diffusion, so if the drug is
in the plasma long enough, it is distributed to all tissues and fluids,
including the fetal circulation, since it crosses the placental barrier.
a.

Physiochemical Factors
In their undissociated form, the barbiturates have a rather high

affinity for non-polar solvents, which correlates with their pharmacological
properties.

The more highly lipid soluble compounds are short-acting agents,

with a rapid onset of action.

A fraction of the barbiturate is reversibly-

bound to plasma proteins, chiefly albumin (Goldbaum and Smith, 1954).

Pro-

tein binding appears to depend on the same structural features that determines
affinity for non-polar solvents.

With the exception of body fat, the capacity

of tissues to concentrate barbiturates depends largely on protein binding.
Fat depots can contain very high concentrations of the ultrashort acting
barbiturates which possess high lipid solubility.

Highly lipid-soluble drugs,

such as thiopental, reach maximum concentrations in the brain within two or
three passages of the blood.

During the first few minutes after injection,

thiopental is found in highest concentration in the brain areas that have the
greatest blood flow (cortex, geniculate bodies and colliculi).

On the other

hand, barbital and phenobarbital, with low partition coefficients, penetrate
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the BBB slowly, and 15 minutes or more might be needed for sleep induction
after IV injection, but they have a longer duration of action.

Regional

differences in brain blood flow have little effect on the distribution of
slowly-penetrating agents.

If the alkalinity of the plasma is increased,

as after hyperventilation or by infusion of sodium bicarbonate solution,
the plasma concentration of the undissociated, lipid-soluble form of the
drug falls.

This results in the outward flux of the drug from tissue to

plasma, lightening anesthesia because brain concentrations of the drug are
decreased.
b.

Physiological Factors
Differences in barbiturate metabolism have been shown among

species (Quinn et al., 1958) and strains (Vessell, 1968a, b).
varies with age, especially between the adult and newborn.

Metabolism

In the latter,

liver metabolizing enzymes are lacking (Jondorf et al., 1958).
fluences, such as deficiencies

(Conney~

Dietary in-

al., 1961) and fasting, both solids

(Dixon et al., 1960) and liquids (Borcelleca and Manthei, 1957) alter drug
metabolism.

The differences in drug metabolism between sexes has been shown

in the rat to be due to the influence of sex hormones
Rennner 1958a).

(Quinn~

al., 1958;

The pharmacological action of HB is prolonged after adrena-

lectomy (Rennner, 1958a, b) but decreased after thyroxin pretreatment (Conney
and Garren, 1961).

Barbiturate metabolism is altered by such pathological

states as the presence of tumors (Rosso et al., 1968), liver disease (see
below, under Metabolism), CNS lesions (Nair et al., 1970; Kostowski and
Dolfini, 1969) or X-irradiation (Nair and Zeitlin, 1967).

Other drugs can
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alter barbiturate response

through inhibition or stimulation of metabolism

(see below) or pharmacological antagonism or potentiation.

Changes in

ambient temperature can alter the rate of barbiturate metabolism and its
pharmacological effects (see below).
2.

Termination of Activity and Metabolism
Three processes are responsible for termination of the central

depressant actions of barbiturates:
degradation and renal excretion.

physical redistribution, metabolic

These tend to decrease plasma concentration,

resulting in a withdrawal of the drug from its CNS site(s) of action.

Physical

redistribution plays an especially-important role for the highly lipid soluble,
ultrashort acting compounds like thiopental.

The rapid emergence from hyp-

nosis occurs as the barbiturate shifts from the brain to other tissue compartments (Areas of high blood flow such as the brain, exhibit maximum drug
concentrations within minutes, while areas with lessor blood flow, such as
muscle and fat, require much longer periods to become saturated.)

Thus as

these tissues slowly take up the drug, plasma concentration drops, causing
the outward diffusion from the brain and subsequent loss of anesthesia, even
though very little drug is metabolized,
Many barbiturates are transformed to inactive metabolites in the
liver.

Their metabolites are usually less lipid soluble, more polar and more

water soluble, factors which tend to increase their renal excretion.

Metabo-

lism is usually via oxidation of the side chains in position 5, although ethyl
groups are resistant, so barbital is excreted almost unchanged.

The reaction

occurs in vitro in the microsomal fraction of liver homogenates, requiring
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molecular oxygen and NADPH, to form an epoxide, which is hydroxylated to the
glycol.

Secondary reactions such as oxidation of primary or secondary

alcohols to carboxylic acids or ketones are carried out by enzyme in the
nonparticulate fraction of liver homogenates.

These products may appear

in the urine as free compounds or the glucoronic acid conjugates.

N-alkyl

barbiturates may be converted to active metabolites by oxidation, such as
metharbital and mephobarbital forming barbital and phenobarbital, respectively.

In addition, desulfuration of thiobarbiturates and ring cleavage occur

to a very small extent.

Only barbital is primarily dependant upon renal

excretion, although as much as 30/o of phenobarbital, diallylbarbituric acid
and aprobarbituric acid may be excreted unchanged by the kidney.
Since barbiturates are metabolized primarily in the liver, it is
important to know whether they and other drugs have hepatotoxic effects.
In normal sugjects, hypnotic doses of barbiturates do not alter the results
of any of the usual clinical tests of hepatic function.

The large doses

ingested daily by barbiturate addicts do not injure the liver in any detectable way.

Even in patients with severe liver disease, the tests reveal no

deleterious changes (Sessions

et~.,

1954).

The barbiturates do not dis-

appear less rapidly from the blood than in normal individuals.

Experimental

animals with a large portion of the liver removed surgically or severely
damaged by carbon tetrachloride do sleep longer than normal controls after
the administration of most barbiturates.

Other drugs, such as SKF S2SA and

JB 516, specifically inhibit the liver microsomal metabolizing system and
greatly enhance most barbiturate hypnosis.

In experimental animals, nutri-

tional deficiencies, diabetes and obstructive jaundice can prolong the action
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of barbiturates.

Stress can prolong barbiturate action, possibly due to

adrenocortical action on hepatic drug metabolizing enzymes.
Of great importance is the fact that barbiturates can induce the
enzymes responsible for their own metabolism.

All barbiturates are not

equally effective in this respect; phenobarbital has a very prominent action,
while HB is quite weak.

This accounts, in part, for the development of

tolerance (and cross tolerance) to barbiturates.

This phenomena can even be

seen on the ultrastructural level in the liver, in terms of greatly increased
amounts of endoplasmic reticulum (which contains the degradative enzymes)
after only several doses of the barbiturate (Chedid and Nair, 1972).

In

addition, the barbiturates stimulate the production of enzymes responsible
for metabolizing many other drugs, such as that of the coumarin anticoagulants.
Barbital, which is not metabolized by the liver (and whose effects therefore
are not prolonged by severe liver injury as mentioned above or environmental
temperature changes as mentioned below), markedly enhances the enzyme activity
responsible for metabolizing other barbiturates.
In vitro study of drug metabolism by microsomal enzyme has shown that
a narrow temperature range is imperative to retain enzyme activity (+37°C.
for rat liver; Leadbeater and Davies, 1964).

Rink~

al. (1956) found that

in the isolated perfused rat liver a temperature fall from +37° to +24°C.
extended the half-life of thiopental from 46 minutes to 537 minutes.
equally important for in vivo experiments.

This is

The response produced by the drug

should be correlated with body temperature, and one should consider the influence that alters physiological temperature regulation.

Barbiturates

render most laboratory animals almost poikilothermic, since these drugs
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paralyze temperature regulation (Fuhrman, 1947).

Sotaniemi (1967) sunnnarizes

several studies related to temperature and barbiturate metabolism and concludes "that the duration of sleep produced by short-acting barbiturates was
extended in cold environment, whereas no similar prolongation of sleep was
noted with long-acting barbiturates, such as barbital and phenobarbital".
3.

Central Effects
Barbiturates are similar to the gaseous anesthetics in producing all

degrees of CNS depression, ranging from mild sedation to coma and death.

The

degree of depression depends on the particular compound, dose, route of administration, certain physiological factors (see above), the degree of CNS
excitability and previous experience with drugs which might alter metabolism.
The principal use of barbiturates is the production of sleep.

In

controlled studies, they shorten the average time of onset to sleep and
lengthen the duration of sleep (Lasagna, 1956).

Superficially barbiturate-

induced sleep resembles physiological sleep, but, as should be apparent by
now, normal sleep is extremely complex, and drug-induced sleep adds further
to this complexity.

In some individuals, small doses of barbiturates may

produce excitement instead of sedation, probably because of an action similar
to what is seen with ethanol intake; ie. by selective depression of inhibition.
Subtle distortions of mood and impairment of judgement, vigilance, fine and
gross motor movements and auditory discrimination can occur after barbiturate
administration and can persist for many hours beyond the hypnotic effects.
Some of these effects might be due to brain or plasma levels of metabolites,
which are usually without effect but do remain in the body long after the
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parent drug concentration has fallen to low levels.
a.

EEG Effects
Small doses of barbiturates increase the high frequency EEG (15-

35 Hz), producing "barbiturate activation", which appears first in the frontal
cortex and then spreads to the parietal and occipital cortex.

It is accom-

panied by clouding of consciousness and occasionally euphoria.

As the dose

is increased, large amplitude, random slow waves (2-8 Hz) similar to those
occurring during normal sleep appear and consciousness is lost, although
response to strong, painful stimuli is retained.

Higher doses further de-

crease the amplitude with occasional brief periods of electrical silence--the "burst suppression" pattern.

The periods of electrical activity disap-

pears, a pattern similar to the depression produced by volatile anesthetics.
The EEG during barbiturate-induced sleep resembles normal sleep except for
the occasional bursts of spindles (14 Hz) and REM episodes, often preceded
by several seconds of "saw tooth" waves (2-3 Hz).

During the regular ad-

ministration of barbiturates, the amount of REM sleep per night is reduced
at first, but gradually returns to normal, as tolerance to the REM-suppression
develops.

When the drug is discontinued, there is a rebound increase in REM

sleep and irregularities in REM sleep may continue for many nights.

b.

CNS Excitability
In anesthetic doses, all barbiturates are effective antidotes to

convulsant drugs and are capable of suppressing convulsions of strychnine
poisoning, tetanus and status epilepticus.

Phenobarbital has a selective

anticonvulsant action, making it useful for symptomatic prevention of

r
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epileptic seizures, especially of the grand mal type.

Unlike other barbitu-

rates, in anesthetic doses it completely abolishes the electrical excitability
of the monkey motor cortex.

In smaller doses, in most structures it elevates

the threshold for minimal motor response and initiation of an afterdischarge
shortens the duration of the afterdischarge and prolongs the recovery time for
convulsive capacity.
c.

Analgesia
Barbiturates, unlike the volatile anesthetics, lack significant

ability to obtund pain in doses not impairing consciousness.

Any analgetic

effects are probably due to reduction of the psychic phase of the pain,
rather than to a changed perception of pain.

Ultrashort barbiturates such

as thiopental, RB and methoxital are conunonly injected IV to induce or sustain
surgical anesthesia; to supplement inhalation anesthetics.

They provide a

rapid and pleasant induction, absence of salivation and reduce post-anesthetic
excitement and vomiting.
d.

Respiration
Barbiturates are respiratory depressants, affecting the drive to

respiration and the rhythmic respiratory movements.

These drives include that

of the respiratory centers in the medullary and pontine RAS (neurogenic), a
chemical drive, dependent on PC02 and arterial and CSF pH and a hypoxic drive.
In the waking state approximately two-thirds of normal ventilation is due to
the neurogenic drive.

Sleep induced by hypnotic doses of barbiturates in-

volves no more respiratory depression than occurs in normal sleep.

With

higher doses the neurogenic drive is first affected, leaving the direct
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action of COz and hydrogen ions on the respiratory centers, which also is
lost as the dose is increased further.

Death from barbiturate poisoning is

usually attributed to respiratory failure by direct paralysis of the medullary respiratory center.

The neural elements controlling muscles for

respiration are resistant to barbiturates and can continue to discharge
after other rhythmic activity has ceased.

Analeptics, such picrotoxin and

pentylenetetrazol stimulate respiration either by resensitizing the medullary
center to
4.

co 2

or acting directly on the center.

Peripheral Effects on Barbiturates
a.

Cardiovascular (CV)
In sedative or hypnotic doses barbiturates do not produce signi-

ficant CV effects, except for a slight decrease in blood pressure and heart
rate and a slight increase in cerebral blood flow, such as occur in normal
sleep or in a recumbent position.

Larger or IV doses produce a marked

hypotension for several minutes in normals and hypertensives.

Doses large

enough to cause anesthesia generally produce a sustained decrease in the
mean arterial and pulse pressure.
the tendency is for an increase.

The action or heart rate is variable, but
In high doses barbiturates can exert

direct effects on cardiac and vascular musculature, such as reducing contractile force.

Cardiac output may be reduced, probably due to blood

redistribution into the splanchnic bed and extremeties.

The important

circulatory effect of barbiturates comes from their central depressing influence on vasomotor tone and control.

Barbiturates do not sensitize the

heart to Epi and are beneficial in reducing irregularities produced by
cyclopropane.
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b.

Gastrointestinal (GI}
The oxybarbiturates tend to decrease GI tone and the amplitude

of the rhythmic contractions.

Hypnotic doses decrease colon and small in-

testine motility and increase the motility but decrease emptying time of
the stomach, similar to that during normal sleep.
juice secretion is reduced.

Gastric and pancreatic

In vitro barbiturates depress intestinal loop

activity and reduce histamine-stimulated secretion in gastric pouches.
c.

Urogenital
Hypnotic doses of barbiturates have only slight effects on

urinary excretion, possibly due to sleep alone.

In adults anesthetic doses

decrease glomerular filtration rate, urine flow and electrolyte excretion.
Large doses depress the tone and contractility of the ureters and urinary
bladder.

The uterus is resistant to barbiturates and hypnotic doses do not

significantly impair uterine activity during labor, however anesthetic doses
do decrease the force and frequency of uterine contractions and since they
cross the placental barrier, may impair the infants' respiration.
5.

Mode and Sites of Action
As general depressants, barbiturates depress the activity of nerves

skeletal, smooth and cardiac muscle and reduce tissue oxygen consumption, as
well as respiration of cell-free preparations of liver and brain mitochondria.
These effects require a wide range of concentrations, generally higher than
those necessary to produce CNS depression and it is unlikely that a conunon
mechanism is involved.
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a. Biochemical Effects
During barbiturate anesthesia there is a decrease in energyyielding reactions in the brain; oxygen uptake and lactate and heat production are decreased.

Certain barbiturates have been shown to depress

uptake of inorganic phosphate in mitochondrial preparations with only a
slight decrease in oxygen uptake, therefore it has been suggested that this
"uncoupling" of phosphorylation from oxidation might be responsible for their
depressant effects.

Unfortunately not all barbiturates produce this un-

coupling and some compounds which do are not hypnotics (eg. salicylates).
In vivo effects include a decrease in the level of brain inorganic phosphate,
an increase incorporation of phosphate into ATP and an increase in the level
of phosphocreatine.

These results suggest that the depression of oxygen

consumption is due to reduced neuronal activity (Jenkins, 1969, p. 239).
Doses of barbiturates which cause sedation without loss of consciousness are without effect on cerebral circulation or metabolism (Kety et al.,
1948).

However larger doses always decrease cerebral oxygen consumption,

with variable effects on blood flow.

It seems that barbiturates exhibit no

direct action on cerebral vasculature and changes are secondary to other
effects.
b.

Neurophysiological Effects
It is generally believed that the synapse is the site of action

of hypnotic compounds, since chemical transmission is more susceptible to
interference by barbiturates than is conduction along nerve or muscle fibers.
At skeletal neuromuscular junctions barbiturates render the postsynaptic
membrane insensitive to the depolarizing effects of ACh (Thesleff, 1956).

,
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Barbiturates enhance the neuromuscular blocking effects of d-tubocurarine
and decamethonium.

The response of intestinal smooth muscle and certain

neuroeffector organs, such as the submaxillary gland, to ACh and other
spasmogenic agents is reduced by barbiturates.

Little work has been done

on the effect of barbiturates on adrenergic junctions, but some barbiturates
may cause presynaptic liberation of transmitter.

Barbiturates selectively

depress sympathetic ganglia transmission in concentration without effect on
nerve conduction, junctions or smooth muscle (Exley, 1954).

The response of

ganglion cells to preganglionic stimulation and choline esters is diminished
by barbiturates, but they are not depolarized and respond to potassium
chloride.

Transmission is severely impaired by doses that do not prevent

the release of ACh from preganglionic endings, although high doses of barbiturates may also reduce the efflux of ACh from stimulated fibers.

This effect

might account for the fall in blood pressure produced by some barbiturates.
Using intracellular recording techniques, the monosynaptic EPSP has
been shown to be depressed by barbiturates in concentrations that have no
effect on resting transmembrane potentials or the electrical properties of
the membrane, probably by decreasing the release
et al., 1964).

of transmitter (L0yning

Polysynaptic pathways are somewhat more susceptible to

barbiturates than monosynaptic reflexes (Wikler, 1945) but this cannot
account for their hypnotic effects, since more selective polysynaptic depressants (eg. mephanesin) have little hypnotic effect.
Barbiturates have some local anesthetic action, increasing the
threshold to electrical stimulation, reducing the amplitude of the spike
potential and negative afterpotential, prolonging the relative and absolute
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refractory periods and slowing conduction velocity (Heinbecker and Bartley,

1940).

Large doses elevate the threshold for sensory stimulation.

Schoepfle

(1957) demonstrated that a solution of thiopental was five times more potent
than equivalent amounts of procaine in rendering single fibers of frog
sciatic nerves completely inexcitable with little or no effect on resting
membrane potential or transmembrane

resistance.

In lobster axons, barbitu-

rates reduce the maximum sodium and potassium transmembrane conductance and
slow the rate of onset of sodium conductance after small depolarizing
potentials.
c.

Reticular Activating System (RAS)
Although attempts have been made to localize the action of bar-

biturates to certain gross regions of the brain stem, such as the MB tegmentum or hypothalamus, drugs of this class apparently act at all levels of the
nervous system.

Nevertheless, the complex RF is exquisitely sensitive to the

depressant effects of the barbiturates and other anesthetic agents.

Whatever

their effects elsewhere in the nervous system, it is the effect on the
reticular system that seems to be responsible for the inability to maintain
wakefulness under the influence of barbiturates.

The present view of the

importance of the RF in drug-induced sleep is based on a large body of evidence accumulated since the pioneering work of Moruzzi and Magoun (1949)
(see review by Killam, 1962).

In doses that only slightly affect transmission

in the primary sensory pathways, barbiturates increase the threshold of the
RF to direct electrical stimulation and depress the potentials evoked in the
system by a variety of sensory stimuli.

Lesions in the MB RF can reproduce
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the characteristic EEG of barbiturate-induced sleep, while lesions of the
primary sensory pathways do not.
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G·

Gannna-butyrolactone
1.

Sedative Actions.
The sedative or hypnotic activity of short chain fatty acids (from

c2 to ClO) was studied by several investigators (Samson and Dahl, 1955;
White and Samson, 1956;

Holm~vist

and Ingvar, 1957) before the introduction

of modern techniques of continuous EEG recordings.

Primary interest has

since focused on two C4 compounds, ganuna-hydroxybutyrate (GHB) and gannnabutyrolactone (GBL), a cyclic form that is converted to GHB by the action
of a liver and plasma lactonase (Roth and Giarman, 1966; see Fig. 4

).

Jouany et al., (1960) who observed that low doses of butyric acid produced
sleep and higher doses, anesthesia, were subsequently prompted to examine
the action of the derivatives, GHB and GBL.

Benda and Perles (1960) and

Laborit et al. (1960) examined the EEG and physiological responses after GBL
and GHB.

They observed sleep-like states and anticonvulsant activity, as well

as general anesthesia at higher doses.

After a short latency, 50 mg/kg of

GBL or GHB induce both states of sleep and a secondary increase in PS (Jouvet
~al.,

1961).

The induction of PS was inconsistently found in the normal

cat and was not observed in the rat (Marcus
1965 ).

~al.,

1967; Winters and Spooner,

CS and C6 compounds are even more effective than the C4 agents in

triggering PS (Matsuzaki et al., 1964; Delorme et al., 1966a).

In decorti-

cate, mesencephalic or pontile cats, PS can always be induced almost inunediately after IV injection, provided the compound is injected after the absolute
refractory period (of 10-15 minutes) following the last PS episode.

After a

short latency, C4 and C6 compounds consistently produce a typical PS phase.
The C4-C6 compounds appear to act at the level of the pons, since they still

r
I

J~OJ

lactonase ..

GBL

Glutamic acid

ll
fH2-1H2

/C,

O~

OH

CCOOH

0

o<-ketoglutaric acid

Succlnic acid

r
Succinyl CoA

llS

induce PS in pontile cats but are ineffective after mediopontine transection
(Tokizane, 1966; Matsuzaki, 1969) or after lesions of the dorsolateral pontine
tegmentum (Jouvet et al., 1961).

These compounds antagonize the inhibitory

effects of atropine upon PS in pontile cats but are ineffective in inducing
pS

during the PS-suppressor effect of MAOis (Delorme et al., 1965).
2.

Active Form
Jenny et al. (1962) and others reported a similarity of the EEG patterns

between anesthetic doses of GHB and PB.

Winters and Spooner (1965; 1966)

showed that at high doses (200-600 mg/kg), GHB produces a polygraphic pattern
similar to PB and alpha-chloralose.

They reported that after GHB a pro-

gression of various types of epileptiform EEG patterns were obtained.

They

suggested that GHB induced a state similar to generalized non-convulsant
epilepsy, which could act to disconnect the cortex from subcortical regions.
An alternate conclusion is suggested by the finding of Wikler (1952), who

demonstrated a "divorce" or dissociation phenomena between the EEG and behavioral effects of several drugs.
The aforementioned studies stimulated neurochemical investigations of
the mechanism of action of these compounds.

There has been a great deal of

controversy as to whether GHB or GBL is the active product and which of these
is a normal constituent in the brain that might play a role in normal sleep,
as a "natural hypnogen".

Giarman and Roth (1964) initially were unable to

demonstrate GHB in the brain, although Bessman and Fishbein (1963) did.
Subsequently Roth and Giarman (1970) corroborated this finding when they
utilized a more sensitive technique than in their earlier studies.

Bessman
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and Skolnik (1964) reported that the onset and duration of anesthesia correlated with the presence of the lactone in the brain, after either GHB or
GBL was administered to rats.

On the other hand, Giarman and Roth (1964)

found that when rats were given GBL (500 mg/kg, IV) high brain concentrations
(10-2M) were achieved within one minute, followed by a decline due to redistribution from the brain and rapid conversion to GHB.

When brain GHB

content reached about 70 µg/gm, the righting reflex was lost.

Recovery

occurred when brain GHB fell below this critical level, suggesting that
anesthesia is related to brain GHB content and not GBL.
(1970) obtained similar results.

Guidotti and Ballotti

Roth!:!., al. (1966) added further evidence

that GHB was the active form in experiments that examined the effects of GHB
and GBL in blockingtransmission through the SCG and after direct injection
into the CNS.

Only GHB produced depression in the rat after intracisternal

injection, while a greater delay in the onset of transmission blockade in the
SCG was seen with GBL than GHB, suggesting that the delay might be due to
conversion to the active form.

When administered into the thalamus and

hippocampus of unanesthetized monkeys by micro-injection, GHB innnediately
produced a slow-wave, high-amplitude EEG.

GBL was without effect.

Besson

et al. (1971) found that anesthetic doses of GHB greatly reduced the dorsal
root potential produced by segmnetary stimulation, while the dorsal root
potential produced by cortical stimulation was unaffected.
described (Besson et

~

They previously

1968) a similar action connnon to a variety of

anesthetics, which act presumably by a presynaptic mechanism.
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3.

GABA in the CNS and Relationship to GBL
The close structural similarity between GBL and GABA (cf. Fig. 4

suggested that GBL might act on the GABA system.

)

The physiological actions

of GABA are interrelated with L-glutamic acid (GA), the main precursor of
GABA (cf. Fig. 4

).

This conversion is catalyzed by the enzyme glutamic

acid decarboxylase (GAD; EC 4.1.1.15) and is essentially irreversible (cf.
Roberts, 1960).

The major pathway of GABA degradation is via transamination

(GABA: 2-oxoglutarate aminotransferase; EC 2.6.1.19) with a-ketoglutarate to
form GA and succinic semialdehyde, requiring pyridoxal phosphate as a cofactor
(Baxter and Roberts, 1958).
High levels of GABA are found in the peripheral nerves of crustaceans
and in the mammalian CNS (Awapara et al., 1950; cf. Baxter, 1970).

Kuffler

and Eyzaguirie (1955) proposed that GABA might play an inhibitory role in the
CNS.

An inhibitory factor (Factor I) isolated from the brain was found to

consist primarily of GABA (Bazemore et al., 1957).

In the monkey brain, GABA

levels are highest in the substantia nigra, globus pallidus and hypothalamus
(Fahn and Cote, 1968).

The thalamus and cerebral cortex contain lesser amounts,

while white matter contains the least.

Cerebellar GABA content is highest in

axons of cells shown electrophysiologically to be inhibitory (Purkinje, basket,
stellate and Golgi type II), supporting the theory that GABA has an inhibitory
role in the CNS.
1962).

GA is the most abundant amino acid in brain tissue (Tallan,

Highest levels are found in the cerebrum and lowest levels in the

spinal cord (Shaw and Heine, 1965).

Extracellular administration of GABA

produced hyperpolarization and increased membrane conductance in cortical
neurons (Krnjevic and Schwartz, 1967), Deiter's cells (Obata et al., 1967)
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and spinal motoneurons

(Curtis~

al., 1968) and is capable of blocking most

types of cortical activity (Bradley, 1969).

Peripheral injection of GABA

produces no significant effects on evoked cortical potentials and intracarotid injections have only brief, transient effects (cf. Baxter, 1970),
probably due to the lack of penetration of the BBB.
complete BBB.

Young animals have in-

In chicks, GABA (1.5 mg/kg) produces ataxia, incoordination,

depression and a lack of responsiveness to visual stimuli (Scholes, 1965).
A number of recent studies have attempted to correlate the central
levels of GABA and related compounds with the physiological state and pharmacological treatment of the animal.

A homeostatic function for GABA during

hypoxia is possible since after exposure of rats to 8% oxygen for 10 minutes
brain levels are significantly elevated (Wood, 1967).

Exposure of animals to

hyperbaric oxygen lowers brain GABA content and induces seizures.

Seizure

susceptibility is inversely proportional to GABA levels (Wood et al., 1969).
GABA injections (IP) protect animals against hyperbaric oxygen-mediated convulsions, but the effect is not specific and can be achieved with other amino
acids and salts (Wood and Watson, 1964).

Some convulsant drugs (eg. semi-

carbazide and thiosemicarbazide) lower brain GABA content, while others (such
as hydrazine) elevate GABA levels (cf. Baxter, 1970).

Anticonvulsant agents

(such as hydroxylamine and glutamic acid hydrazide, GAH), which elevate GABA,
do not protect against the convulsant effect of thiosemicarbazide at times
when CNS GABA levels are distinctly elevated.

Although GAH, hydroxylamine and

AOAA all elevate GABA levels, only the latter two protect against pentylenetetrazol convulsions, illustrating that there is no direct correlation with
convulsions and CNS GABA content.
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Apart from the possible involvement of GHB and GBL with GABA, only
limited evidence links GABA with sleep phenomena.
(Mandel and Godin, 1964; Micic

~al.,

Deprivation of sleep

1967) and induction of sleep with

strong light (Godin and Mandel, 1965) elevate rat brain GABA.

In cats with

brain stem transections at the upper MB (cerveau isol~), the cortical EEG
shows continuous spindling characteristic of sleep.

This "activated sleep"

is accompanied by a release of GABA from the perforated cortical pial surface
of 2 µg/hr./cm 2 .

This rate is three times that in normal, intact, aroused

animals or animals with brain stem transections of the upper cervical cord
(encephale isole) with aroused EEG patterns (Jasper et al., 1965)
pattern is reversed for the rate of release for GA.

The

In rats treated with

ethanol and GBL or GHB, the combination produced sleep (loss of the righting
reflex) of much greater duration than that obtained by adding the durations
of individual components (McCabe et al., 1971).
Several alternate routes of metabolism for GABA have been proposed,
based on the product recovery and isolation of enzymes capable of catalyzing
these transformations.

Their physiological significance is unclear but the

fact that several of them involve other brain amines, suggests an interrelationship of these amine systems.

GABA can combine with arginine to form

gamma-guanidobutyric acid, which is found in the CNS and has an inhibitory
action when applied to the mammalian cerebral cortex

(Takahashi~

al., 1961).

Large amounts of gannna-guanidobutyric acid have been found at the epileptic
focus of human cerebral cortex (Jinnai et al., 1966).

Two histamine related

products are formed from GABA, homocarnosine (GABA-histidine) and homoanserine (GABA-L-methyl histidine).

Both compounds are found in the brain.
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Ga.mma-amino-~-hydroxybutyric

acid (GABOB) was detected in rat brain and has

inhibitor actions (Hayashi, 1959) although there is some controversy about
itS presence in the CNS.
(Nishimato et al., 1964).

GABOB has been used clinically to treat epilepsy
GABA is trimethylated in brain tissue in vitro

to form ganuna-butyrobetaine (Hosein et al., 1962) and this product can be
hydroxylated in vivo and in vitro to carnitine, although no significant
amount of carnitine is formed from 14C-GABA administered peripherally to rats
and mice (Lindstedt and Lindstedt, 1965).

Gannna-butyrobetaine, carnitine and

the CoA esters, acetyl-L-carnitine and acetyl-L-carnityl CoA have "ACh-like"
actions (Hosein and Orzeck, 1966).

Ganuna-aminobutyrylcholine is found in

the brain and although it does not cross the BBB, it has anticonvulsant
effects. Homopantothenic acid and alpha-gamma-diaminobutyric acid which are
structurally related to GABA have also been found in the brain.
4.

Involvement of Other AJilines with GBL
Giarman and Schmidt (1963) demonstrated that GHB increased ACh content

in the brain stem (the dorsal pontine tegmentlllll).

Parenteral administration of

GHB, GBL or 1,4-butanediol (which is also converted to GHB, in vivo) results
in a marked increase in brain DA with little or no effect on such amines as
NE and SIIT (Gessa et al., 1966; Roth and Suhr, 1970) or GABA (Giarman and
Schmidt, 1963).

Roth and Suhr (1970) showed that the elevated brain DA has

the same regional distribution as the normal endogenous amine.

Aghajanian and

Roth (1970), utilizing fluorescence microscopy, demonstrated that the selective increase in DA occurs exclusively within the terminals of DA-containing
neurons.

This is in contrast to the generalized increase in brain fluorescence
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after MAOis.

The GHB-induced increase in DA is due to newly-formed DA, since

it does not occur after inhibition of DA synthesis with AMPr, but is still
seen after amine depletion with reserpine (Gessa

~al.,

1968).

These in-

vestigators showed that GHB and related compounds do not inhibit MAO or COMT.

rn

addition to the elevation in DA, Roth and Suhr (1970) and Roth (1971)

demonstrated a corresponding reduction in subcortical HVA.

The former study

also reported that GBL produced a selective increase in the specific activity
of brain DA, but not NE, in rats injected with 1 4c-tyrosine (IV).

They con-

eluded that GBL (and GHB) increase brain DA primarily by selectively blocking
its release from DA-containing neurons.
5.

Mechanism of Action
A number of mechanisms of action for GBL and GHB have been proposed,

ranging from physical to neurochemical, and are surmnarized here.

These

compounds might inhibit the metabolic activity of cerebral tissue, as they do
in muscle and yeast (Samson et al., 1956).

They might act upon cerebral

metabolism by affecting the pentose shunt (cf. Laborit, 1964) or the metabolism of GABA (Fishbein and Bessman, 1964; Roth and Giarman, 1969).

Mitoma

and Neubauer (1968) demonstrated that GHB is converted to GABA, although there
is no elevation of brain GABA after GHB administration.

Godin et al. (1968)

demonstrated that GHB increases cerebral glucose, decreases lactate and the
incorporation of glucose carbon into GA, glutamine, aspartic acid and GABA in
rat brain.

A similar elevation of glucose in mouse brain, without a corre-

lation with sedation or anesthesia was reported by Leonard and Watkinson
(1971),

Godin~ al. (1968) showed that GHB can form succinate or GABA after
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o~idation

to succinic semialdehyde by lactate DH (cf. Fig. 4

).

DeFeudis

and collier (1970) reported a similar conversion of GHB to GABA and indicated
that it proceeds via Krebs cycle intermediates.
The selective increase in brain DA and ACh (and decrease in HVA)
suggests that the action of GBL might involve these amines.

Since the locus

coeruleus contains both ACh and DA (Shute and Lewis, 1966; Gerardy

~al.,

1969) and pontine neurons seem to participate in triggering PS, the effects
of the C4-C6 compounds might be related to their selective effect on the pons.
rn the intact animal, the effects upon striatal DA might conceal the pontine
effect.
Several investigators have suggested that the C4-C6 fatty acids might
act at the membrane level (Dahl, 1968; Rizzoli and Galzigna, 1970) by reacting
with membrane lipids and perhaps interfering with the movement of critical
ions.

Butyrate can bind with lecithin (in synaptic structures),

SHT and

DA by forming a molecular complex when it passes through synaptic membranes.
The formation of this complex might alter the equilibrium in the synaptic
cleft and induce the release of additional transmitter or it might interfere
with ACh release (Rizzoli and Galzigna, 1970).

This hypothesis might also

explain the absolute refractory period, when it is impossible to trigger PS
pharmacologically or electrically because insufficient transmitter is available in the nerve terminals.

When a sufficient amount of transmitter is

subsequently synthesized, the fatty acids are then able to trigger PS

0
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g.

Alteration of Drug-induced Sleep
Various physiological and pharmacological factors have been shown to

alter the effects of hypnotic drugs.

Environmental light is one which can

bring about circadian changes in the effects of a variety of drugs, including
hypnotics.

This aspect of drug effectiveness, only recently considered,

probably deserves consideration in almost all pharmacological studies and
will be discussed in the section on Biological rhythms.

Other factors also

discussed below, are under the headings of physiological and pharmacological
changes.
1.

Physiological Effects
Vesell (1968a, b) thoroughly examined the duration of action of hexo-

barbital (HB) anesthesia (125 mg/kg, IP) in a number of species of mice.
Some species sleep longer and have correspondingly lower liver hexobarbital
oxidase (HBO) activity than animals that have short sleep durations.

Genetic

crosses between long-sleepers retained the long sleep duration and HBO
activities, while crosses between long and short sleeping species had sleeping
times and HBO activities intermediate to the two.

The trait of male mice

sleeping longer than females was maximal in inbred strains and diminished
by outbreeding.

The duration of RB-sleep in a NIH strain decreases pro-

gressively and significantly from one week of age and plateaus at three weeks,
corresponding to the time-course of development of liver HBO activity.

The

age, sex, strain and species of experimental animals therefore are important
in drug response.

HB sleeping time decreased, while HBO activity increased

in animals removed from their usual hardwood bedding and placed on red cedar
(softwood) bedding for six days.

Softwoods contain enzyme-inducing substances,
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such as terpenes.

The changes in sleeping time and enzyme activity were

reversed by putting the mice back on hardwood bedding.

A painful stimulus

applied at regular intervals significantly shortens HB sleep without altering
HBO activity.

Crowding of animals also tends to shorten HB sleep.

Mice

maintained at 20°C. slept longer and had correspondingly lower HBO activity
than those kept at 25°C. or 30°C.

However, mice given HB are unable to

survive environments of 15°C, or 37°C.
a.

Temperature
Fuhrman (1946) sunnnarized some of the earlier work done in

mannnals and lower animals on body temperature and drug action, including
toxic and hypnotic effects.

A number of investigators report that rats and

mice at lower environmental temperatures sleep longer with a given dose of a
barbiturate.

Fuhrman (1946) reported that mice maintained at 27°C. slept

almost four times as long after the onset of PB-induced sleep as those maintained at 37°C.

There was no difference in sleeping time for barbital-

treated animals at the two temperatures, indicating that the prolonged PB
sleep was due to its decreased metabolism.

Buchel and Tanguy (1967) reported

similar findings in mice for doses of PB and HB producing sleep of a duration
greater than 50 minutes.

Mice maintained at a simulated altitude of 18,000

feet (hypobaric) for five days had a shorter loss of the righting reflex
with HB, zoxazolamine and mephenesin but not with PB (Hawkins et al., 1971).
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b.

Diet
Kalyanpur et

~·

(1968) examined the influence of dietary

factors on PB and barbital-induced sleep duration.

These include high pro-

tein and high carbohydrate diets as well as vitamins (thiamine, nicotinic
acid, tryptophane, and the B complex) and steroids (desoxycorticosterone,
4-chlorotesterone, aldosterone, progesterone, stilbestrol, with the latter
three administered on both an acute and chronic basis).

Thiamine, nicotinic

acid, biotin, progesterone, high carbohydrate and high protein diets significantly prolong PB sleep.

Tryptophane, nicotinamide and pyridoxine and the

steroids (except for progesterone administered acutely) decreased PB sleep.
Lamson et al. (1951) tested glucose and related substances for their ability
to restore hypnosis to guinea pigs awakening from barbiturate hypnosis.

IP

doses of glucose, galactose, levulose, several Kreb's cycle intermediaries,
ascorbate, yeast, glutamic acid, glycerol and epinephrine were effective in
"re-introducing" sleep in awakening animals, while sucrose, nicotinamide,
pantothenic acid, glycine, alanine, ATP and DPN were not.

There were marked

species differences in the response; guinea pigs reacted to all active substances, while rabbits, hamsters, pigeons and chickens respond to a lesser
extent.

Rats do not respond to glucose but do to lactate and pyruvate.

Mice

respond very slightly, while goldfish and tadpoles do not respond at all.
Lactate, pyruvate and glutamate decreased the onset of barbital anesthesia,
presumably by increasing its rate of entry into the brain.
antagonized by ACh.

The effect was

The authors hypothesized that the various active meta-

bolites act by decreasing ACh synthesis, since they inhibit choline acetylase,
which in turn would allow for a higher level of brain barbital.
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c.

Sex
The duration and intensity of drug response is often greater in

the female adult than in the male adult rat.

Brodie (1956) reported that

female rats given HB slept four times as long as males, and had correspondingly lower metabolizing enzyme activity.

Female rats administered testos-

terone slept less and had higher enzyme activity than controls, while males
given estradiol slept longer and had lower enzyme activity than controls.
These results indicate that the female is not more sensitive to the drug,
but that the sex hormones influence drug metabolism.

However, Brodie (1956)

further stated that in mice, guinea pigs, rabbits and dogs such sex differences were not demonstable.
Selye (1947, p. 59) demonstrated that steroids themselves are able
to induce sleep.

In order of decreasing potency, the steroids listed are:

pregnanQdione, desoxycorticosterone acetate, progesterone, testosterone and
estadiol.

Winter and Flataker (1952) studied the effects of steroids on the

response of mice to HB anesthesia.

Sleep duration was shortened by cortisone

(SC)and ACTH (IP) treatment but not by dexoxycorticosterone acetate (SC).
Rupe et al. (1963) demonstrated that in rats stressed by hind leg ligation
for 2.5 hours prior to testing, the duration of sleep from PB, HB and
meprobamate, decreased in comparison to unstressed controls.

The effect was

absent in adrenalectomized rats and could be restored by treatment with ACTH
or corticosterone.

Similarly, Bousquet et al (1965) showed that the duration

of response to HB, PB) meprobamate and zoxazolamine was significantly reduced
in stressed animals, while that to barbital and phenobarbital was unaffected.
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The duration of response to RB in adrenalectomized or hypophysectomized rats
~as

unalterable, suggesting that the effects of stress on drug response are

mediated over the pituitary-adrenal axis.

Rumke and Noordhoek (1969) reported

that lynestrenol (a progesterone-like compound) decreased HB sleeping time,
~hile

enhancing its in vivo liver metabolism.
d.

Hormones
Feeding mice 2% desiccated thyroid in their food prolonged PB

and thiopental-induced sleep

(Prange~

al., 1966).

Propylthiouracil (0.2%

in the drinking water) decreased PB sleep but not thiopental sleep.

In rats,

thyroxin (100-1000 µgm, IM) only slightly prolonged PB in sleep, while thyroidectomy greatly prolonged PB sleep.

The authors concluded that propyl-

thiouracil and thyroid feeding of mice prolonged sleep by decreasing the
activity of the metabolizing system, even though in rats thyroxin produced
only slight increases in PB-sleep.

Prolongation of PB in thyroidectomized

rats is probably due to the general decrease in metabolic rate and the
accompanying decreased body temperature.

Conney and Garren (1961) reported

that pretreatment of male rats with thyroxin prolonged the duration of action
of HB by decreasing the activity of the liver enzyme metabolizing system.
e.

Pathology
Kostowski and Dolfini (1969) reported that lesions of the midbrain

raphe increase PB sleep in rats, even though such lesions have been shown to
decrease SWS (Mouret~ al., 1967) and cause persistent behavioral and EEG
arousal (Kostowski et al., 1968).

Bilateral lesions in the posterior hypo-

thalamus suppress HBO activity, while lesions in the caudate nucleus,
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hippocampus, preoptic hypothalamus or cerebral cortex produced no change
(Nair~

al., 1970).

However sleeping time was significantly prolonged after

hippocampal, preoptic and posterior hypothalamic lesions.
cortical lesions decreased HB sleep.

Caudate but not

They suggested that HBO activity is

regulated by the posterior hypothalamus, possibly through the release of
hypophyseal tropic hormones.

Exposure of young rats to sublethal X-irradia-

tion inhibited the normal rapid increase in HBO activity occurring at three
weeks of age, but was reversed three weeks later (Yam and DuBois, 1967).
The X-irradiation appears only to delay the increase of enzyme activity.
Exposure of the head only or hypophysectomy without irradiation also inhibit
development of the HBO system, indicating a possible involvement of central
hormonal regulation of HBO activity.

Starvation prolonged HB sleep (Dixon

et al., 1960; Fujii et al., 1968) while cache.xia produced by feeding rats a
rancid, standard biotin deficient diet decreased PB sleep (Peters and Boyd,
1966).
2.

Pharmacological Effects
Kato and Chiesara (1962) reported that a number of centrally-acting

drugs decreased the duration of PB sleep (25 mg/kg, IP) in rats.

They

include phenobarbital, phenaglycodol, glutethimide, nikethamide, meprobamate,
chlorbutol and chlorpromazine.

The effect developed 24 hours after treatment

and was maximal after another 24 hours.
similarly-treated animals was increased.

PB metabolism in liver slices of
Boissier et al., (1967a,b) examined

the central effects of sympatholytics on a subhypnotic dose of PB (25-30
mg/kg) in mice and rats.

At the higher doses employed, phenoxybenzamine,

r
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dibenzamine, phentolamine, yohimbine, dihydroergotamine, propranolol,
guanethidine, a-methyl-DOPA and chlorpromazine caused a high percentage of
mice to sleep, when administered 35-65 minutes prior to PB and they reduced
spontaneous activity and rectal temperature.
without effect.

Consolo~

Bretylium (8-32 mg/kg) was

al. (1965) and Sadre and Tiwari (1966) also re-

ported the prolongation of PB sleep by chlorpromazine.
the prolongation of PB hypnosis in mice by the

Peters (1972) studied

~-blocker,

alprenolol.

The

increased duration of sleep was not related to an altered tissue distribution
or hypothermia.

Alprenolol decreased NADiri"' phosphate oxidase, cytochrome c

reductase and cytochrome P450 reductase activities and cytochrome P450
content.

Naik et al. (1969) demonstrated potentiation of PB sleep by the

analeptics nikethamide and pentylenetetrazol and antagonism by picrotoxin.
Paradoxially, all three compounds produced a similar elevation in brain PB
levels.
The effect of pretreatment with a-methy-L-tyrosine (same as AMPT)
on the duration of PB sleep, alone and in combination with chlorpromazine)
reserpine or meprobamate was tested by

Menon~

al. (1967).

The only signi-

ficant increases in PB sleep occurred in AM.PT-treated animals concomitantly
given reserpine or chlorpromazine.

Richards

~al.

(1965) examined) with

respect to sleep duration and arousal time (from an electrical stimulus))
the effects of pretreatment of mice with chlorpromazine, reserpine) meprobamate and hyroxyzine, given immediately before HB (100 mg/kg, IP).

All

prolonged sleep significantly at the higher doses and at their lowest doses
With meprobamate and hydroxyzine.

Smith (1961) reported that reserpine

(100 µgm/kg, SC) given 20 hours prior to barbital (200 mg/kg, IP) significantly
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potentiated barbital sleep in rats.

LSD (1 mg/kg) given 30 minutes prior to

barbital antagonized this effect of reserpine.

However, Salmoiraghi and Page

(1957) demonstrated that low doses of LSD or bromo LSD (2 µgm/kg, one hour
prior to RB) enhanced the prolongation of RB sleep (70 mg/kg) produced by
SHT (20 mg/kg, 10 minutes prior to RB) and reserpine (5 mg/kg, one hour prior
to RB).

Child et al. (1961) demonstrated that reserpine ( 2 mg/kg, IP) pre-

treatment, 1-6 hours before its administration, shortened barbitone-induced
sleep.

Sleep returned to normal by the 2nd day, increased on days 3-4 then

became normal again.

The rate of penetration of barbitone into the brain as

measured by brain levels was reduced by reserpine pretreatment.
To produce stress in rats,

Bousquet~

al. (1965) administered hista-

mine (5 mg/kg, IV) 2.5 hours prior to RB and obtained decreased RB sleeping
time.

Winter and Flataker (1952) demonstrated in mice that the antihistamine,

diphenhydramine (10 mg/kg, 30 minutes prior to the anesthetic) prolonged
sleep induced by RB or ether.

Winter (1948) reported that the antihistamines,

diphenhydramine, pyranisamine, tripelennamine, and promethazine, prolonged
HB (100 mg/kg, IP) sleep in mice and that diphenhydramine prolonged PB (50
mg/kg, IP) sleep.

He also found that diphenhyramine prolonged PB-sleep (35

mg/kg, IP) in guinea pigs.

Pierre and Cahn (1956) found that 5HT (5 mg/kg and

20 mg/kg) administered 5 minutes and 10 minutes respectively after thiopental
(40 mg/kg, IP) significantly prolonged sleep, but not after PB, thialbarbital,
urethane or ether.

Buchel et al. (1960) also reported prolonged sleeping

times in mice after SHT (SO mg/kg, IP and SC) which decreased after iproniazid
(150 mg/kg, IP) or JB 516 (10 mg/kg, IP) given 24 hours prior to the HB.
Iproniazid was effective in blocking the prolongation of RB sleep produced
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by 5 HTP (25 mg/kg, IV) given 5 minutes prior to HB.

Baldieri (1965) showed

that pargyline (2.5-10 mg/kg, IP), given 15 minutes prior to PB (30 mg/kg,
IP) prolonged PB sleep in rats.
Proctor et al. (1964) demonstrated that several anticholinesterases
enhanced the hypnotic activity of HB in mice.

TEPP prolonged HB sleep and

its effect could be antagonized by atropine but not by atropine methyl bromide.
perphenazine combined with TEPP greatly enhances HB sleep and was similarly
blocked by atropine but not atropine methyl bromide.

Barnes andMeyers (1964)

reported that eserine, given concomitently with PB, decreased sleep, as did
amphetamine, alone or with eserine.

Neostigmine had no effect on PB sleeping

time, suggesting that the cholinergic mechanisms activated were central.
Significant prolongation of PB sleep (65 mg/kg) in mice was produced
after a one hour pretreatment with aminopyrine and phenylbutazone (both at
25 mg/kg; Eckhardt et al., 1958).

Prednisone (25 mg/kg), morphine (1 or

25 mg/kg) or acetylsalicylic acid (25 or 250 mg/kg, orally) were without
effect.

The effective drugs significantly elevated brain PB content.

How-

ever, Coldwell and Peters (1968) reported that a one hour pretreatment with
acetylsalicylic acid (0.2-1.9 mg/kg, orally) significantly potentiated
hypnosis in rats, at several doses of PB or thiopental.

Quinine and quini-

dine (both SO mg/kg, IP) prolonged PB-induced sleep in mice and rats (Boulos
~al.,

1970).

Both drugs decreased the rate of loss of PB content in goat

plasma, without a change in the volume of distribution and were potent competitive inhibitors of PB metabolism in rat liver homogenates.

Quinine did

not alter PB brain levels significantly in mice, 5 minutes after PB or upon
awakening.
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Seto and Keup (1969) tested a number of alkylmethoxybenzene and
alkylmethylene-dioxybenzene essential oils on PB (50 mg/kg) and ethanol

(3.5 gm/kg)-induced sleeping time in female mice.

Myristicin, isomyristicin,

safrole and elemicin at doses of 20 mg/kg double PB sleeping time.

At a

dose level of 50 mg/kg, asarone, isoelemicin, ortho-anethole, eugenol methyl
ester and isoeugenol methyl ester double sleeping time over controls.
Asarone (at 75 mg/kg) was the only essential oil capable of doubling the
sleeping time over control, ethanol-treated mice.

Several other essential

oils tested were much less effective in prolonging PB or ethanol-induced
sleep.

Jori et al. (1969) reported that in rats eucalyptol (500 mg/kg, SC,

18 or 36 hours pretreatment) significantly decreased PB sleeping times and
brain PB content.

Other constituents of essential oils, such as guaiacol,

menthol, oil of Pinus pumilio,

a- and

~-pinene,

are not effective in altering

PB sleep duration.
Conney (1967) reviewed the pharmacological implications of liver
microsomal enzyme induction by a wide spectrum of drugs, including hypnotics,
anesthetic gases, CNS stimulants, anticonvulsants, tranquilizers, muscle
relaxants, antihistamines, alkaloids, insecticides and steroids.

Some of

these act as competitive inhibitors of drug metabolism, in oxidative and
demethylation reactions.

Rennner (1962), Conney and Burns (1959) and other

investigators demonstrated the stimulating effect of barbiturates on microsomal metabolizing enzymes.

Most inducers are like phenobarbital.

They

stimulate various pathways of metabolism by the liver microsome system,
including oxidation, reduction, glucuronide fromation and deesterification.
Polycyclic aromatic hydrocarbons stimulate a more limited group of reactions,
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such as some hydroxylating pathways.
also differs.

The course and intensity of induction

Phenobarbital, given daily, produces a maximum in induced

enzyme activity (3-10 fold increase over control) after at least three days,
while a single IP injection of dieldrin (40 mg/kg) or DDT (200 mg/kg) in rats
elevates HB and acetophenetidin metabolism to maximum (2-3 times control)
in 5-10 days (Ghazal et al., 1964).

Enzyme induction results in a more rapid

metabolism and usually a decreased drug effect, i.e., diminished toxicity or
duration of hypnotic sleep.

In some cases, however, the metabolite might be

the active form, leading to exaggerated effects.
Brodie (1956) described the potent enzyme inhibitory action of SKF
525A.

Animals treated with this compound and then administered a hypnotic,

such as HB, sleep much longer than controls.

SKF 525A, which has no sedative

action of its own, also prolongs the action of amphetamine.

It acts by in-

hibiting hydroxylation, N-dealkylation, some O-dealkylation, deamination,
sulfoxide formation, reduction of azo and aromatic nitro compounds, some
hydrolysis reactions and the formation of glucuronides.

However, there are

species and drug exceptions to the above.
The alteration of the effects of the non-barbiturate hypnotics,
chloral hydrate and ethanol should be briefly considered.

Fastier et al.

(1957) reported that chloral hydrate (250 mg/kg, IP) sleeping time was prolonged by adrenaline, noradrenaline, phenylephrine, methoxamine, 5HT,
histamine, ergotamine, yohimbine and atropine.

They stated this effect was

not due to circulatory actions but possibly due to lowering body temperature.
Buchel et

~·

(1960) demonstrated in mice that SHT (10 mg/kg, SC) produced

sleep when given 3 hrs prior to a subhypnotic dose of chloral hydrate

r
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(26 mg/kg, IP).

(The peak effect occurred 30 minutes after SHT).

Chloral

hydrate sleep (32S mg/kg, IP) was prolonged by SHT (SO mg/kg, SC and IP, up
to 60 minutes prior) or SHTP (2S mg/kg, IV, S minutes prior).

Buchel and

Levy (1960) found that in mice, reserpine (S mg/kg) produced sleep after a
subhypnotic dose of chloral hydrate (200 mg/kg), which was antagonized by
JB Sl6 (S-10 mg/kg) and ipronized (S0-100 mg/kg).

Reserpine (2 and S mg/kg)

prolonged a hypnotic dose of chloral hydrate (300 mg/kg), which was antagonized by JB Sl6 (2.S and S mg/kg, 20 minutes prior) and iproniazid (SO
mg/kg, 22 and 46 minutes prior) but not by iproniazid (2S mg/kg).

5HTP

(5-25 mg/kg, IV) and DOPA (10-2S mg/kg, IV) reinduced sleep in animals
awakening from chloral hydrate (200-22S mg/kg).

The effects of both com-

pounds were antagonized by iproniazid (lSO mg/kg, IP) given 24 hours prior
to the hypnotic.

Sadre and Tiwari (1966) showed that histamine (10 mg/kg)

and chlorpromazine (10 mg/kg), alone or together, prolonged sleep induced by
chloral hydrate (400 mg/kg) in mice.

Lechat and Levy (1969) reported that

in mice, DL-DOPA (lSO mg/kg, IP) 10 minutes prior to chloral hydrate (250
and 325 mg/kg, IP), doubled sleep duration, and was antagonized by the MAOI
furazolidone (500 mg/kg, orally, 24 hours prior).
Blum et al. (1971) reported that in mice, pyrazole, an inhibitor of
liver alcohol dehydrogenase, produced a dose-dependant prolongation of
ethanol-induced sleep, when given 30 minutes prior to ethanol.

Blum et al.

(1972b) showed that glycine (0.9 mmoles/100 gm, IP) given 5 minutes after
ethanol significantly prolonged sleep over controls.

This effect appears

to be due to central actions and not to altered ethanol metabolism.
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carlsson et al. (1972) demonstrated in rats and mice that AMPT (40 or 200
mg/kg), which in itself causes no significant depression of motor activity,
reduced the normal increase in motor activity produced by small doses of
ethanol (1 or 2 gm/kg).

Blum~

al. (1972a) found that AMPT (3 x 80 mg/kg

or 400 mg/kg) enhanced ethanol-induced sleep time in mice.

AMPT-L-DOPA

treated animals had a reduction of the AMPT-alone increase in ethanol sleep,
with a 60% increase in whole brain DA.

L-DOPA alone (3 x 400 mg/kg/day)

appears to prolong ethanol sleep, although they did not mention if this
increase was significant.
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III.
A.

MATERIALS AND METHODS

Experimental Animals

Male albino rats of the Sprague-Dawley strain (Holtzman Breeders,
Madison, Wisconsin) weighing 300-400 grams each, were used in these experiments.

Males were chosen in order to reduce variability introduced by

hormonal cycles, which is greater in the female.

They were housed in groups

of six in stainless steel wire mesh cages, 29 x 23 x 23 cm.

A uniform

mixture of Pel-e-cel (absorbant compressed cellulose; Paxton Products,
Paxton, N. J.) and Litter-green (McFadden Industries, Inc., Kansas City,
Missouri) was used in trays beneath cages, such that animals had no direct
contact.
Male albino mice of the Swiss-Webster strain (Simonson), weighing
20-35 gm each, were maintained in clear plastic cages, 28.5 x 18 x 13 cm,
6 -8 per cage .
Purina Rat Chow pellets and tap water were provided ad libitum.
The composition of the Rat Chow consisted of approximately 23% protein, 5%
fat, 4% crude fiber and 6% ash, plus vitamins and minerals (figures provided
by Ralston Purina Co., St. Louis, Missouri).

Feeding, watering and cage

cleaning were performed at random times of day to prevent these procedures
from causing an exogenous rhythm.
B.

Animal Housing Conditions

The rack of animal cages was kept in a quiet, well ventilated,
windowless room, measuring 2.7 x 3.7 x 4.1 meters.
ture of 23

±.

Stable ambient tempera-

l°C,, relative humidity of 25 + 5% and barometric pressure of

r

r
137
730-760 nun of mercury were monitored by a Lambrecht KG recorder.
Animals were adapted to a lighting schedule of 0800-2000 hours
c.s.T. light and 2000-0800 hours dark, using an automatic 24-hour timer.
Fluorescent Vita-lites supplied by Duro-Test Corp. (North Bergen, N. J.)
provided a lighting spectrum approximating daylight.

Cages were 5-6 feet

from the lights, resulting in a radiation intensity of 20-50 µ watt/cm 2 , as
measured on a radiant flux meter (12-46 footcandles, using a Gossen Luna-Pro
light meter).

All animals were adapted to these conditions for a minimum of

three weeks prior to use in experiments.
During the dark phase, various procedures, such as feeding, drug
injections, etc., were performed under red light (25 watts, about 750 µ watts/
cm2 radiant energy but about 8 footcandles of light).
C.

Experimental Procedures
1.

Measurement of drug-induced sleep.
The duration of drug-induced sleep was measured as the time

from the loss (onset) to the recovery of the righting reflex.

Recovery is

defined by Vesell (1968b) as the ability of the animal to place both forefeet simultaneously on the ground twice within 15 seconds, when placed on
its back.

According to Vesell (1968a, b) unstimulated animals will sleep

longer than stimulated ones.

In order to standardize stimulation the tails

of the animals were pinched approximately every three minutes, once they
began to emerge from deep sleep (as evidencaiby slight movements of their
limbs).
The durations of PB-sleep were first determined for the various
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pretreatments at each of the four times (0600, 1200, 1800, 2400 hours) during
the 24-hour period.

A second set of animals were given the same pretreatment

dosages and PB at these times, but sacrificed half-way through the previouslydetermined sleeping times (t 1/2).

Vehicle-treated controls were sacrificed

at the same time as treated animals.

From these results a control curve

could be established, showing a time course for monoamine changes at the four
times.

The amine content of brain parts from treated animals could then be

compared with the control curve at the appropriate time.

During the dark

phase, injected animals were maintained under red light or in darkness, and
removed quickly to an adjacent, dimly-lit room for decapitation.
2.

Drug dosages
Pentobarbital sodium (PB) was dissolved in 0.9% saline (25

mg/ml) and administered (50 mg/kg, IP) to control groups which received only
the vehicle used in pretreatment, and treated groups, which received one of
the pretreatments described below.

Gamma-butyrolactone (GBL), a liquid, was

diluted with saline, to yield a final GBL concentration of 350 mg/ml in 0.9%
saline.
animals.

GBL (350 mg/kg, IP) was administered to controls and pretreated
In order to examine their effects with respect to the time of day,

these drugs were administered at six-hour intervals.
To investigate the role of biogenic amines in drug-induced sleep,
several pretreatments which alter CNS amine levels, were utilized prior to
testing for the duration of sleep produced by PB or GBL.
clude amine depletors and precursors.

Pretreatments in-

Pretreatment drug doses and times of

administration were chosen to optimize the change in CNS levels of one or
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more monoamine being studied.

These were selected, whenever possible, from

previously-published reports.
The DA (and NE) precursor, DL-DOPA, was administered at a dose of
500 mg/kg, IP (equivalent to 250 mg/kg of L-DOPA, the active isomer), one
hour prior to the sleep-inducing drug.

Because of the low water solubility

of this high dose, and the desire to use low injection volumes (about 1.0 ml
or less), the DOPA was suspended in 1% methyl cellulose (250 mg/ml).

Pargy-

line, an MAO inhibitor (6 mg/kg, IP, in 0.9% saline) was given 30 minutes
after DOPA.
(Chamber~

This treatment primarily elevates DA and NE to a lesser extent
al., 1971).

The DOPA-pargyline treatment is used to raise and

maintain the elevated brain amine levels.

Alpha methyl £-tyrosine (AMPT,

200 mg/kg, IP, dissolved in lN NaOH and neutralized with an equal volume of
lN HCl to produce a fine suspension, 66.67 mg/ml) was administered 4 hours
prior to· PB or GBL.

This amine acid analogue of tyrosine depletes NE stores

by competing for tyrosine hydroxylase.

£-Chlorophenylalanine (pCPA) has been

shown by several investigators to deplete brain SHT while only decreasing CA
concentrations slightly (Koe and Weissman, 1965; Mouret et al., 1967).

Three

doses of 100 mg/kg, IP (in 1% methyl cellulose) were administered 72, 48 and
24 hours prior to the administration of PB.
A set of experiments were conducted in mice, testing the effect of
cholinergic drugs on PB-sleep.

Neostigmine or physostigmine (0.3 mg/kg, IP)

were administered 30 minutes prior to PB (SO mg/kg, IP).
The following table lists the drugs used, summarizes their doses
and the intervals prior to the administration of PB or GBL.

In every
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instance, the hypnotics were given at six-hour intervals (i.e., 0600, 1200,
1800 and 2400 hours).
these times.

The pretreatments were always timed with respect to

Injections, during the dark phase, were conducted under red

light. (Some of the drugs used are shown in Fig. S).
TIME PRIOR TO
HYPNOTIC INJECTION

Q.fil!.Q.

DOSE (mg/kg)

pCPA

3 x 100

72, 48, 24

hours

Koe and Weissman, 1966

L-AMPT

200

4

hours

Hollinger, 1969

DL-DOPApargyline

soo

1
30

hour
minutes

Walker et al., 1971

6

1-Hd

100

1

hour

Boissier

soo

1

hour

Taylor and Snyder,
1972

1000

1

hour

Taylor and Snyder,1972
Campcsand Jurupe, 1970

L-TP

soo

1

hour

Moir and Eccleston,
1969
Campos and Jurupe,1970

DPH

so

1

hour

Boissier et al., 1970

DB

lS

24

hours

Medina~

2S

(same time)

M

so

REFERENCE

~al.,

1970

al., 1969

Barchas et al., 1967

II

hour

DL-SlITP

100

1

Neostigmine

0.3

30

minutes

Proctor~

Physostigmine

0.3

30

minutes

Proctor et al., 1964

5MT

20

1 hour

N-acetyl 5HT

20

1 hour

5HIAA

20

1 hour

5MIAA

20

1 hour

al., 1964

p

Pen to barbital

o<-methyl-p-tyrosine

0

HO

yOOH
CH2y-NH2

CH~

12-chlorophenylalanlne

O

Cl

CH2CHNH
I
2
COOH

Decaborane ( 8 10H14)

Diphenhydramlne
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3.

Brain Dissection
Rats were decapitated by means of a Harvard decapitator.

The skin covering the skull was incised with a pointed surgical scissors
and the brain exposed by an incision beginning at the foramenmagnum and
following the midline suture.

The dura was incised ventral surface upward.

The brain was freed from the skull by severing the cranial nerves and placed
on a saline-moistened gauze pad which rested on an ice-cold aluminum block.
using fine curved tweezers, the hypothalamus (Fig. 6

) was removed by under-

cutting it from the rest of the brain and placed in liquid nitrogen within
2 minutes after sacrifice.

The brain was reoriented to its normal position,

the cerebral hemispheres separated to expose the caudate nuclei (CN, Fig. 6 ),
which were removed by undercutting and then placed in the liquid nitrogen
(-195

8°C).

The cerebrum was removed by cutting the cerebral peduncles

above the stria terminalis.

This constitutes the anterior border of the

tissue designated "midbrain" (MB, Fig. 6 ) .

The posterior limit was cut

from the top of the pons on the ventral side to the bottom of the inferior
colliculi on the dorsal side.

The tissue was then placed in liquid nitrogen.

Midbrain includes the thalamus and subthalamus, as well as the subcollicular
tissue.

The cerebellum was removed from the remaining brain.

designated as "stem" (lower brain stem) (Fig. 6

The region

) was obtained by cutting

posteriorly at the decussation of the pyramidal tracts (sulcus medianus
dorsalis).

This tissue was placed in liquid nitrogen in less than 5 minutes

after sacrifice.

The tissues were maintained in liquid nitrogen for several

minutes to insure complete freezing.

The brain parts were then sealed in
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parafilm) labelled and stored in the deep freezer (-25°C.) until they were
analysed for amines (vide infra).
The reasons for selecting brain areas instead of utilizing the whole
brain for analyses are as follows:

It has become increasingly clear that

analysis of the amines of the whole brain results in a "homogenizing" of
important differences among various brain areas) which have unique anatomical, physiological and neurochemical characteristics.

The hypothalamus

(Hpth), a center for autonomic function, has high concentrations of NE and
lesser amounts of 5HT.

It contains a number of nuclei which send fibers out

to other areas of the brain and peripheral nervous system.

The MB lies above

the Hpth and is often combined with it for amine analysis.

The MB contains

moderate amounts of NE and lesser amounts of 5HT.

It includes NE-containing

areas and the head of the 5HT-containing raphe system, which are involved in
the control of sleep.

The MB includes the superior and inferior colliculi

which are involved in visual and auditory reflexes, respectively, processes
that are modulated during sleep.

The brain stem, caudal to the MB, contains

the NE-containing locus coeruleus, as well as the main portion of the raphe
system.

The CN is important because it is part of the basal ganglia, which

is involved with motor control.

The CN has very high concentrations of DA

and high ACh concentrations and high AChE activity.
4.

Brain Amine Analysis
Monoamine levels in the CNS were determined fluorometrically

using slight modifications of the method of

Shellenberger and Gordon (1971).

The basis of this and similar methods (Chang, 1964; Ansell and Beeson, 1968)
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is the adsorption of catecholamines on alumina (batch technique) and the
removal of serotonin from the remaining supernatant by organic extraction.
An acid eluate of the alumina is buffered to neutral pH and oxidized for form
a fluorescent trihydroxyindole derivative.

Serotonin is determined by reaction

with ninhydrin in a pH 7.0 buffer to form the fluorescent compound.
a.

Reagents:
1.

0.4 N perchloric acid:

to 56.8 ml of 70.8% solution

per liter of distilled water, add 1.0 gm sodium metabisulfite (Na2S304) and
0.5 gm disodium EDTA per liter.
2.

Tricine solution:

17.9 gm Tricine (N-tris(hydrocy-

methyl) methylglycine) and 25 gm disodium EDTA in each liter of 0.52SN NaOH
(42 ml per liter of distilled water of a SOio NaOH solution, 12.S N.
3.

0.5 M borate buffer, pH 10.0:

30.92 gm per liter of

distilled water of boric acid (results in pH of about 3.4) then adjusted to
pH 10 with NaOH pellets and saturated with NaCl and
4.

~-heptanol

0.05 M phosphate buffer, pH 7.0:

(about 1 ml).

3.11 gm HaHzP0 ·
4

H 0 and .34 gm Na 2HP0 per liter distilled water.
4
2
5.

Phosphate buffer - EDTA solution:

Add 9.0 gm disodium

EDTA to 1.0 liter of 0.1 M phosphate buffer (4.27 gm NazHP04 and 9.52 gm KHz
Po

4

per liter distilled water) and adjust to pH 7.0 with 5.0 N NaOH (made

from 50% NaOH) .
6.

0.1 N iodine reagent:

are dissolved in distilled water
7.

and~

4.0 gm KI and 1.0 gm iodine

to a final volume of 80 ml.

Alkaline sodium sulfite:

Dilute 1.0 ml (250 mg/ml

in distilled water), sodJum sulfite (kept in freezer until used), to 10 ml

r
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with 5.0 N NaOH
8.

0.1 M ninhydrin:

445.4 mg ninhydrine dissolved in

25 ml distilled water (the ninhydrin solution is stored in the freezer).
b.

Amine Separation
At the time of analysis individual brain parts are weighed

on a Roller-Smith torsion balance (Model LG) and placed in 3 mls of cold 0.4 N
perchloric acid contained in Kontes Duall tissue grinder tubes (size 22) and
maintained in crushed ice (see Fig.

7 ).

The tissues are then homogenized

using a· motor-driven Teflon pestle (Kontes).

After homogenization the tubes

are kept in ice for about 10 minutes and then centrifuged for 10 min. at
maximum speed (2200 rpm or 1000 g) on an IEC Model K centrifuge (radius head,
7.5 inches).

The supernatant was removed and placed in 35 ml Wilkens-Anderson

reaction vessels.

The pellets were rehomogenized in 2.5 ml of 0.4 N per-

chloric acid, centrifuged and the second supernatants added to the first.
Standard tubes were prepared at this point utilizing high and low concentrations of each standard in 5.5 ml of 0.4 N perchloric acid.

Perchloric

acid alone served as a reagent blank.
The pH of each supernatant is then adjusted to 7.8

±.

0.2 (usually

7.8 - 7.9) with Tricine buffer, using a Beckman fine tip combination electrode calibrated to pH 8.0 with standard buffer on a Beckman Model 72 pH meter.
To this supernatant about 300 mg of activated alumina was added.

The alumina

(aluminum oxide, Woelm) was prepared by washing several hundred grams in tap
water overnight in a Hurricane Photo Washer.

In this device water enters

from the bottom and agitates the alumina constantly so that the fine particles are washed away.

The remaining alumina was washed in boiling HCl

Ill"'"

Figure 7: Amine analysis flowsheet
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TISSUE
homogenized in
3.0 and 2.5ml of
0.4N perchoric acid
adjust to pH 7.8 with TRIGINE
SHAKE WITH 300mg ALUMINA, centrifuge
ALUMINA(CAs)

-------

- - - - - - Supn(5HT)

1) wash with distilled ~O

1) NaCl saturate, add 15.0ml heptanol

2) elute with 0.05N perchloric
acid, take l.Oml aliquots

2) adjust to pH 9.8 with K co
2 3
3) vortex mix 1-1 0 5 min., centrifuge

3) ADD l.5ml phospbate buffer, pH 7.0
4) aspirate aqueous phase

+

0.2ml iodine , wait 2 min.
+
0.5ml alkaline sulfite

5) wash heptanol with pH 10 borate buffer,
centrifuge

+

0.4ml glacial acetic acid
4)
5)

HEAT

2 min.@ 95°c., then
cool in ice bath

READ NE, 380nmA, 495nm E

6)

reheat for 10 min.

7)

cool, wait 30 min.
READ DA, 325nm

A~

380nm E

6) transfer 13.5ml heptanol
ADD 2.5ml phosphate buffer, pH 7.0
7) SHAKE, centrifuge
8) aspirate heptanol
9) to l.Oml aliquots,
ADD O.lml ninhydrin
HEAT 25 min. @ l00°c., cool 1 hour
10) READ 5HT, 385nm A, 190nm E
~

.j:'
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(Anton and Sayre, 1962), then in distilled water until the pH of the water
reached 3.4.

It was dried in batches in a large watch glass under a General

Electric infrared heat lamp and stored in sealed polyethylene (Nalgene)
bottles in a dessicator.
The reaction vessels were then shaken by hand and a horizontal shaker
for a total of 20 min. to suspend all the alumina, and centrifuged for 5 min.
at 1000 r.p.m. (200 g).

The supernatants were transferred to another set of

reaction vessels for the 5 lIT analysis.

The alumina was washed twice with

20 mls deionized, distilled water, pH 7.0 (distilled water from the tap
passed through Barnstead mixed resin cartridge, D5041).
wash was aspirated.

Most of the first

After the second wash the alumina was centrifuged at

1000 r.p.m. for 5 min., and the wash aspirated carefully and completely.

The

washed alumina was stored during the isolation of 5IIT in the refrigerator
(4°C.), until the catecholamines were eluted for analysis.

To the superna-

tant from the alumina, containing the 5IIT about 3 gms of NaCl was added and
shaken to assure salt and saturation.

15 ml of

~-heptanol

(redistilled from

Eastman 381) to remove impurities which cause high blanks and lower recoveries)
was added to the salt-saturated solutions.

(Vacuum distillation of the

heptanol is necessary if SIIT recoveries from heptanol are low, because of
interfering impurities.)

To extract the SIIT from the aqueous to the organic

phase, the solutions were adjusted to pH 9.8

+ 0.4 using about 300 mg

K2co 3 (0.3 ml of a 1 gm per ml distilled water solution).

Immediately after

addition of the K2co 3 each vessel was shaken to avoid SIIT loss resulting from
localized regions in the solution of high pH.

All reaction vessels are mixed

on a vortex mixer for 3-5 min., then centrifuged at 1000 r.p.m.

Using a
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water-vacuum aspirator with a Pasteur pipette on the end and a small hole in
the tubing just above the top of the pipette, the tip of the pipette is
plunged quickly through the upper heptanol layer into the aqueous phase, the
crystals of NaCl and K2co 3 gently dislodged and the bottom layer aspirated by
covering the hole in the tubing with the index finger.
this can be done with very little loss of heptanol.

With care and practice

The heptanol layer was

then washed twice with 50 ml of pH 10 borate buffer, vortex mixed for 60-90
seconds, and centrifuged at 1000 r.p.m. for 5 min.

The borate buffer layer

could be removed by aspiration as described above or directly by careful
pipetting (in either case without any borate contamination) 13.5 ml of the
upper heptanol layer and placing it in a clean reaction vessel.

2.5 ml of

0.05 M phosphate buffer, pH 7.0, was added to the 13.5 ml of heptanol and the
vessels were vortex mixed for 40-60 seconds, centrifuged at 1000 r.p.m. for
5 min and the heptanol aspirated (using a vacuum flask to save it for distillation and reuse).

1.0 ml samples of the phosphate buffer are removed for

SHT analysis, taking care to exclude heptanol, which interferes with the
fluorescence after the ninhydrin reaction.
c.

Estimation of the amines:
To 1.0 ml of the phosphate buffer placed in Corning dis-

posable culture tubes, 0.1 ml of 0.1 M ninhydrin

reagent was added and heated

in an oven at 100°C. for 25 min. after removal before reading the fluorescence
in an Aminco-Bowman SPF.

The samples are left at room temperature for 1 hour.

An activation peak of 385 nm and emission peak of 490 nm (uncorrected) are
~sed.

For tissues blanks duplicate 1.0 ml samples of the phosphate buffer
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aliquots, heated and cooled without ninhydrin, are read immediately after
adding 0.1 ml ninhydrin reagent.
3.0 ml of 0.05 N perchloric acid was added to the washed alumina,
vortex and hand shaken for about 5 min to elute the catecholamines, then
centrifuged for 5 min at 1000 r.p.m.

1.0 ml aliquots of the perchloric acid

eluate are placed in disposable test tubes and brought to pH 6.5
1.5 ml of 0.1 M phosphate-buffer-EDTA.

+ 0.2 with

0.2 ml of 0.1 N iodine reagent are

added to each tube, shaken immediately and exactly 2 min later 0.5 ml of the
alkaline sulfite are added and shaken.

After 2 min the samples are acidified

to pH 4.4 - 4.8 with 0.4 ml of glacial acetic acid.

Duplicate 1.0 ml ali-

quotes for tissue blanks are developed by adding the alkaline sulfite first,
then the iodine and acetic acid.

The tubes were heated in a water bath

(95 - 100°C.) for 2 min, cooled in ice water for 3-5 min, then NE fluorescence
read at room temperature (activation peak at 380 nm, emission peak at 495 nm,
uncorrected).

After reading for NE, the tubes were returned to the water

bath and heated for 10 min to develop the DA fluorophore, then removed and
transferred to an ice bath for cooling.

The fluorescence produced in this

manner is stable indefinitely as long as the samples are kept at 4°C but will
decline 15-20% after 30 min at room temperature before becoming stable indefinately.

The DA fluorescence is read after 30 min or the next day at an

activation peak of 325 nm and emission peak of 380 nm (uncorrected).
Tissue content of amines is calculated to give µg/mg tissue weight,
after correcting for tissue blank readings, by comparison with standards
extracted through the procedure.

After correcting standards and samples for

the blanks, the fluorescence units of the standards are plotted on the Y-axis
versus the concentration on the x-axis.
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The corrected fluorescence units for the samples are used with the standard
plots to detennine the tissue concentration of each amine.

Results are

expressed in terms of µgm/gm wet tissue weight by multiplying the tissue
content times the tissue factor (1.0 divided by the tissue weight in grams).
All drugs utilized in these studies were extracted through the amine
procedure, to check for possible interference with the amines themselves.
The only drug found to produce interference was DOPA, which interfered with
the DA analysis.

To remove the DOPA, the CAs were eluted with two 2 ml ali-

quots of 0.05 N perchloric acid, adjusted to pH 6.5 with tricine buffer and
applied to pH 6.5 buffered AG 50 W-X4 resin colunms (Glisson et al., 1972).
NE and DA are adsorbed, while DOPA is not.

NE and DA were eluted with 12 mls

of 1 N HCl, the pH readjusted and processed in the usual manner.
5.

Fluorometry Utilizing the Aminco-Bowman Spectrophotofluoro-

meter
Detenninations of tissue amine levels by fluorescent methods
were performed on an roninco-Bowman Spectrophotofluorometer (SPF) with

th~

off-axis attachment and transistorized photomultiplier microphotometer with
a RCA 1P21 photomultiplier tube.

After the xenon lamp has warmed up for

about thirty minutes, the photomultiplier is switched on, and its voltage
set at· 800 volts.

The microphotometer is then adjusted to zero.

Before each

reading session the lamp is adjusted to peak response (greatest sensitivity)
against a quinine sulfate standard (2.5 µg/ml in 0.1 N sulfuric acid) using
an activation wavelength of 250 nm and emission at 350 nm (uncorrected).

In

this case, as with other standards, the wavelengths cited are uncorrected and
for each reading session activation and emission wavelengths must be deter-
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mined precisely by "peaking" them with the respective standards (usually
within 5-10 nm of the "uncorrected" wavelengths cited).

Reading the quinine

standard first provides a day-to-day check on the sensitivity of the total
SPF system.

If the reading has dropped off, the lamp position is adjusted

to restore readings to previous levels.

If the reading cannot be restored

by these procedures, it indicates that the mirrors might require cleaning
or that the lamp is failing.
The low concentration internal standard was usually set at 40 on the
microphotometer scale, the other standards read and tissue samples compared
with the standard curve established, plotting concentration (x-axis) versus
corrected fluorescence units (y-axis).
6.

Rectal Temperature
Rectal temperature was measured in rats using a Yellow Springs

Telethermometer, with a rectal temperature probe (No. 401).
lubricated

wi~h

The probe was

the light mineral oil and inserted approximately 7 cm into

the colon, for 1.5 - 2.0 minutes before the temperature was recorded.
In control and treated animals, rectal temperatures were obtained
every 15-20 minutes.
the x-axis.

Temperature was plotted on the y-axis, versus time on

In order to compare the temperature pattern of controls and

treated animals, the intercepts of the plots for individual animals were noted
at ten-minute intervals (i.e., 5, 15, 25, 35 minutes, etc.) and the means at
each time determined and replotted to represent an average pattern for control and treated animals.

This permits comparison of differences between

control and treated groups, as well as between different times of day.

I
I

\

I
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7 0 Statistical analyses
a. Calculation of mean, standard deviation and standard error
of the mean
The calculation of the arithmetic mean
deviation (S.D.) and the standard error of the mean

(X),

(s.E.)

the standard

were computed on a

Smith-Corona Cogito 1016PR calculator utilizing the tape input (Iota 1) to
enter prerecorded programso The program provided by Smith-Corona (Statistics
1001) uses the following formulas:

x

=

"2!.x/N

S.D. = J(X

where

X

individual values

N

total number of X values

- XJN)
N - 1

As the program is written, after all entries have been made, the calculator
prints out values corresponding to the following:

N,

x,

x2 ,

X,

S.D. and S.E.

b. Calculation of t and determination of Py the degree of
significance
The unpaired t-test utilized, computed t as follows:

x1 - x2

t
(Ni-l)(S.D. 1 )

+

(N2 -l)(S.D. )

(N 1-l)

+

(N -l)
2

2

) (ki' kJ

!
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The output from the program gives the value of t for a comparison between the
two groups, when the group size(N), mean(X) and the standard deviation(S.D.)
for each group are entered. The P value corresponding to the t calculated is
found in a table of the signi1icance limits of the Student i-test distribution,
using the appropriate degrees of freedom. The P values obtained are expressed
as being less than a degree of confidence (per cent probability), read on the
2P scale. A value of P less than 0.05 (95% confidence limit) was used as the
criterion for significant differences between groups.
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IV.
A.

RESULTS

Duration of Hypnotic Sleep on a 24-Hour Basis
1.

Pentobarbital
The duration of sleep produced by PB (50 mg/kg, IP) was examined by

two procedures.

Initially it was administered to untreated groups of rats at

0600, 1200, 1800 and 2400 hours and the duration of PB-induced sleep determined
(Table 1, Fig. 8).

The duration of sleep with PB alone is maximal at 1200 hours

and minimal at 2400 hours.

The difference between the peak and trough are

significant at the P < .01 level.
from that at 1800 hours (P < .01).

The peak value also differs significantly
The results at 1800 and 2400 hours do

not differ significantly from each other.

There is no significant difference

when results at 0600 hours are compared with the other times.

However, the

difference between 0600 and 2400 hours has borderline significance (P < 0.1,
>0.05).
A second pattern for PB-sleep was obtained by the administration of
PB together with the pretreatment vehicle, at the same time that the drug
treated group received their drug doses.

This vehicle-treated group con-

stituted the "CONTROL" group, for comparison with the treated groups.
Several controls were rw1 with each treated group.

They were pooled with

other similar controls to obtain the control values at the four times in the
24-hour period.

As seen in Fig. 8, this pattern does not exhibit the sharp

peak and trough seen with the PB-alone.

However, because of the large number

of animals used for this pooled control, significant differences were

df

Table 1: The duration of pentobarbital sleep

0600

1200

1800

2400

Pentobarbital
(alone)

10408+18.6

115.6+17.8

87.3+ 8.1

86.7+ 809

(6)

(6)

Pentobarbital
(pooled)

115.5+11. 7

119.5+ 9. 7

109.3+1401

101.3+ 809

(18)

(17)

(17)

(16)

(5)

(5)

D E+

Cd E+

Table indicates the duration of drug-induced sleep, in minutes, for animals receiving PB alone
and the pooled controls receiving the vehicles used in the drug pretreatment studies. Sleeping times
are means

~standard

deviation, with the number of animals used in parantheseso

+Letter designations indicate point to point comparisons within each 24-hour patterns as follows:
aA

(0600 vs 1200 hours), bB (0600 vs 1800 hours), cC (0600 vs 2400 hours), dD (1200 vs 1800 hours),

eE (1200 vs 2400 hours) and fF (1800 vs 2400 hours). Lower case indicates P <0.05 and capitals indicate
P < 0 01 for sj gnificant differences.
0
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2400
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obtained at 0600 and 2400 hours (P < .001), 1200 vs 1800 hours (P < .02 and
1200 vs 2400 hours (P < .001).
--------

The results obtained by both procedures corrobate earlier studies

demonstrating a peak duration of drug-induced sleep during the light period
and a trough during the dark period.
2.

Ganuna-butyrolactone
The effect of administration of GBL (350 mg/kg, IP) at six-hour in-

tervals can be seen in Fig. 9,(Table 9, GBL (alone) and GBL (pooled)).

The

duration of sleep with GBL (alone) was longest during the light phase, at
1800 hours and differs significantly from the trough at 0600 hours at the
0.05 level.

The peak also differs significantly from the adjacent measure-

ments (1200 and 2400 hours) with P < 0.05.

The sleep pattern of saline in-

jected (GBL (pooled) animals (vide infra) differed quantitatively but not
qualitatively from GBL (alone).
B.

Effects of Drug Pretreatment on Pentobarbital Sleep Duration
1.

Drugs Affecting the NE and DA Systems
a.

DOPA-pargyline
DOPA-pargyline pretreatment (500 and 6 mg/kg, IP, respectively)

very significantly prolongs the duration of PB-sleep over controls at all
times tested, with P < 0.001.

(Figs. 10 - 12, Table 3).

Although these in-

creases over respective controls ranged from 103% at 0600 to 146.3% at 2400
hours, the pattern must be considered flat from a statistical examination
since there are no significant increases in sleep duration between any of
the DOPA-pargyline-treated groups, during the 24-hour period.

;,

-

.........-~

Table 2:

The duration of gamma-butyrolactone sleep

0600

1200

1800

2400

GBL (alone)

68 2+9 3

79 0 3+6 0 7

110.3+16.3

77 .0+11.2

B d F+

(4)

(5)

GBL (pooled)

911 0+3 6

110 1+4.5

96 0 4+16 0 2

88.3+10.0

A c d E+

0

0

(3)

(5)

0

0

(6)

0

(8)

(11)

(7)

Table indicates the duration of drug-induced sleep, in minutesj for animals receiving GBL (350mg/
kg) alone and the pooled controls also receiving the vehicle used in the drug pretreatment study.
Sleeping times are means ~ standard deviation 1 with the number of animals used in parentheses.
+For explanation of letter designations see Table 1.
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~

160

120
110
100

90

GBL (pooled)

AcdE

80

GBL (alone)

B df

70

0600

Figure 9:

1200

GBL-Induced Sleep

1800

2400

Table 3:

·~

The duration of pentobarbital-sleep after pretreatment with drugs affecting the NE and DA
systems
0600

1200

1800

2400

115.5+11. 7

119.5+ 9. 7

109.3+14. l

101.3+ 8.9

(18)

(17)

(17)

(16)

Treatment
CONTROL

DOPA+
pargyline

234.5+37.9**

245.5+22.8**

(5)

(4)

AMPT

112.8+13.5

143.1+23.7*

(6)

(4)

237 .3+14. l**

(5)

106~8+

(3)

Cd E+

249.6+22.8**

(5)
7.0

177.3+14.5**

(~

Ce y+

Table indicates the duration of drug-induced sleep, in minutes, for animals receiving the pretreatments plus PB (50mg/kg~ IP). Sleeping times are means±. standard deviationJ with the number of
animals used in parentheses. Significant differences from controls are indicated by* (P<0.05) and

** (P<0.01).
+For explanation of letter designations see Table 1.
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Circadian pattern of pentobarbital-induced sleep after pretreatment with druga affecting the NE and DA systems.

(Open cire les

indicate significant differences from CONTROL, P<0.05 or
for explanation of letter designations see Table 1).
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b.

Alpha-methyl p-tyrosine
The effects of pretreatment with AMPl' (200 mg/kg, IP) are more

complex (Figs. 10-12, Table 3
at 1200 and 2400 hours.

).

A biphasic pattern is obtained, with peaks

There is no significant difference in the duration

of sleep between control and AMPT-treated animals at 0600 and 1800 hours.
However, there are significant increases in sleep duration over controls
at the two peaks, viz. at 1200 (19.8% increase) and 2400 hours (75.0% increase), at the 0.05 and 0.001 level, respectively.

There are also signifi-

cant differences in sleep duration of AMPT-treated animals, when the following
comparisons are made:

0600 vs 2400 hours (P < 0.001); 1200 vs 2400 hours

(P < 0.05) and 1800 vs 2400 hours (P < 0.005).
2.

Drugs Affecting the 5HT System
a.

p-Chlorophenylalanine
pCPA, a 5HT depleton, very significantly prolongs PB-sleep at

each point in the 24-hour pattern (P < 0.001 level; Figs. 13-17, Table 4
The increases over control are as follows:
1800 (49.8%) and 2400 hours (45.9%).
1200 to 1800 hours (Fig. 17 ).

0600 (19.5%), 1200 (34.4%),

The pattern is diurnal, peaking at

The duration of sleep differed significantly

between 0600 and 1200 hours (P < 0.05) and between 0600 and 1800 hours
(P < 0.005) but not between other time points.
b.

Tryptophan
TP,

of secondary precursor of 5HT, significantly increased

PB-sleep over control at each point in the curve (P < 0.001 (Figs. 13-17,
Table 4

), as follows:

).

43.4% (0600), 32.3% (1200), 59.1% (1800)and

•

n

The duration of pentobarbital-sleep after pretreatment with drugs affecting the 5HT system

Table 4:

0600

1200

1800

2400

115.5+ll. 7
(18)

ll9.5+ 9. 7
(17)

109~3+14.l

101.3+ 8.9
(16)

Cd E+

pCPA

137.9+12.7**

161.1+17 .3**

163.7+ 8.6**

147.9+24.5**

a··B+

TP

165.6+15.5**

154.0+16.6**

f+

Treatment
CONTROL

(6)

(17)

(i)

(5)

(5)

158.0+22.l**

173.8+ 7.3**

(9)

(6)

(6)

(5)

131.3+16.3

144.0+15.4**

(3)

(6)

104.3+ 5.5

146.3+21. l**

(3)

(3)

M25

ll4.6+22.2

155.8+ 6.6**

131.2+10.3*

125.2+ 9.3** A D E+

M50

192.3+32.0**

157.3+13.0**

141.5+15.4**

159.8+24.,l**

5HTP

(4)
(3)

(4)

(4)

(4)

(5)

n+

(5)

b+

(4)

Table indicates the duration of drug-induced sleep, in minutes, for animals receiving the pretreatments plus PB (50mg/kg, IP).

Sleeping times are means ~standard deviation, with the number of

animals used in parentheses. Significant differences from controls are indicated by* (P<0.05) and

** (P

<0

0

01).

+i<'or explanation of letter designations see Table 1
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52.0% (2400).

The pattern was relatively flat.

The only significant

variation in the duration of sleep was the decrease from the 1800 hour
value at 2400 hours (P<0.05).
c.

5-Hydroxytryptophan
5HTP, the primary precursor of 5HT, produced a relatively

flat pattern in PB-sleep duration (Figs. 13-17, Table 4).

Significant

differences from control occurred at 1200 and 2400 hours (in each case, P

< 0.001), while the difference between the sleep duration at 0600 hours
and controls was approximately P<0,05.

The increases over control were 20.5%

at 1200 hours, 34.7% at 2400 hours and 13.7% at 0600 hours.

The only sig-

nificant differences among treated groups was between the 1200 and 1800
hour groups (FC0.01).
d.

Melatonin
Melatonin, (M), which was administered at two dose levels(25

and 50 mg/kg, IP), yielded qualitatively and quantitatively different results
for each dose (Figs.13-17, Table 4).

Both increase PB-sleep at every time

point (except for the 25mg/kg (M25) dose at 0600 hours).

Melatonin-modi-

fied sleep at a dose of 25mg/kg peaks at 1200 hours during the light period,
while at the higher dose (50mg/kg, M50) the curve is shifted to peak at
0600 hours, during the dark period.

The M25 dose significantly increases

PB-sleep duration over controls at 1200 hours (P<0.001; 30.4%), 1800 hours
(P<0.05; 20.0%) and 2400 hours (P<0.001; 23.6%).

At this dose signifiurnt

differences occur between treated groups for 0600 vs, 1200 hours (P<O" OG),
1200 vs. 1800 hours (P<0.05) and 1200 vs. 2400 hours (P<0.001).

At the

M50 dose, the PB-sleep duration for all treated groups is significantly

greater than their respective controls (F(0.001).
1800 hours to 66.6%

at~

hours.

173
It ranges from 29.5% at

In a comparison of M25 with M50 treatment

the only significant difference occurs between the 0600 and 1800 hours groups
(P<0.05).
e.

Compounds Structurally- related to 5HT
The effects of several compounds structurally related to 5HT

were tested in mice for their ability to enhance PB-sleep at a single time
point (1500 hours) during their normally-quiescent period.

The compounds

were administered one hour prior to PB, at a dose of 20mg/kg ( in 1% methyl
cellulose).

Table 5 shows significant increases in PB-sleep is produced by

5-methoxytryptamine (P<0.02; 74.6%) and N-acetyl 5HT (P<0,025; 105.4%),
a precursor of M.

5HIAA and 5-methoxy indoleacetic acid

are without signi-

ficant effects.
3.

Drugs Affecting the Histamine System
The possible role of CNS histamine (H) in PB-induced sleep was ex-

amined utilizing its precursor, histidine (Hd), a depletor, decaborane(DB)
and an antihistamine, diphenhydramine (DPH).
a.

L-His tid ine
Three doses of L-Hd, were administered to rats.

The lowest doae

(100 mg/kg, HdlOO) significantly increases PB-sleep over controls at 0600
hours (P<0.05; 15.6%), 1200 hours (P<0.001; 22.0%) and 2400 hours (K0.05;
21.2%) (Figs.18-22, Table 6).

The only significant difference between

treated groups is betwHn the 1200 and 1800 hours groups (P<0.05) .

The

intermediate Hd dose (500mg/kg, Hd 500) increases PB-sleep significantly
over controls at 1800 hours (P<0.001; 47.6%), but decreases PB-sleep

r
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Table 5:

The effects of compounds structura Hy-related to 5HT on pentobarbital-sleep, in mice,

Compound

PB-sleep duration

CONTROL

31. 9+5. 1 (7)

5MT

55.6+12.4 (8)*

N-acetyl 5HT

65.4+11, 7 (7)*

5HIAA

40.5+13,3 (8)

5MIAA

40.5+10.4 (8)

Table indicates the duration of drug-induced sleep, in minutes, for
animals receiving the pretreatment plus PB (50mg/kg, IP) at 1500 hours only.
Sleeping times are means.:!: standard deviation, with the number of animals
used in parentheses.

Significant differences from controls are indicated by

'J

Table 6:

The duration of pentobarbital-sleep after pretreatment with drugs affecting the histamine
system
2400

.QiQQ

!&QQ

1800

115.5+11. 7
(18)

119.5+ 9.7
(17)

109.3+14.l
(17)

101~3+

133.5+12.2*

145.8+ 9.7**

124 0 0+11.0

122.8+18.7*

(4)

(4)

(3)

(5)

Hd500

122.3+14.0

131.8+25.9

HdlOOO

152.3+ 3.5**
196.0+35.6**

Treatment

CONTROL

HdlOO

(3)
(3)

DB

(6)
DPH

289.8+38.7**

(4)

8.9

C t't E+

(16)
d+

161.3+27.6**

87.8+ 9.3*

c e F

142.3+34.7*

168.4+19.2**

114.6+20.6*

c F+

202.0+59.5**

213.5+27.9**

217.7+52.4**

(6)

(4)

(6)

230.3+12.4**

177 .8+54.1**

281.8+60.4**

(4)
(4)

(4)

(3)
(5)

(4)

+

(4)

(5)

a b f+

(4)

Table indicates the duration of drug-induced sleep, in minutes, for animals receiving the pretreatments plus PB (50mg/kg, IP). Sleeping times are means.±. standard deviation, with the number of
animals used in parentheses. Significant differences from controls are indicated by* (P<0.05) and
** (P ( 0 01)
0

0

+:For explanation of letter designations see Table 1.
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indicate significant differences from CONTROL, P<0,05 or greater;
for explanation of letter designations see Table 1),
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significantly at 2400 hours (P < 0.05; 13.4%).

The trough value for this

treatment occurs at 2400 hours and differs significantly (P < 0.05) from the
values at 0600, 1200 and 1800 hours.
\

The highest dose of Hd (1000 mg/kg,

Hd 1000) produces a similar pattern, exhibiting a peak duration of PB-sleep
at 1800 hours and a trough at 2400 hours.

PB-sleep duration increases signi-

ficantly over controls at 0600 hours (P < 0.001; 31.9%), 1200 hours (P < 0.05;

19.1%), 1800 hours (P < 0.001; 54.1%) and 2400 hours (P < 0.05; 13.1%).

The

trough value at 2400 hours differs significantly from the peak value at 1800
hours (P < 0.05) and from the value at 0600 hours (P < 0.05).

Differences
at 0600,

observed between the dosage groups at a given time are as follows:

the difference in the duration of PB-sleep between the HdlOO and HdSOO groups
is not significant, but the difference between the Hd 1000 value and that for
Hd 500 is significant (P < 0.025) and borderline for the Hd 100 dose.
are no significant differences between the doses at 1200 hours.

There

At 1800 hours

there is a significant difference in sleep duration between the Hd 100 and Hd

1000 groups (P < 0. OS).

The Hd 500 value at 2400 hours differs significantly

(P < 0.05) from the other two groups.
b.

Decaborane
Pretreatment with DB very significantly prolongs PB-sleep over

controls at each point tested (P < 0.001; Figs. 18-22, Table 6
increases over controls were as follows:

The

0600 hours (69.8%), 1200 hours

(69.1%), 1800 hours (95.4%) and 2400 hours (114.8%).
exhibit a significant diurnal variation.

).

The pattern

doe~

No significant differences in

sleep duration occur between the treated groups at the times tested.

not
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c.

Diphenhydramine
DPH significantly increases PB-sleep at each experimental time

point (P < 0.001; Figs. 18-22 , Table 6
as follows:

).

The increases over control are

0600 hours (151.0%), 1200 hours (92.7%), 1800 hours (62.7%) and

2400 hours (178.1%).

The pattern is circadian, with a peak at 2400-0600

hours and a trough at 1800 hours.

The differences in PB-sleep duration at

the peak (2400-0600 hours) and the trough are significant (P < 0.05).
4.

Drugs Affecting the Cholinergic System
The effect in mice of physostigmine (0.3 mg/kg, IP) and neostigmine

(0.3 mg/kg, IP) tertiary and quaternary anticholinesterases, respectively,
on hypnosis induced by PB (SO mg/kg, IP) was examined.

The pattern for saline

pretreated is relatively flat and the controls do not exhibit significant
dirunal fluctuations, (Fig. 23 ) although there appears to be a peak at 1800
hours and a trough at 2400 hours.
With physostigmine the only significant increase over controls occurs
at 2400 hours (P < 0.05; 71.8%; Fig. 23

Table 7 ) .

There are no significant

differences between each of the physostigmine-treated groups.

Neostigmine

pretreatment produces significant increases in sleep duration at each experimental time point.

The following increases were noted:

0600 hours

(105.2%; P < 0.001), 1200 hours (67 .6%; P < 0.01), 1800 hours (57 .8/

0 ;

0.06) and

~hours

(101.8%; P < 0.02).

P <

Table 7:

The duration of pentobarbital-sleep after pretreatment with two cholinesterase inhibitors,
in mice
0600

1200

1800

2400

36.3+22.2

36.5+22.5
(11)

41.7+26.0
(9)

26.3+18.3
(11)

61.1+ 8.2**

53.0+23.4*

(9)

(9)

65.8+19.8

(8)

(8)

44.7+30.5

41.0+28.l

(Io)

(ll)

55.2+19. 7
(10)

45.1+18.2*
(9)

Treatment
CONTRDL

(12)
Neostigmine

Physostigmine

74.4+17. l**

c+

Table indicates the duration of drug-induced sleep, in minutes, for mice receiving the pretreatments plus PB (50mg/kg, IP).

Sleeping times are means :!:. standard deviation, with the number of

animals used in parentheses.

Significant differences from controls are indicated by

*(P(0.05) and

** (P<0.01).
+.For explanation of letter designations see Table 1.
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Figure 23:

1800
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2400

Pentobarbital-induced sleep after pretreatment with two anticholinesterases.

(Open circles indicate significant differences

from CONTROL, P<0.05 or greater;
nations see Table 1).

for explanation of letter desig-
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C.

Effects of Histidine Pretreatment on GBL Sleep Duration
Pretreatment of rats with Hd (100 and 500mg/kg, IP) one hour

prior to GBL (350mg/kg, IP) resulted in only one significant difference in
GBL-sleep duration over saline-treated controls.

It occurred at 1800 hours

for the Hd500 (29.7%, P 0,05; Table 8).
D.

CNS Amines at t
1.

!

Following Pretreatment and PB Regimens

Time-course for Amine levels in Controls
Vehicle-treated controls were sacrificed at approximately the same

time as tre ted animals (i.e., t

!

or half-way through the previously-

determined sleep duration for each pretreatment drug) and the brain amine
concentrations determined at the four experimental times during the 24-hour
period.

The time-course of amine concentrations are plotted for each of the

four experimental times (Figs24-27).
the induction of PB-sleep.
t

t

The X-axis represents the time after

The times plotted on the X-axis depend on the

time at which each pretreatment group (control and treated) was sacri-

ficed.
weight)o

The Y-axis represents the amine concentrations (ugm/gm wet tissue

,

........---~~~~~~~~-

Table 8: The duration of gannna-butyrolactone-sleep after pretreatment with histidine

0600

1200

1800

2400

CONTROL

98.0+ 3.6

llO. l+ 4.5

96.4+16.2
(11)

88.3+10.0

HdlOO

91.9+1 .9

108.7+

1~5

100.1+15.l

91.5+15.6

(4)

(4)

125.0+ 5.7*

93.8+ 4.0

Treatment

Hd500

(6)

(8)

(4)

(3)

98.3+ 9.5

103.1+13.l

(4)

(8}

A c d E+

CD

(2)

b F+

(6)

Table indicates the duration of drug-induced sleep, in minutes, for animals receiving the histidine
pretreatment plus GBL (350mg/kg, IP). Sleeping times are means ±.standard deviation, with the number of
animals used in parentheses. Significant differences from controls are indicated by

*

(P< 0 0 05).

+.For explanation of letter designations see Table 1.
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The time-course of CNS amine concentrations of CONTROLS -- 0600 hours.
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concentrations for CONTROLS, which are compared to the TREATED groups, are
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The time-course of CNS amine concentrations of CONTROLS -- 1200 hours.
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The time-course of CNS amine concentrations of CONTROLS -- 1800 hours.
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The time-course of CNS amine concentrations of COl'iTROLS -- 2400 hours.

Mean

concentrations for CONTROLS, which are compared to TR.EA TED groups, are plotted
at their corresponding t } time.
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At 0600 hours, the only significant alteration in the MB amine timecourse pattern (Fig. 24) occurs between the 5HT values at 60 and 70 minutes
(P < 0.02).

There is a significant reduction of CN NE levels at 120 minutes

as compared with the value at 145 minutes (P < 0.02).

Brain stem 5HT is

elevated significantly at 120 minutes, over the values at 85 or 145 minutes
(both P < 0.001).

Hypothalamic DA concentrations exhibit a significant

difference between the values at 70 and 85 minutes (P < 0.05).
At 1200 hours MB NE levels differ significantly between 80 and 100
minutes (P < 0.05).

MB DA levels exhibit significant differences between 80

and 100 minutes (P < 0.01) and 100 and 115 minutes (P < 0.025).

There are

significant variations in CN DA concentrations between the following times:
70 vs. 80 minutes (P < 0.05), 80 vs. 100 minutes (P < 0.001) and 115 vs. 125
minutes (P < 0.01).

Hypothalamic DA content at 145 minutes is increased

significantly from that at 115 minutes (P < 0.05)(Fig. 25).
At 1800 hours, significant differences between MB DA levels occur
between 60 and 65 minutes (P < 0.01) and 80 and 90 minutes (P < 0.05).
5HT content between 60 and 65 minutes differs significantly.

MB

Brain stem DA

reaches a minimum at 90 minutes, which differ significantly from the value at
120 minutes (P < 0.05).

Hypothalamic NE levels at 60 minutes are elevated

from that at 65 minutes (P < 0.025).

Hypothalamic 5HT content is reduced

significantly at 90 minutes, and differs from 80 minutes (P < 0.05) and 120
minutes (P < O.OOl)(Fig. 26),
At 2400 hours there are significant differences in MB NE levels
between the following times:

75 vs. 85 minutes (P < 0.01), 85 vs. 110

minutes (P < 0.001) and 110 vs. 125 minutes (P < 0.005).

Between 75 and 85

r
r
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minutes and 125 and 145 minutes MB DA levels differ significantly (both
P~0.005).

MB 5HT is elevated at 125 minutes, differing significantly from

that at 100 (P<0.002) and 145 minutes

(P~0.05).

CN NE concentration is de-

creased significantly at 110 minutes from the values at 85 minutes (P<0.02)
and 125 minutes (P<-0.05).
CN DA concentrations:

There are several significant differences between

50 vs. 60 minutes

0.02) and 110 vs. 125 minutes (P<0.025).

(~0.005),

75 vs. 85 minutes (P<

Brain stem NE levels are signi-

ficantly lower at 110 minutes than at 125 minutes ( P<0.02 ).
DA levels vary significantly:

Brain stem

75 vs. 85 minutes ( P<0.05 ), 85 vs. 110

minutes ( P<0.02 ), 110 vs. 125 minutes ( P<0.02 ) and 125 vs. 145 minutes
( P<0.05 ).

Hypothalamic DA concentrations reach a minimum at 145 minutes

differing significantly from the value at 125 minutes ( P<0.01).

Hypotha-

lamic 5HT concentrations differ significantly between the 85 and 110
minutes determinations (
2.

P~0.05)

(Fig. 27 ).

Drugs affecting the NE and DA systems
a.

DOPA-pargyline
DL-DOPA ( 500 mg/kg, IP ) and pargyline ( 6 mg/kg, IP )

administered to rats one hour and 30 minutes, respectively, prior to
PB ( 50 mg/kg, IP).

DOPA-pargyline treatment significantly increased

DA ( P<0.05 or less ) above control in almost all parts of the brain
examined ( 15/16 ).

(Table 9, Figs. 28 - 29 ).

following increases were obtained:

At 0600 hours the

MB ( 724.7%, P<0.02 ), CN ( 44.0%,

P<0.05 ), brain stem ( 1045.7%, P<0.005) and hypothalamus ( 1457.5%

193
Table 9:

MB NE

CNS concentrations of NE, DA and 5HT after DOPA-pargyline
pretreatment with PB, on a 24-hour basis.
0600

1200

1800

2400

c

,69+.14

• 88+. 03

.81+.17

,75+.04

(3)

(2)

(3)

(3)

T

.74+.05

.93+.08

.79+.02

(3)

(4)

. 79+.17

c

1. 79+.25

2.52+.54

2 .02+.25

(2)

(3)

2 .55+ .4·1

(3)

T

1. 97+. l 7

2.41+.18

2. 71+.21

(3)

(4)

2.37+.62

c

. 08+. 03

.19+.06

.18+.02

.17+.05

T

.19+.04*

.32+.07

.44+.07**

(3)

(4)

.42+.14*

c

.83+.04

. 93+.16

.85+.13

(2)

(3)

(3)

T

.92+.02*

. 99+ .13

1.00+. 26

1. 08+.19

(4)

(4)

(4)

.26+ .13

.16+. 03

Hpth NE

CN NE

(3)

(2)

Stem NE

(3)
(3)

MB .M

c
T

.15+.005

.13+.008

CN DA

(4)

(3)
(4)

(2)

(2)

(3)

1.21+.29*

1.13+.40*

3.09+.22**

(3)

(4)

(3)

.42+.04

.18+.05

Hpth DA

c

(4)

.18+.06

(3)

(4)

(3)
(4)

(3)

(4)
.96+.08

(3)
2.64+.46**

(3)
.35+.04

(2)

(3)

(2)

T

2.74+.67**

4.17+. 96**

9.81+.75**

(4)

(4)

(3)

c

6.81+1.58

8.47+.61

7.37+2.04

6.12+.93

(3)

(2)

T

9.80+.33*

(3)

(3)

10.41+.88

(3)

(3)

(3)

12.49+2.66*

11. 54+2. 18*

(4)

Stem DA

c
T

6. 55+1. 41 **

(3)
.23+.004

.10+.04

.ll+.07

.17+.0l

(3)

(2)

(3)

(2)

1.30+.44*

3.66+.89**

(3)

(4)

2.26+.52*
(3)

1.15+.28**

(3)

r
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Table 9 (continued)

MB 5HT

1800

0600

1200

c

. 56+. 11

.57+.03

1. 02+. 23

(3)

(2)

(3)

T

.37+.06

.44+.05

.36+.06*

2400
1. 00+.15

(3)
.40+.08**

(3)

(3)

(2)

(3)

.49+.15

.85+.16

2.03+.06

(2)

(2)

.39+.15

(3)
.48+.10

.87+.09

2.26+.92

1.16+.22**

(3)

(3)
.30+.13

Hpth 5HT

c
T

CN 5HT

c
T

(3)

(3)

(3)

.22+.05

.42+.12

.40+.12

(3)

(2)

(3)

(3)

.25+.05

. 60+.15

.47+.10

.29+.07

(3)

(3)

(3)

(3)

.73+.02

.85+.07

.74+.17

. 60+' 12

(3)

(2)

(3)

(3)

.44+.08

.48+.09

(3)

(3)

Stem 5HT

c
T

.57+.10

(3)

.65+.07*

(3)

Table indicates amine concentrations (ugm/gm) of NE, DA and 5HT in
midbrain (MB), hypothalamus (Hpth), caudate nucleus (CN) and brain stem
(Stem) of rats receiving DOPA-pargyline pretreatment and PB (50mg/kg, IP).
Animals were sacrificed midway through the previously-determined sleeping
time. Values are means + standard deviation, with the number of animals used
in parentheses. Significant differences from control are noted by* (P<0.05)
or** (P<0.01).
C = Control; T= Treated
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Legend for Figure 28

The effects of DOPA-pargyline pretreatment with pentobarbital, on the
concentrations of NE, DA and 5HT -- CONTROLS.

C~S

Mean amine concentrations

are plotted on a three-cycle scale(Y-axis), with the X-axis the daily time
(hours).

Letter designations adjacent to the amine pattern indicate point

to point comparisons within each 24-hour pattern: a A (0600 vs 1200 hours),
b B (0600 vs 1800 hours), c C (0600 vs 2400 hours), d D (1200 vs 1800 hours),
e E (1200 vs 2400 hours) and f F (1800 vs 2400 hours).

Lower case indicates

P<0.05 and capitals indicate P<0.01 for significant differences.
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Legend for Figure 29

The effects of DOPA-pargyline pretreatment with pentobarbital, on the C~S
concentrations of NE, DA and 5HT -- TREATED.
notation of figure, see legend to Figure 28.

For complete explanation of
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p

0.005).

NE levels also increase in the .Q'i. (13705%, P

stem (10.4%, P <:0.025).

0 0 02) and brain

At !,gQQ, hours, DA levels increase as follows:

MB

(745.5%, P<.0.05), ~ ~ (111203%, P<Oo05) and hypothalamus (891.6%,
p(0.01).

On the other hand, 5HT levels decrease significantly in the brain

stem (23.Q%, P ( 0.05). At 1800 hours DA concentrations are significantly
elevated in the MB (1094.4%, p( 0.001), CN (69.6%, P<Oo05), brain stem
(1992.4%, p <o.005) and hypothalamus (5394.6%, P <0.001).

MB 5HT decreases

significantly (64.4%, P<0.05), while .Q'i. NE increases significantly (132.1%,
p <0.05).

At g!Q.Q. hours the significant increases in DA levels were:

(1536.6%, P <0.001), .Qli (89 0 0%, P

<0.02),

MB

brain stem (879.5%, P <Oo02) and

hypothalamus (1753.4%, P<0.01). Significant increases occur for CN NE
(154.1%, P

<0

0

005) and hypothalamus 5HT (200.4%, P ( 0.01).

Of the 24-hour

patterns obtained for the three amines, 9 of 12 are circadian, while the
remainder are unvarying.

Fluctuation of patterns was found for NE in the MB,

CN and hypothalamus; for DA in MB .. brain

Qi, brain stem and hypothalamus.

~

For details of this aspect of the study

refer to Figs. 28-29, Table 9 and to Appendix
b.

and hypothalamus and for 5HT in

B •

Alpha-methyl-E,-tyrosine
.AMPT (200mg/kg, IP) was administered four hours prior to PB.

In almost all cases, NE and DA levels are significantly decreased from controls (TablelO, Figs,30-31 ).

At 0600 hours, NE concentrations are signif-

icantly lower in the MB (52.6%, P<0.005), CN (61.2%, p<0.001), ~stem
(45 8%, P ( 0 005) and the hypothalamus (53 9%, P<,0.005)o
0

0

0

DA levels are

reduced significantly in the CN (77 .8%, P < 0.001) and hypothalamus (86.3%,
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Table 10:

MB NE

CNS concentrations of NE, DA and 5HT after AMPT pretreatment
with PB, on a 24-hour basis
0600

1200

1800

2400

c

.69+.04

.70+.12

.82+.08

.92+.04

(4)

(4)

(3)

T

. 33+ .14**

.39+.03**

.37+.04**

(4)
.38+.05**

(4)

(4)

(5)

(4)

2.27+.44

2.12+.34

2.62+.13

2.94+.59

(4)

(6)

(3)

Hpth NE

c
T

1.05+.15**

1.01+.23**

1.03+.19**

(4)
1.11+.18**

(4)

(4)

(5)

(4)

.17+.10

.16+.04

.19+. 03

.23+.06

(5)

(3)

CN NE

c
T
Stem NE

c
T

(2)

.07+.04**

(4)

(5)

(4)

.94+.13

.83+.09

.84+.08

.92+.15

(4)

(6)

(3)

.51+.02**

c

.43+.05**

(6)

.40+.07**

(5)

(4)

. 45+. 03**

(4)

c

.12+.02

.13+.05

.25+.0l

(3)

(3)

(2)

.11+. 02

.09+.0l

(3)

(4)

(4)

(4)

.36+.10

.18+.07

.54+. 17

. 44+.15

(3)
T
CN DA

(4)

.17+. 05

-----

T
Hpth DA

.10+. 03*

(4)

(3)
MB DA

.13+.03

c
T

.05+.02*

(4)

.10+.02**

(3)

.25+.01

(2)
.14+.03*-ll-

(4)

.15+.07

.30+. 09

(3)

(4)

(2)

(3)

8 .24+1. 00

9.26+1.52

(4)

7.33+1.49

(5)

10. 02+1. 88

(3)

1.83+.39**

1.99+.53**

2.20+.81**

.12+.07*

(4)
2 .87+

'.~:i**

(4)

(4)

(5)

.11+. 05

.13+.06

(3)

.26+.08

(4)

(2)

(2)

.17+.06

.03+.03

(5)

(3)

(4)

Stem DA

c
T

.08+.006

(3)

.29+.10*

(6)

.02+.00;3

r
r
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Table 10 (continued)

MB 5HT

c

0600

1200

1800

2400

.30+.08

.53+.08

.35+.06

A8+.20

.85+.14**

.39+.07

.48+.08

(4)
'I'

,60+.02**

(3)

(2)

(4)

(3)

(3)

(3)

(3)

.59+.09

.96+.18

L 00+.13

.52+.05
( 3)
.48+.23

Hpth 5HT

c

(4)
T
CN 5HT

c
T

.68+.18

(3)

.53+.07*

(4)

(3)

.33+.21

(3)
(.97)
(1)

(4)

.37+.0l

(3)

.34+.17

(4)
.31+.06

.37+.05

.16+.05

(3)

(3)

(4)

.39+.04

. 68+. 05

.19+,04

(3)

(4)

(3)

,92+.28

.16+.05

(3)

(3)

(4)

Stem 5HT

c

T

.58+.05**

(3)

Table indicates amine concentrations (ugm/gm) of NE, DA and 5HT in
the four areas indicated in Table 9, for animals receiving AMPT pretreatment
and PB (50mg/kg, IP). Animals were sacrificed midway through the previouslydetermined sleeping time. Values are means ± standard deviation, with the
number of animals used in parentheses. Significant differences from control
are noted by* (P<0.05) or** (P<0.01).
C •Control; T =Treated
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P<0.01).

On the other hand, 5HT concentrations are elevated significantly

202

in the MB (99.9%, P<0.005) and brain stem (48.3%, P<0.01).

--

-

At !_gQQ hours, NE levels decrease signigicantly in the MB ( 43. 6%, P<
0.01), brain stem (48.2%, P<0.001) and hypothalamus (52.1%, P<0.005).

DA

concentrations are lowered significantly in the CN (78.5%, P<0.001), but
increase in the brain stem (131.8%, P<0.05).

5HT levels increase signifi-

cantly in the M!!_ (60.3%, P<0.025), but decrease in the hypothalamus (44.5%,
P<O. 02).
At 1800 hours NE levels decrease significantly in the MB (55.4%,P<
0.001), CN (43.9%, P<0.02), brain stem (51.6%, J>'(0.001) and hypothalamus
(60,5%, P<0.001).

DA concentrations are reduced significantly in the MB

(58.6%, P<0.001) and CN (70.Q%, P<0,001).
NE levels at 2400 hours are decreased significantly in the MB (58.9%,
P(0.001), brain stem (50,8%, P<0.001) and hypothalamus (62.2%, P<0.001)
and there is a significant reduction of DA levels in the MB (44.0%, P<0.01),
CN (71.4%, P<0.001) and hypothalamus (74.7%, P<0.02).

Of the 12 amine

patterns, after AMPT treatment 7 display diurnal rhythms.

These can be

examined in detail in Figs.30-3l,Table 10 and in Appendix B .
3.

Drugs Affecting the Serotonin System
a.

£-Chlorophenylalanine
pCPA (3 x lOOmg/kg, IP) depletes brain 5HT significantly in all

brain tissues examined, at each time point studied, with relatively minor
effects on CAs (Table 11, Figs.32-33).

At 0600 hours, 5HT concentratio.1s

are reduced significantly in the MB (97.0%, P<0.01), CN (87.8%, P<0.01),
brain stem (94.8%, P<0.01) and hypothalamus (P<0.01).

At 1200 hours, 5HT

203
Table 11:

MB NE

c
T

CNS concentrations of NE, DA and 5HT after pcPA pretreatment
wi.th PB, on a 24-hour basis
0600

1200

1800

2400

.67+.08

,69+.06

. 74+. ll

. 68+ .10

(3)

(3)

(4)

(3)

.65+.03

'64+. 11

.59+ .14

.67+.10

2.00+.18

(3)

(5)

(5)

(5)

Hpth NE

c
T

CN NE

c
T

1. 99+,31

2.18+.23

(3)

(3)

(4)

1. 94+.53

1. 76+,27

(3)

(4)

.16+.03

.19+.07

,23+.06

(3)

(3)

(3)

.19+.02

.19+.04

.18+.02

(3)

(5)

.14+.03*

.97+.12

,97+.18

.87+.09

,82+.10

(3)

(3)

(4)

2.11+.21

1. 28+. 20**
(5)

(5)

(3)
2.03+.34

(5)
.16+,04

(3)

(5)

Stem NE

c
T

.86+.13

.70+,05*

'70+. 07**

(3)
.67+.10

(3)

(5)

(5)

(5)

.09+.03

'11+. 02

.16+,0l

. 09+. 03

(3)

(3)

(3)

(3)

.11+. 03

.10+.03
(5)

MB DA

c
T

,09+.02

'08+. 02*

(3)

(5)

(4)

.26+.02

.29+,06

.44+.12

(3)

(2)

(3)

.28+,05

,25+.06

(3)

(5)

(4)

(4)

6.35+1.05

6.42+,87

10,06+2,78

(3)

(3)

(3)

4. 71+1.16

4.87+.80*

7.33+.49

(3)

(5)

(5)

5. 17+1. 03
(3)
5 .4.i .80

.09+.02
(2)
,03+.04

,08+.02

,07+.02

.08+.01

(3)

(4)

(3)

,08+.0l

.08+,03

,07+.04

(3)

(5)

(4)

(5)

Hpth DA

c
T

.12+,03**

.26+.06
(3)
.18+.08

CN DA

c
T

(5)

Stem DA

c
T
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Table 11 (continued)

0600

1200

1800

2400

c

.93+.31

.70+.20

. 71+.20

.61+.09

(3)

(2)

(4)

T

,03+.0l**

MB 5HT
.08+.04**

.08+.02**

(2)
.36+.09*

(3)

(5)

(4)

(4)

c

.40+. ll

.72+.20

.87+.15

.89+.41

T

~)**

,08+.07**

. 05+. 003*

Hpth 5HT

~-)

(3)
.24+.12**

(2)

(3)

(5)

(3)

(3)

. 24+. 02

,38+.13

.49+.14

CN 5HT

c

,33+.07

T

,04+.07**

(3)

(2)

.02+.02**

(4)
.10+. 03**

(3)
.13+.0l*

(3)

(4)

(4)

(3)

.46+.14

.75+.09

. 64+.12

.50+. 08

Stem 5HT

c

(3)
T

.02+.04**

(3)

(3)

.10+.03**

(5)

(2)
.03+.02**

(4)

(3)
.07+.03**

(5)

Table indicates amine concentrations (ugm/gm) of NE, DA and 5HT in
the four areas indicated in Table 9, for animals receiving pCPA pretreatment
and PB ( 50mg/kg, IP). Animals were sacrificed midway through the previousl,vdetermined sleeping time. Values are means ±standard deviation, with the
number of animals used in parentheses.
Significant differences from control are noted by* (P<0.05) or** (P<0.01).
C =Control; T =Treated
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The effects of pCPA pretreatment with pentobarbital, on the CNS concentrations
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see legend to Figure 28.
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levels decrease significantly in the MB (89.3%, P<0.001), CN (92.1'.~.
P<0.001), brain stem (86.8%, P<0.001) and hypothalamus (6G.9?~. P(0.01).
DA levels decrease significantly in the MB (29.1%, P<0.05) and CN (24,2%,
P<0.05), while NE is reduced in the brain stem (27.7%, P::::0.02).
At 1800 hours 5HT content is reduced significantly in the MB (89.0%,
P<0.001), CN (74.5%, P<0.005), brain stem (95.0%,P<0.001) and hypothalamus
(90.5%, P<0.001).

NE levels are reduced in the CN (39.7%, P<0.02), brain
~

stem (19.9%, P<0.01) and hypothalamus (41.6%, P<0.001).
is reduced significantly (72.7%, P<0.005).

~~-

Hypothalamic DA

At 2400 hours there is a si~ni-

ficant decrease of 5HT in the MB (40.4%, P<0.05), CN (72.9%, P<0.02), brain
stem (86.6%, p<0.001) and hypothalamus (94,1%, P<0.025).
were seen in 8 of 12 amine patterns studied.

Fluctuating patterns

For additional details, cf.

Figs.32-33, Table 11 and Appendix B.
b.

Tryptophan(Figures 34-35, Table 12)
TP (500mg/kg,IP) was administered one hour prior to PB.

At

0600 hours 5HT concentrations in treated animals are increased significantly
in

the ~B (40.5%, P<0.005) and the hypothalamus (130.7%, P(0.005), ~in the

hypothalamus is reduced significantly (15,7%, P<0.05),

At 1200 hours TP

decreased DA significantly in the MB (30.4%, P<0.05), brain stem (81.0%,
P<0,005) and hypothalamus (29.3%, p<o,05).
cantly (48.5%, P<0.05).

CN NE levels decrease signifi-

Atl800 hours, hypothalamic 5HT is increased E"i~-

nificantly (692.0%, P<0.01), while MB NE decreases significantly (26.:2"1'.,
P<O. On).

J\ t

2400 houn1, bra in stem 5HT levels increase significantly

(42.9%, P<0.05), while hypothalamic DA decreases significantly (42.0%, P<

r
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Table 12:

MB NE

c
T

CNS concentrations of NE, DA and 5HT after 'TP pretreatment
with PB, on a 24-hour basis
0600

1200

1800

2400

,67+.04

.69+.06

.98+.08

'68+ .10

(3)

(3)

,73+.ll*

.70+,09

. 62+. 03

.65+.05

(2)

(3)

(4)

(5)

(5)

(5)

2' 07+ .11

L99+. 31

L 96+. 02

2.01+.rn

(3)

(3)

(2)

(3)

T

L 75+. l 7*
(T4)

2, 10+.50

2,21+.35

2,04+.27

(5)

(5)

(5)

c

.13+.02

.19+.07

(3)

(3)

Hpth NE

c

CN

~'E

T

.19+.03

,16+.04

,15+.04

.14+. 04

(5)

(5)

(5)

.79+.04

.97+.18

1.10+.14

. 82+' l 0

(3)

(3)

(3)

(3)

.76+.08

. 80+. 03

.92+.08

.79+.08

(4)

(5)

(5)

(5)

.12+.05

.12+.02

(3)

(3)

,12+.02

(4)

.10+.02*

(2)

(3)

Stem NE

c
T

MB DA

c
T

.12+.006

.08+.02*

.11+. 002

(2)

.13+.05

. 09+' G:3

(3)
'14+. 03

(4)

(5)

(4)

.18+.03

.29+.06

,22+.0l

.26+,06

.20+.02*

,22+.12

.15+.02*

(5)

Hpth DA

c

(3)
T

I'\

.28+.14

(2)

(2)

(4)

(5)

(4)

G.63+1.17

6.42+.87

7 .58+ 10

(3)

(3)

(2)

4.06+.73

5.31+.82

6,99+,81

(3)
(4)

DA

c
T

(4)

(5)

0

(5)

G. 17 + l, 0.'3
( :1)
6.5F+ .. 74

Cs)

:'t"'m DA

c

,08+.005

T

.08+.02

(2)
(4)

• 08+. 02

(3)
.01+.0l**

(3)

. 04+. 03

(2)
. ll+. 04

(5)

.08+.006
(3)
.08+.02

(5)
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Table 12 (continued)

0600

MB 5HT

c

.47+.04

(3)

1200

0

70+.20

1800
.80+.07

(2)

(2)

2400
(. 55)
(1)

.79+.16

L49+.43

(4)

(5)

(4)

(5)

c

.31+.04

.72+.20

.31+.0l

.89+.41

T

.72+.ll**

.82+.05

2.47+.44**

.80+ .11

T

.60+.12**

.6:~+.20

Hp th 5HT

Ci\ 5HT

(3)

(3)

(2)

(3)

(4)

(3)

.28+.06

.24+.02

.34+.08

(3)

(2)

(2)

(3)

.29+.06

.37+.08

.51+.19

.45+.12

(4)

(5)

(5)

(5)

c

.46+.02

.76+.09

.49+.05

..50+. 08

T

.53+.13

.78+.08

.67+.16

.72+.1;3+-

(4)

(5)

(5)

c
T

(3)

(5)
.49+. 14

Stem 5HT

(2)

(3)

(2)

nn
(5)

Table indicates amine concentrations (ugm/gm) of NE, DA and 5HT in
tlw four areas indicated in Table 9, for animals receiving TP pretreatment

and PB (50mg/kg, IP). Animals were sacrificed midway through the previousJydetermined sleeping time. Values are means .±.standard deviation, with the number of animals used in parentheses. Significant differences from control are
noted by* (P 0.05) or** (P 0.01).
r = Control; T = Treated

,

r
FigurP 34

10

TPc
5

5

MB-Hpth

CN-Stem

CN DA

HpthNE

1.0

Hpth5HT a

1.0
Stem NE bf

MBNE B df
..... , MB5HT

0.5

0.5r Stem5Hr de

HpthoA
CNNE b

0.1
-----MBDA

05

0.1
Stem DA

.05

.010600

1200

1800

2400

.01
0600

1200

1800

2400
[\,:,

......

--

---------

~

210a

Legend for Figure 34

The effects of TP pretreatment with pentobarbital, on the CNS concentrations
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A majority (10/12) amine patterns showed significant variation over the
24-hour experimental period.

Details of these findings can be seen by refer-

ring to Figs.34-35, Table 12 and Appendix B.
c,

Melatonin(Figures36-37, Table 13)
M (25mg/kg, IP) was administered simultaneously with PB,

At

0600 hours M increases MB 5HT levels significantly (76,3%, P<0.01) from controls, while MB DA decreases significantly (43.9%, P<0.02) (Table 13, Figs.3637).

At 1200 hours brain stem 5HT levels are reduced (46.3%, P<0.01) and

hypothalamic DA decreases (76,1%, P<0.02).

Atl800 hours, M lowers CN DA

significantly (11.8%, J><0.05). Diurnal variations were obtained in 8/12
amine patterns.

These are described in detail in Fig.37, Table 13 and in

Appendix B.
4.

Drugs affecting the Histamine System
a.

L-Histidine
L-Hd (500mg/kg, IP) was administered one hour prior to PB.

At

0600 hours, MB 5HT is significantly increased over controls (107.8%, P<0.02).
DA concentrations are reduced in the brain stem (67.1%, P(0.05) but elevated
in the hypothalamus (332,8%, P<0,005).

At 1200 hours, brain stem 5HT de-

creases significantly (28.3%, P<0.02).

At 2400 hours, significant elevat ons

occur in MB DA (135.0%, P<0.005) and hypothalamic 5HT (73.6%, P<0.01)
concentrations.

Details of the diurnal fluctuBtions of amine patterns (7 of

12) after Hd500 are indicated in Fig.39, Table 14 and Appendix B.
b.

Decaborane(Figures40-41, Table 15)
DB (15mg/kg, IP) was administered 24 hours prior to PB.

The

Table

13:

CNS concentrations of NE, DA and 5HT after M25 pretreatment with PB, on a 24-hour basis
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0600

1200

1800

2400

c

.69+.04

.69+.06

.61+.12

(3)

(3)

.70+.10

(4)

T

.73+.12

MB NE

Hpth NE

(3)

.63+.08

.64+.ll

.68+.04

(4)

(4)

(5)

(5)

c

2.27+.44

1.99+.31

1. 76+.40

2.13+.21

(4)

(3)

(3)

(3)

T

1. 98+.49

1.69+.49

1.75+.19

(5)

(4)

(5)

1.99+.41

c

.17+.10

.19+.07

.14+.09

.14+.04

(2)

(3)

(3)

(3)

T

.14+.04

.10+.02

.15+.0l

.14+.02

(4)

(4)

(5)

(5)

c

.94+.13

.97+.18

.91+.07

.85+.05

(4)

(3)

(3)

(3)

T

.89+.14

• 79+.14

.91+.14

(4)

(5)

.87+.04

• ll+.02

.13+.0l

.09+.04

(3)

(2)

(3)

.09+.05

(4)

.12+.0l

.09+.03

(4)

(4)

(4)

c

.26+.09

.29+.06

.18+.03

(2)

.26+.09

(2)

(3)

T

.17±..01

.16±..03

.22±..01

c

8.24+1.00

6.42+ .87

8.12+ .19

6.83+ .11

(4)

(3)

(3)

6.90+ .87

7 .06+1.37

CN NE

Stem NE

(5)

(5)

(5)

MB DA

c

.12+.02

T

.07+.0l*

(3)

Hpth DA

(3)

.07±..03*

CN DA
T

(5)

Stem DA

c
T

• ll+.05

(3)
.06+.02

(5)

(3)

7.17+ .58*

(5)

.08+.02

.10+.03

(3)

(2)

.05+.03

.05+.03

(3)

(5)

(3)
7 .15+1. 09

(5)
.05+.05

(3)
.03+.001

(4)

r
Table 13 (continued)

MB 5HT

214

1800

2400

85+ 009

048+ 008

1.05+.21

.97+.17

(4)

(4)

(5)

.61+.15

c

.59+.09

.72+.20

.61+.25

(3)

(3)

.30+.04

(4)

T

.64+.15

.84+.05

.38+.21

(5)

(4)

(4)

.28+ 010

c

.33+.21

.24+.02

.28+.04

(4)

(2)

(3)

(2)

T

.43+.09

.26+. 02

.47+.13

(5)

(4)

(5)

.46+.13

c

.39+.04

.76+.09

.66+.ll

(3)

(3)

T

.60+.31

0600

gQQ

c

.30+.08

• 70+ 020

T

.53+.09**

(4)

(2)

0

(3)

(3)

(5)

Hpth 5HT

(2)

(4)

CN 5HT
036+ 0 04

(4)

Stem 5HT

(3)

(5)

.41+.,12**

(4)

.82+ 014

(5)

.41+.07

(3)
0

38+ 018

(4)

Table indicates amine concentrations (ugm/gm) of NE, DA and 5HT in
the four areas indicated in Table 9, for animals receiving M25 pretreatment and PB (50mg/kg, IP). Animals were sacrificed midway through the
previously-determined sleeping time. Values are means ~ standard deviation,
with the number of animals used in parentheses. Significant differences
from control are noted by * (P (0.05) or ** (P< 0,01).
C = Control; T = Treated
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Legend for Figure 36

The effects of M25 pretreatment with pentobarbital, on the CNS concentrations
of NE, DA and 5HT -- CONTROL.

For complete explanation of notations of

figure, see legend to Figure 28.
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Table 14:

CNS concentrations of NE, DA and 5HT after Hd500 pretreatment with PB, on a 24-hour basis

217

0600

1200

1800

2400

c

.69+.04

.70+.12

• 74+.ll

.77+ 010

T

.70+.08

MB NE

(4)
(4)

(4)

(4)

(4)

.75+.08

.76+~13

.85+.08

2.12+.34

2'.18+.23

2.11+.35

(5)

CD

(4)

Hpth NE

c

CN NE

2.27+.44

(4)

(6)

T

2.57±_.46

2.31±..53

2.13±_.37

1 0 17±_037

c

.17+.10

.16+.05

.23+.06

.21+.08

T

(2)
.52+.14

(3)

(5)

.17+.04

(5)

(4)

(4)

(3)

(4)

.22+.03

.18+.04

(7)

(4)

.87+.09

.90+.ll

Stem NE

c
T

.94+.13

(4)

.89+.14

(4)
MB DA

c

Hpth DA

.12+.02

(3)

.83+.09

(6)

(4)

• 78+~ 10

.93+~10

(5)

(7)

.13+.05

.16+.0l

(3)

(2)

T

.26±_. l 7

.26±_.07

.11±_.04

c

.26+.09

.18+.07

.44+.12

T

(3)
1.11+.28**

(4)

(4)
.22+.07

(3)

(3)
.37+. 11

(6)

(4)
.90+.ll

(4)

.21+.07

(3)

.50±_.05**
(.35)
( 1)
( .29)

( 1)

CN DA

c
T

8.24+1.00

(4)
7.91+1.28

(3)

9.26+1.52

(5)
ll.96+3.02

(2)

10.06+2.78

(3)
9.06+1.46

(7)

10.48+ .87

(3)
9.82+1.84

(4)

Stem DA

c
T

11+ 005

.13+.06

(3)

.07+o02

(4)

(4)

.04+.02*

(3)

.09+.03

.07+.0l

.13+.07

0

(4)

(2)

(2)

.08+.02

(3)

Table 14 (continued)
0600
MB 5HT

21 8

1800

2400

.53+~07

.71+.20

.64+.19

(3)

(4)

.!_gQQ

c

.3o+.o8

T

.63;t.18*

~ 60;t.14

.66;t.15

0

c

.59+.09

.98+.18

.87+.15

.45+.10

T

.73+.24

.79+.15

1.02+.04

c

.33+.21

.36+.007

(4)

(2)

(4)

(4)

T

.30+.15

.29+~12

.39+.09

(4)

(2)

(5)

o44+. 10

c

.39+.04

.68+.05

.64+.12

.51+.19

(4)

(2)

(4)

T

.35+.ll

.49+. 10*

• 65+. 14

• 62+. 17

(4)

(4)
80;t.. 13

Hpth 5HT

CN 5HT

(4)

(4)

(3)

(4)

(2)

(4.
.78+.10**

(2)

(3)

.38+.,13

.41+.08

(3)

Stem 5HT

(3)

(4)

(5)

CD

(3)

Table indicates amine concentrations (ugm/gm) of NE, DA and 5HT in the
four areas indicated in Table 9, for animals receiving Hd500 pretreatment and PB (50m.g/kg, IP). Animals were sacrificed midway through the
previously-determined sleeping time. Values are means ±. standard deviation,
with the number of animals used in parentheses. Significant differences
from control are noted by * (P < 0.05) or ** (P < 0.01).
C = Control; T = Treated
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Legend for Figure 38

The effects of Hd500 pretreatment with pentoharbital, on the CNS concentrations of NE, DA and 5HT -- CONTROL.
of figure, see legend to Figure 28.
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Table 15:

CNS concentrations of NE, DA and 5HT after DB pretreatment
with PB, on a 24-hour basis

-0600

gQ2

1800

2400

• 90+.12

.40+.02

221

MBNE

c

.68+.09

(3)
T

.28+.05**

(5)
Hpth NE

c

1.93+.18

(3)
T

.42+.19**

(4)

.56+.02

(2)
.22+.03**

(5)
2.04+.22

(3)
.43+.09**

(4)

(3)
.24+.03

(4)
1.99+.14

(3)
.47+.07**

(4)

(2)
.17+.0l**

(3)
.96+.09

(2)
.23+.09**

(4)

CNNE

c

.10+.02

(3)
T

.l0+.06

(5)

.14+.02

(3)
.07~03

.18+.02

(3)
.09+.02

.05t1-03

(2)
.05+.0l

(5

(3)

.7ll+.14

.97+.13

.66+.006

.33+.04**

.31+.06**

(4)

Stem NE

c
T

.81+.04

(3)

.37+.05**

(5)

(3)

.35+.04**

(5)

(3)

(4)

(2)

(4)

MB DA

c

.13+.03

(3)
T

.39+.12*

(5)
Hpth DA

c
T

.18+.04

(3)

.76+.05**

(4)
CN DA

c

6.22+1.37

(3)
T

8.21+ .57*

(5)

.04+.003

(2)
.13+.05

(5)
.12+.007

(2)
.14+. 05

(3)
11. 63+ • ll

(3)
ll.71+ .• 10

(5)

.18+.06

(3)
.17+.07

(3)
.20+.03

(3)
.21+.03

(4)
7.47+1.07

.16+.07

(2)
.10+. 02

(3)
.23+.02

(2)
.12+.06

(2)

(3)

9.81+ .86
(2J
10.47 + .56
(4)

• ll+. 03

.03+.02

(3)
ll.64+ .28

Stem DA

c
T

.09+.02

(3)
.31+.14**

(4)

.08+.03

(3)
.10+.04

(4)

(3)
.39+.13*

(3)

(2)
.43+.07**

(3)

Table 15 (continued)

MB 5Irr

222

-0600

1200

1800

2400

c

.52+.07

.76+.04

.89+.15

.33+.,09

T

(.28)
(1)

.54+.08*

c

.40+.14

.84+.09

T

1.77+.52*

(3)

(2)
(3)

(3)
.19+.02**

(3)

(2)
.14+.02*

(3)

Hpth 5HT

(2)
(3)

CN 5IIT

c

.25+.05

T

.67+.52

(3)

(4)

(3)

.18+.05**

(4)

.35+.14

(3)
.20+.03*

(5)

.95+.53

.35+.05

.14+.06

.07+.04**

(3)

(2)

(4)

(4)

.37+.10

.13+.05

(3)

(2)

.lOE)OOl*
(2

.06+.03

.62+. 11

.03+.02

(3)

Stem 5HT

c

.59+. 02

T

.21+.04**

(3)

(2)

.53+.15

(2)
.82+.18

(3)

(3)
.16+.07*

(2)

(2)
.10+.02

(2)

Table indicates amine concentrations (ugm/gm) of NE 1 DA and 5HT in
the four areas indicated in Table 9 1 for animals receiving DB pretreatment and PB (50mgjkg, IP). Animals were sacrificed midway through the
previously-determined sleeping time. Values are means .:!:. standard deviation,
with the number of animals used in parentheses. Significant differences
from control are noted by * (P<0.05) or ** (P<0.01).
C • Control; T • Treated
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Legend for Figure 40

The effects of DB pretreatment with pentobarbital, on the CNS concentrations
of NE, DA and 5HT -·-· CONTROL.

For complete explanation of notations of

figure, see legend to Figure 28.
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Legend for Figure 41

The effects of DB pretreatment with pentobarbital, on the CNS concentrations
of NE, DA and 5HT -- THEA TED.

For complete explanation of notations of

figure, see legend to Figure 28.
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control values for the 0600 group at 100 minutes were obtained by interpolating between the amine values determined for 85 and 120 minutes, in order
to compare differences between tre treated and control groups at this time.
At 0600 hours, there is a significant decrease of MB NE (58.1%, P<0.001)
but MB and CN DA increase

(19004% and 32% respectively, each P<Oo05).

stem NE levels decrease significantly (54,8%, P~O.OOl)o

Brain

Brain stem DA
------

increases and 5HT is reduced from control (65.2% and 65.4% respectively,
each P<0.005).

Hypothalamic NE decreases (78.1%, P<0.001), while signifi-

cant increases occur in the levels of hypothalamic DA (325.5%, P<0.001) and
5HT (340.6%, P<0.02) values.
At 1200 hours NE levels are reduced significantly in the MB (61.1%, P<
0,001), CN (49.3%, P<0.02), brain~ {55.6%, P<0,001) and hypothalamus
( 78. 7%, P<O. 001).

5HT concentrations are decreased significantly in the MB

(29.0%, P<0.05), CN (4405%, ]l('0,05) and hypothalamus (78.9%, P<0.001).

At

1800 hours, only a single control animal was available, limiting the opportunity for statistical analyseso

Relative to this control, NE levels appear

reduced in the MB, CN, brain stem and hypothalamus, while DA levels are
Plevated in the MB, CN and brain stem.

5HT levels appear to be decreased in

the MB, CN, brain stem and hypothalamus.
At 2400 hours, NE levels are significantly decreased in the MB

(58.:3~.

P<0.001), brain stem (65,5%, P<0,005) and hypothalamus (7603%, P<0.001).
DA concentrations are elevated significantly in the brain stem (155407%,
P<0.005).

5HT levels decrease significantly in the MB (58.3%, P<0.05) r'nd

hypothalamus (79,5%, P<0.005).

Significant circadian variations in 11 of 12

umine patterns examined were obtained after DB pretreatment,

226
c.

Diphenhydramine(Figures 42-43, Table 16)
DPH (50mg/kg, IP) was administered one hour prior to PB.

At

0600 hours, DPH increases MB 5HT concentrations over controls (39.2%, P<0.025)
but hypothalamic NE is reduced significantly (25.6%, P<0,001).

At 1200

hours, there is a significant elevation of CN 5HT (97,0%, P<0.02).

At 1800

hours MB NE levels are reduced significantly (19.4%, P<0.01).
Eight of twelve amine patterns vary significantly during the 24-hour
period of measurement,

The details of these variations can be seen in Fig.43

Table 16 and Appendix B.
5.

Gamma-butyrolactone(Figures 44-45, Table 17)
Amine concentrations in MB, CN, brain stem and hypothalamus were

evaluated half-way through the previously-determined sleep period at 0600,
1200, 1800 and 2400 hours (Table 17).

The results over the 24-hour period

for controls are plotted separately (Fig, 44) from GBL-treated (Fig. 45).
The controls, receiving saline, of course did not sleep.
There are significant changes in amine concentrations of GBL-treated
animals, compared with controls, in the following cases:

MB 5HT, 1200 hours

(77,8% increase, P<0,001); CN DA, 1200 hours (41,3% increase, P<0.05);
brain stem 5HT, 1200 hours (50% increase, P<0,05); MB 5HT, 1800 hours (64.7~
increase 9 P<.0.05), ~othalamic DA, 1800 hours (128.17: increase, P<0.02)
and l!Ypothalamic NE, 2400 hours (20.4% decrease, P<0.05).
Circadian fluctuations in the amine patterns were seen in 6 of 12 cases.
The details of these variations can be seen in Fig. 45, Table 17 or Appndix B.

Table 16:

CNS concentrations of NE, DA and 5HT after DPH pretreatment
with PB, on a 24-hour basis

-0600

1&QQ.

-1800

2400

.98+.08

.65+.ll

.79+.05**

.52+.04

MB NE

c
T

.76+.06

(4)

.70+.05

(6)

.64+.17

(5)

.76+.20

(3)

(2)

(4)

(6)

(3)

Hpth NE

c
T

2.22+.19

(4)

1.65+.08**

(5)

1.91+.38

(5)

1.63+.50

(4)

1.96+.03

(2)

1.59+.46

(4)

2.05+.16

.99+.21

(5)

(3)

CNNE

c
T

.19+.03

(3)

.18+.02

(i)

Stem NE

c

T

.93+.06

(4)

.89+.10

(6)
MB DA

c

.11+ .02

(3)
T

.13+.007

(6)

.12+.05

(5)

.18~05

.19+.03

.10+.05

.20+.04

.16+.07

(2)

(3

(6)

.88+.16

1.10+.14

(5)
.73+.16

(4)
.21+.06

(4)
.20+.06

(3)

(4)

(3)
.81+.13

(2)

(4)

.99+.09

.74+.06

(6)

(3)

• ll+.002

.06+.001

(2)

(3)

.15+.04

.06+.003

(6)

(3)

Hpth DA

c
T

(.25~

(1
.18+.03

(3)

.221)07
(3
.26+.02

(2)

.22+.0l

(2)

.14+.05

(4)

.26+.10

(5)

(.03)
(1)

7.58+.10

7 .06+1.57

CN DA

c

7.01+.21

(4)
T

7.49+.53

(5)

10.48+.58

(5)
13.33+2.03

(3)

(2)
6.63+1.59

(6)

(4)
7 99+ .26
0

(3)

Stem DA

c

.07+.003

(2)

T

• 08+.02

(4)

.07+.003

(3)
.07+.0l

(3)

.05+.0l

(2)
.06+.02

(6)

.05+.02

(3)

.03+.003

(3)

227

228

Table 16 (continued)

MB 5HT

0600

1200

c

.44+.05

.52+.19

.75+~07

~66+~10

T

.61+.09*

,.57+ 0 12

.75+.12

• 63+.14

(4)

(5)

(3)

(3)

c

.35+.0l

• 76+.05

T

0

-1800
(2)

(6)

2400

(3)

(3)

Hpth 5HT

(3)

42+ 0 06

(3)
CN 5HT

c
T

(3)

.91+.15

(3)

.22+.06

.32+~06

(4)

(2)

0

15+ 0 02

(4)

.62+o01*

(2)

.31+~007

(2)
.55+.14

(6)
.34+.08

0

49+ 0 12

(3)
.45~03

(3

(6)

(.34)
( 1)
(ol8)
(1)

.49+~05

.60+.06

(2)
.44+.06

Stem 5HT

c
T

.45+.03

(3)

.44+.23

(3)

.63+.15

(4)

.64+.15

(4)

(2)
.45+.09

(6)

(4)
.51+.17

(3)

Table indicates amine concentrations (ugm/gm) of NE, DA and 5HT in
the four areas indicated in Table 9, for animals receiving DPH pretreatment and PB (50mgjkg, IP). Animals were sacrificed midway through the
previously~etermined sleeping time.
Values are means ~ standard deviation,
with the number of animals used in parentheses. Significant differences
from control are noted by * (P< 0.05) or ** (P <0.01).
C = Control; T = Treated
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Legend for Figure 42

The effects of DPH pretreatment with pentobarbital, on the CNS concentrations
of NE, DA and 5HT -- CONTROL.

Fo:r complete explanation of notations of

figure, see legend to Figure 28.
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Table

MBNE

c
T

CNS concentrations of NE, DA and 5HT after GBL, on a
24-hour basis
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0600

1200

1800

2400

.80+.01

.90+.08

.83+.04

.87+.09

(?)

.88+.05

(4)

(4)
.91+.08

(5)

(4)
.85+.09

(5)

(4)
.88+.07

(5)

Hpth NE

c
T

2.39+.37

(4)
2.33+.05

(3)
CN NE

c

.18+.02

(4)
T

.17+.007

(4)

2.79+.49

(4)
2.12+.51

(5)
.20+.02

(4)

.22+.04

(4)

2.74+.40

(4)
2.43+.25

(5)

3.23+.16

(4)
2.57+.47*

(5)

.21+.02

.17+.05

.19+.05

.23+.08

(4)

(5)

(4)
(4)

Stem NE

c
T

1.03+.13

(4)
1.08+.13

(4)

1.05+.06

(4)
1.21+.15

(5)

.95+.08

(4)
1.02+.09

(4)

l.21+.009

(3)
1.14+.14

(5)

MB DA

c
T

.18+.03

(3)

.25+.05

(4)

.18+.05

(4)
.21+. 05

(5)

.20+. 05

(4)
.26+.06

(5)

.21+.04

(4)
.26+.06

(4)

Hpth DA

c
T

.34+.05

(4)
.33+.13

(4)

.61+.13

(3)
.46+.06

(4)

.,44+.12

(4)
1.00+.32*

(4)

.44+.03

(3)
.44+.15

(4)

CN DA

c

6.46+.90

(4)
T

7. 72+lo00

(4)

6.17+.66

(4)

8.72+1.66*

(4)

7.75+1.36

(4)
9.40+1.04

(5)

5. 72+1. 61

(4)
8.33+2.22

(4)

Stem DA

c

.20+.04

(4)
T

.16+.06

en

.05+.0l

(4)
.05+.007

(4)

.n+.01

.06+e03

.14+.03

.10+.03

(4)

(4)

(3)
(4)

232

Table 17 (continued)

MB 5HT

0600

1200

1800

c

.67+.10

.35+.05

.31+.14

(3)

(4)

T

.54+.30

.62+.07**

(3)

.52+.07**

(5)

2400
1.09+.23

(4)
1.42+.44

(4)

(5)

c

.78+.28

.71+.14

.74+.36

(4)

(3)

(3)

T

.86+.07

.82+.14

.81+.18

1.32+.45

c

.36+.06

.37+.06

.48+.13

.34+.16

(3)

(4)

(3)

T

.28+.08

.40+.03

.67+.31

.38+.07

(4)

Hpth 5HT

(3)

(4)

CN 5HT

(2)
(4)

(5)

(5)

(3)

(5)

.54+.06

.53+.13

1.20+.22

(5)

(3)

Stem 5HT

c

.53+.13

T

.47+.04

(4)

(3)

(3)
.81+.15*

(4)

(4)
.62+.03

(4)

.60+.08

(4)
.73+.10

(4)

Table indicates amine concentrations (ugm/gm) of NE, DA and 5HT in
the four areas indicated in Table 9, for animals receiving GBL (350mg/kg,
IP). Animals were sacrificed midway through the previously-<letermined
sleeping time. Values are means :!:. standard deviation, with the number
of animals used in parentheses. Significant differences from control are
noted by * (P<0.05) or ** (P<0.01).
C = Control; T = Treated
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\!E, DA and 5IIT concentrations in the CNS for GBL--CONTROL animals.
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NE, DA and 5HT concentrations in the CNS for GBL--TREATED animals.

For

complete explanation of notations of figure, see legend to Figure 2R.
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E.

The Effect on Rectal Temperature of Pentobarbital Alone and in Combination
with Drug Pretreatments
1. Untreated animals
Rectal temperatures were measured in groups of eight 7ats at 0600,

1200, 1800 and 2400 hours (Table 18 ) o The 24-hour pattern for rectal temperature peaks at 2400 hours (38.44

± Oo38°C.)

and is minimal between 1200-1800

hours (36.90 ± 0 0 54 - 36.88 ± 0.68°C 0 ) (Fig. 4~. The trough values differ
significantly from the peak value (each at P<0.001).

The peak also differs

significantly from the value at 0600 hours (P <0.05).

The 0600 hours value

differs significantly from those at 1200 hours (P<0.005) and 1800 hours
(P < 0.01).
2. Treated animals
Rectal temperatures were measured in vehicle-treated control and drugtreated animals during the detenninations of sleep duration after PB. The
patterns for the mean rectal temperatures of controls and treated animals are
plotted at ten-minute intervals for each of the four experimental times
during the 24-hour period (Figs. 47-5~.

These plots of the temperature means

demonstrate the hypothermia produced by PB (controls) and the influence of
drug pretreatment on this patterno Values are tabulated in Table 19-22.
Of all the pretreatment groups examined, the major temperature effects
are produced only by TP (hypothermia), 5Hl'P (hypothennia) and DOPA-pargyline
(resistance to hypothermia).
At 0600 hours, rectal temperatures in TP-treated animals are 1.86 to
3.81°C. lower than controls, and remain lower after the temperature begins to
return to normal in controls.

The pattern for the TP-treated animals differs

1

Tablel8:Tbe 24-bour pattern of rectal temperature in untreated rats

0600

Rectal temperature

( oc. )

37.9+0.6

(8)

1200

36.9+0.5

<sT

1800

2400

36.9+0.7

38 0 4+0 0 4

(8)

Table indicates rectal temperature ( 0 c.) measured at six-hour intervals.

A B c E F+

ts)

Values are means

+ standard deviation, with the number of animals used in parentheses.
+

For explanation of letter designations see Table 1.

!\:)

c,:,
o:i
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36

0600

Figure 46:

1200

.

1800

0

2400

Rectal temperature ( c.) in untreated rats
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0600
38

37

36

35

DOPA/..,

33

Figure 41:

pargyllne

TP

Rectal temperature in CONTROLS and drug pretreated groups, with
pentobarbital -- 0600 hours.

The Y-axis is temperature, in

°c.

and the X-axis is minutes after the onset of pentobarbital sleep.

Table 19:

The time-course of PB hypothermia in controls and
treated rats, 0600

23n

DOPATIME

CO:r-.ITROL

(min.)
38.5+.5
5

(7)
15
25
35
c!5

55

75
85

~

pCPA

HdlOO

5H~

TP

37.7+1.4 37.9+.2 38.4+.4 34.7+.3*

(5)

(5)

(3)

(3)
37.4+.3

37.5+.7
(ll)

37 .3+1.3 37.5+.5 37.6+.2 34.2+.4* 37.2+.9

36,7+.6
(l6)

36.9+1.2 36.7+.6 36.8+.3 34.0+.4* 36.5+.9 36.9+.2

36.1+.7
(16)

36.6+1.2 36.2+.8 36.1+.2 33.5+.6* 35.8+1.0 36.3+.3

35.7+.7
(l6)

36.3+1.3 35.9+.9 35.6+.2 33.1+.6* 35.4+1.0

35.3+.7

36.1+1.3 35.6+.9 35.3+.3 32.9+.6* 35.0+1.0 35.6+.4

(16)
65

~·

(5)

(5)
(5)
(5)
(5)

(5)

( 6)
(6)
(6)
. (6)

(3)

(4)
(5)
(6)
(6)

(3)

(3)
(3)
(3)
(3)

(4)

(3)

(4)

(3)

(4)

(4)
35.9+.~l

(4)
(4)

(4)
(3)

35.0+.7
(15)

35.8+1.5 35.4+1.0 35.2+.5 32.7+.6*34.8+1.l 35.5+,2

34.7+.8
(13)

35.6+1.6 35.2+1.l 35.0+.6 32.5+.5* 34.7+1.2

34.5+.9
(l3)

(5)
(5)
35.5+1.6

(5)

(6)
(6)

(6)
(6)

(3)
(3)

(4)
(4)

(2)

36.7+.2

( 6)
36.1+.2

(6)
35.6+.~i

(6)
35.2+.3

(6)
34.0+.3

(6)
34.5+.4

(6)

35.2+1.3 34.9+.8 32.4+.5* 34.6+1.2

(5)

(6)

(3)

(4)

95

34.2+.8

35.3+1.7 35.l+l.5 35.2+.7* 32.3+.5* 34.7+1.2

3·1. 2+. 5
( 6)

105

34. 2+1. 0

35.1+1.7 34.9+1.3 35.5+.9* 32.4+.6* 34.3+.8

33.8+.7
( 3)

(1o)

(9)
115

(5)

(5)
35. O+l. 8

(5)
125

34. 7+1. 7

(5)
135

34.5+1. 7

(5)
145

34. 4+1. 6

(5)

====

185

34.l+l.2

(5)

(5)

(5)

(6)

(6)
35.9+.8

(6)

(3)

(3)
32.5+.8

(3)

36.4+1. l 32.6+.9

(5)

(3)

36.5+1.4 32.7+1.0

(3)

(3)
32.9+1.l

(3)

(4)

(3)
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significantly from the control pattern at all time points (5-105 minutes,
P ( 0.001 - 0.005). The curves for the other treatments do not differ significantly from control, except for the pcPA values at 95-105 minutes, which are
significantly elevated above controls (P

< 0.025).

At 1200 hours, the fall in rectal temperature of DOPA-pargyline-treated
animals proceeds at a slower rate than for controls. The DOPA-pargyline pattern
is elevated significantly from the control pattern during 25 to 95 minutes
(P< 0.01 - 0.001), ranging from 1.53 to 2.85°c.

The rectal temperature in

5HTP-treated animals is significantly lower than the controls during 5-95
minutes (P<0.001), ranging from 1.62 to 3.22°c. The temperature effects of
the other treatments at this time are not significantly different from control,
except for the following: M25 lower than control during 75-85 minutes (0.92
and 0.37°c., respectively, each P <0.025) and pcPA higher than control at 65
minutes ( 0.88°C., P <0. 05).
At

l&QQ

hours, the rectal temperature in DOPA-pargyline-treated animals

is also above control values. They are significantly greater than the controls
during 15-85 minutes (P (0.05 - <0.001), ranging between 0.88 to 2.01°c. TPtreated animals have a significant lowering of temperature compared with
controls during 5 to 95 minutes (P<0.001), ranging between 2.17 to 3.75°c. In
5HTP-treated animals the rectal temperature is significantly lower than the
control temperature for 15 to 25 minutes and at 65 minutes (P<0.05), with
differences ranging from

1~04

to l.12oc.

At giQQ. hours, the rectal temperatures of DOPA-pargyline-treated
animals are significantly elevated above controls during 15 to 95 minutes
(1.60-3.00, P<0.001). The 5H'IP pattern is significantly lower than the control
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37

36

Figure 48:

Rectal temperatures in CONTROLS and drug pretreated groups, with
pentobarbital -- 1200 hours,
Figure 46.

Figure legends are the same as

Table 20: The time-course of PB hypothermia in control and
treated rats, 1200
DOPACONTROL
TI~£E
pCPA
AMPT
5HTP
M
~·
(min.)
37,7+.3
5
35.3+.3**

(3)
15
25
35
45
55
65

37.3+.5

(8)

33.1+.2** 34.6+.4

34.4+.6

37.2+.5**35.2+.2 35.5+.4

32.8+.2** 34.2+.4

(fa)

34.3+.7
34.7+.5
34.8+.6
35.1+.6
35.4+.9
35. 6+. 9

(2)
125

(4)

(4)
(4)
(4)

(5)

(4)

(4)

(5)

(4)

(5)

(4)

36.7+.5**34.5+.4 35.1+.3

(4)

(5)

36.6+.5**34.5+,4

(4)
36.5+.5

(4)
36.5+,5

(4)
36.4+,4

34.9+.8

(4)
35.l+.6

(3)
235

(5)

(3)

36.9+.6**34.7+.3 35.0+.3

====

225

(5)

37.1+.6**35.0+.2 35.2+.4

(4)
215

(2)

37.3+.5**35.6+.2 35.7+.4
(4)
(4)
(5)

(4)
115

(4)

34.8+.6
(13)

(4)

35.1+.6

(3)

(5)
34.5+.7

(5)

37.9+.l

34.6+.2**36.5+.5 37.1+.3

(3)

37.5+.6**36.2+.2 36.1+.3

(6)
105

37.6+.2

35.2+.6
(l3)

(6)
95

(4)

37.7+.8**36.8+.2 36.5+.3

(6)
85

38.0+.9

HdlOO

(4)

36.5+.6
(ll)

(9)
75

(4)

242

(4)

(5)

34.0+.2** 35.8+.4 36.3+.3

(4)

(4)

(5)

33.5+.2** 35.3 +.2 35.7+.3

(4)
(4)
(4)

(4)
(6)
(6)

32.6+.2** 34.l+.3

(4)

(5)

32.3+.2** 33.8+.3*

(4)

nn

32.2+.2** 33,4+.l*

(4)

(2)

32.2+.2** 33.4+.l*

(4)
32.2+.3

(4)
32.3+.2

(3)
32.4+.2
f3)

(2)
33.4+.2

(2)

(5)

35,l+.4

(5)
34. 7+.4

(5)
34.3+.5

(5)
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Figure 49:

100

210

Rectal temperature in CONTROLS and drug pretreated groups, with
pentobarbital -- 1800 hours.
Figure 46.

Figure legends are the same as
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Table 21: The time-course of PB hypothermia in control and treated rats, 1800
DOPA-

TIME CONTROL
(min.)
5
37.9+.5
15

parg.

AMPT

pcPA

'IT

5HTP

M

38.8+.3

38.0+.6

38.1+.3

34.2+.2

(8)

(5)

(3)

(5)

(3)

37.4+.8
(10)

38.2+J

37.2+.8

37.6+.3

33.7+.2

(5)

(3)

(6)

(3)

36.2+.l
(3)

36~8+.3

33.3+.3

(5)

(3)

*
35.6+,.l
(4J

35.8+.2
(3)

36.5+.8
(12)

** 36.6+1.0
37.8+.3
(3)
(5)

35.9+.8
(13)

** 36.1+1.0 36.2+.3
37.7+.5
(5)
(3)
(5)

33.1+.2

(3)

35.0+.3
(4)

35.3+.2
(5J

45

35.4+,8
(14)

** 35.4+1.l 35.7+.4
37.3+.4
(5)
(3)
(5J

32.9+.2
(3)

34.6+.3
(4)

34.9+.2
(5}

55

35.0+.9
(14)

37.0+.'t* 35.4+1'.0 35.2+.4
(5)
(3)
(5)

32.8+.2
(3)

34.3+.3
(4)

34.6+.3

34.9+.9
(13)

** 35.3+.9
36.7+.4
(4)
(3J

34.9+.5

32.6+.3
(3)

33.9+.2
(4J

34.3+.4
(5}

34.9+1.l
(12)

** 35.2+.6
36.5+.4
(4)
(3)

34.8+.6

32.5+.3
(3)

33.7+.2
(4)

34.1+.3
(4)

34.7+1.4
(9J

*
36.4+.3
(4)

35.2+.3
(3)

34.6+.6
(5J

32.4+~3

33.7+.2
(4J

33.8+.3
(2J

34.4+1.6
(4)

36.1+.3
(4)

35.1+.2
(3)

34.6+.8
(5)

32.3+.3
(3)

105

35.9+.3
(4)

35.4+.4
(3)

34.8+1.0 32.2+.3
(5J
(3}

115

35.7+~4

25
35

65
75
85
95

c

(4)

(5)
(5)

(3J

35.2+1.2 32.1+.3
(5)
(3)

125

35.6+.4

35.5+1.5 32.1+.3
(5)
(3)

135

35.4+.4
(4)

35.9+1.6 32.1+.3
(5)
(3)-

145

35.2+.4

36.l+l.5 32.1+.3
(5)
(3)

----205

(4)

(4)

34.7+.4
(4)

(5)

r
I
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Figure 50:

Rectal temperature in CONTROLS and drug pretreated groups, with
pentobarbital -- 2400 hours.
Figure 46,

Figure legends are the same as
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2400
treated
rats,
Table 22: The time-course of PB hypothermia in control and
DOPAM
pCPA
TIME CONTRDL
AMPT
.E!!&•
fil!'.!E.
(min.)
5
39.2+.0l

(2)
15

37.7+.3
(4)

** 37.7+.7
39.3+.8
(5)

(4)

37.7+.l

37.3+.4
(2)

(2)

37. l+. l
(10)

** 36.7+.5
39.l+.7
(5)
(7)

36.7+.9
(5)

**
36.0+.5
(4)

36.8+.4

35

36.5+.2
(11)

** 36.2+.6
38.9+.7
(8)
(5J

**
36.0+l.O 35.4+.3
(5)
(4)

36.3+.4
(4)

45

36.0+.3
(ll)

38.7+.8
(5)

**
35.5+1.2 35.0+.3
(4)
(5J

35.8+.5

55

35.7+.4
(11)

** 35.3+.3*
38.5+.8
(8)
(5)

65

35.3+.5

** 34.9+.3*
38.3+.7

25

(8)
75
85
95

35.l+.6

**

(5)

35.7+.4
(8)

(8)

** 34.6+.3
38.1+.7

(8)

(5)

(8)

35.4+.6

38.0+.7

34.3+.4

(6)

35.5+1. l

(4)

(5)

38.0+.6

(5)

35.0+.5

(4)

34.2+.7

125

37.8+.5
(5J

34.2+.8
(8J

135

37.7+.6
(5)

34.2+.8
(7}

36.2+1. 0
(5)

34.7+.3
(5J

34.5+1.4

37.9+.6
(5)

205

35.3+.5

(8)

115

36.5+1.l
(5J

35.0+l.,3 34.5+.4
(5)
(4)

34.2+.4
34.2+.6
(8)

195

35.4+.5

34.6+1.3
(5J

37.9+.6
(5)

(8)

(6)

35.2+1.3 34.7+.4
(4)
(5)

(8)

105

-----

**

(3)

34.1+.3
(4)

(6)
(4)
(2)

p
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pattern during 25 to 75 minutes (P

<0.02

- 0.001) with differences ranging

from 0.88 to l.08°C. The AMPT pattern is reduced significantly below that
of control for 55 to 65 minutes after PB, with differences of 0.43 and 0.47°C.,
respecti vely(P

<0.05).

DB (15mg/kg, IP) in rats produces a significant fall in rectal temperature, 24 hours after its administration.

The subsequent administration of

PB causes a more profound and significant decrease in rectal temperature.

In

male mice, the rectal temperature 24 hours after DB is less depressed than in
the rats.

After PB, the fall in rectal temperature is double that of saline

or methyl cellulose controls.
DPH (50mg/kg, IP) in mice, produces a marked fall in rectal temperature,
from 38.1 .:!:. 0.9 to 34.3 ±. 0.7°C.

After PB temperatureedecreases further to

30 5 .:!:. 0.9, as compared to 35.7 .:!:. 2.4°c. for saline or methyl cellulose
0

controls.
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V.
A.

GENERAL DISCUSSION

Introduction
Normal sleep is a complex process, and drug-induced sleep further

conplicates the process.

It is evident that a variety of drug treatments

and/or conditions (environmental, physiological, pathological, etc.) can
inf nence the state of sleep considerably as has been illustrated by experiments described in the thesis and elsewhere.

Sleep induced by drugs has not

hcen studied to any great extent from the standpoint of circadian alteration,
i.e., time-linked drug effects, or with a consideration of the internal

m:licu of the organism as it influences drug affect.

This is an important

consideration because of the periodicity basic to sleep-wakefulness phenomena.
Since biological systems and organisms are in a dynamic state, studies of
their functions ought to include these time-linked aspects.
For these reasons an examination of alterations in the duration of
drug-induced sleep has been made on a 24-hour basis.

Concomitantly brain

amine levels in specific CNS areas, body temperature changes, as well as
their interrelationships have been studied.
A basic question of this study revolves around the possible modes by
which sleep induced by hypnotics might be affected.

Several possibilities

will be enumerated and subsequently examined as they might apply to data
derived from specific drug treatments.
The following are to be considered:
1) amine background upon which the hypnotic acts
2)

the influence of temperature on metabolism and hypnosis

249

B.

3)

actions on metabolizing enzymes (of amines and the hypnotic)

4)

the binding of barbiturate and amines and their bioavailability

Drugs affecting the NE and DA system
1.

DOPA-pargyline
DOPA-pargyline pretreatment significantly prolongs PB-sleep at

eacn Lime tested (Table

3 ).

The curve over the 24 hour period is essentially

flat indicating that at this dosage, sleep duration has reached a ceiling
rP.sponse.

Amine measurements made half-way through the sleep period in such

animals indicate significant increases in DA concentrations in all brain parts,
at almost every experimental time point (15/16 values).

NE levels increased

.c;ignificantly in only 4 of 16 values, viz, the CN at 0600, 1800 and 2400
hcct0;
.-ti1d

brain~

2!+00

hours.

at 0600 hours.

5HT levels are decreased in the MB at 1800

Of these amine changes, the increased DA concentration seems

'.-

cu~·relate

CN

at 1200 hours there is no significant change in DA concentration at a time

hest with the prolongation of sleep (15/16 instances).

In the

when sleep duration is increased over controls.
These results are in opposition to the reports of excitatory effects
for DOPA or DA, administered intraventricularly, intracisternally and
iontophoretically (Spooner and Winters, 1965).

The changes in brain NE and

SHT concentrations coincide only infrequently with the prolongation of PBsleep in this treatment group.

In the face of a PB challenge the usual

excitatory effect of DOPA or DA is inoperative and other mechanisms must be

,.
200
considered.

Lesions of the DA-containing areas in the mesencephalic ventral

tegmentum (in the substantia nigra) produce behaviorally-comatose animals,
but with a relatively normal EEG sleep-wake cycle

(Jones~

al., 1969).

On

the other hand, Connor (1970) demonstrated that direct iontophoretic application of DA to CN neurons produced spike rate depression.
;.·::tr'.

Lammers and

Rossum (1968) reported bizarre stereotypic behavior in rats after the

ad,,inistration of DOPA in combination with a peripheral decarboxylase inhic).c

r.or.

When animals were isolated, they remained in a catatonic state.

The

behavior, which was maximal after one hour, lasted over an eight-hour period.
Ihc prolongation of PB sleep in DOPA-pargyline rats might be a reflection of
catatonia superimposed on depression.

Ansel and Markham (1970) noted

r:1:uwsiness in two of four normal patients given L-DOPA chronically, although
t•iey did not appear sedated.
~xcretion

Messiha et al. (1970) found that DA urinary

was elevated in both depressed and manic patients, and returned to

uormal only in the latter case after lithium therapy.

In the treatment of

Parkinson patients, depression has been reported (Cherington, 1970; Damasio
~al.,

1970).

These studies suggest that under some conditions DOPA and/or

DA can exert depressant effects.
Blum~

al. (1972a)demonstrated that DOPA enhanced ethanol-induced

sleep, which seems to corroborate the present study.

These investigators

suggested that the enhanced sleep might be due to the naturally-occurring,
alcohol-like metabolite of DA, 3,4-dihydroxyphenylethanol (DOPET), whir.h
augments sleep.

A similar argument could be invoked for the results obtained

in the present study.

To establish this it would be necessary to demonstrate

this compound's formation in vivo, and correlate its presence with sleep.
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Although there are no significant differences between sleep periods
at the experimental times, the amine levels of DOPA-pargyline treated animals
do exhih:it significant diurnal fluctuations (Fig
changes include MB, brain

~'

).

These amine

and hypothalamic DA and hypothalamic SHT,

::ill of which peak significantly at 1800 hours.
Mfl

29

CN SHT, brain stem SHT and

NF levels exhibit significant peaks at 1200 hours.

CN and hypothalamic

N"E values are minimal at 0600 hours and maximal at 1800-2400 hours.

These

results indicate that the influence of pretreatment on amine levels in CNS
varies with the tissue and time of the day.

This could be of clinical im-

portance in the selection of the proper time of day,for example, for Parkinsonian patients to ingest L-DOPA, for maximum therapeutic efficacy.
Rectal temperature in DOPA-treated animals decreases at a significant1 y slower rate than in the controls, indicating that this treatment pro.·

c.~':

a n.:s is tance to the normal hypothermia induced by PB.

Myers and Yaksh

(1968) repcrted that in the rat, intraventricular NE and DA (DOPA after
latency) cause hyperthermia.

,t

At every experimental point, except 0600 hours,

the pattern is elevated above controls, and continues to decrease, even when
animals recover from sleep.

A fall in body temperature might significantly

decrease hepatic PB metabolism and thereby prolong its action, but the temperature effect found favors a less depressed metabolic rate than in controls.
It seems unlikely therefore that the body temperature changes play an important role in these effects.
Another possible basis for DOPA-pargyline effects on sleep might be
attributed to the binding of PB (Lasser et al., 1963; Pagnini et al., 1971)
and CAs to plasma proteins.

Danon and Sapira (1972) reported that labelled
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cAs (including NE, DOPA and DA) are bound to human serum albumin, in vitro.
These gel filtration studies demonstrated that the fraction of NE bound
ru.nges from 20% at high protein concentrations to 90% at concentrations of
3 x l0-811.

Goldbaum and Smith (1954) reported that 37/o of PB is bound in

vitro to bovine serum albumin.
d~nus

Pagnini et al. (1971) found that a number of

which are bound to serum albumin in a manner similar to PB, enhance the

di~ration

of PB narcosis in mice.

Increasing the concentrations of these drugs

in vitro results in a further reduction of PB bound to serum albumin.
drugs were without effect on liver metabolism of PB.

The

In mice treated with

one of these drugs (sulfaethylthiazole), brain levels of PB were signific,rntly higher than in animals receiving PB alone.
t 1H'

These findings suggest that

large dose of DOPA or the DA formed from it (and/or possibly their meta-

bclites), might be bound to plasma proteins, thereby displacing PB from sites
•,:Y-1id otherwise bind to.
~tructures,

With more free PB available to act upon the CNS

hypnosis would be prolonged.

It is not likely that the prolonged hypnotic sleep is due to inhibition of the metabolizing enzyme.

Nair (personal corrnnunication) indicated that

the half-life of the enzyme oxidizing PB is about 15 hours.

Since DOPA-

pargyline are administered 60 and 30 minutes, respectively, prior to PB,
there is relatively little time for them to alter enzyme activity.

2.

Alpha-methyl-£-tyrosine
AMPT pretreatment significantly prolongs PB-sleep at 1200 and

2400 hours (Table 3, Figs. 11-12), and significantly decreases NE and DA
levels from controls (Table 10, Fig. 31).

However 5HT levels are
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unchanged in 10/14 values, increase in 3/14 and decrease in 1/14 values.
Brain stem SHT and DA, CN SHT and MB SHT levels exhibit diurnal patterns
with peaks at 1200 hours and troughs at 2400 hours, in the dark.

Hypotha-

lamic DA also peaks significantly in the light (1800 hours) and troughs in
the dark (0600 hours).

CN NE and DA, and MB DA have maxima in the dark phase.

These results demonstrate that even when CNS CAs are depleted, the reduced
amine concentrations vary with the time of day.
Amine reductions from control were as follows:

MB NE, 43.6% - 58.9%;

brain stem NE, 45.8 - 51.6% and hypothalamic NE, 52.1 - 62.6%.

CN NE de-

creases significantly only at 0600 hours (61.3%) and 1800 hours (43.9%).
The percentage depletion from controls for NE in all tissues examined ranges
between 43.6 - 62.2% in 14/16 instances (Table 10).

The percentage de-

pletion from control for CN DA (70.0 - 78.5%, 4/4 values) and hypothalamic
DA (74.7 - 86.3%, 2/4 values) is somewhat higher than for NE.

The extent of

depletion of NE in the tissues over the 24 hour period studied is relatively
constant.

AMPT is a tyrosine hydroxylase inhibitor, exerting its amine-

depleting effects by blocking CA synthesis.

The degree of depletion of NE

and DA is indicative of different rates of turnover (Iversen and Glowinski,
1966).

Udenfriend and Zaltzman-Nirenberg (1963) reported that in the guinea

pig brain the half-time of DA was 2 hours while that of NE was 4 hours.

The

greater depletion of DA could also be due to its greater release.
Rech et al. (1968) reported that AMPT induces behavioral depression
in rats, related to the CA depletion.

Weitzman et al. (1969) found that AMPT

decreases REM sleep, with a compensatory increase in NREM sleep.

Hartman
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~al.

(1971) reported that in the rat oral AMPT increased PS, while IP AMPT

(75 mg/kg) disturbed sleep and decreased PS.

Torda (1968) found no obvious

EEG changes 3 hours after AMPT (80 mg/kg, IP), but did after 18 hours (3 doses
6 hours apart).

SWS increased and PS and wakefulness decreased.

King and

Jewett (1971) described that AMPT in cats enhanced REM sleep, at a time when
NE levels are significantly reduced.
produced sedation in humans.

Sjoerdsma et al. (1965) found that AMPT

Jouvet (1972b) indicated that the effects of

AMPT on PS were variable, but in all species behavioral and EEG waking were
decreased, which could le counteracted by DOPA administration.
indicate that after AMPT administration waking is reduced.
might be expected to enhance PB-sleep.
study at 2400 as well as 1200 hours.

These studies

Such depression

This is demonstrated in the present
The latter result occurs during the

normal sleep period of rodents, when hypnotically-induced sleep reaches a
maximum.

The second, more prominent peak at 2400 hours, comes at a time when

the rats are nonnally awake and active.

There are several amine differences

at 2400 hours compared to 1200 hours that might contribute to the augmented
sleep.

These differences include:

DA at 2400 hours.

MB SIIT and

significantly-reduced MB and hypothalamic

brain~

DA are elevated and hypothalamic 5IIT

is reduced compared to controls at 1200 hours, but not at 2400 hours.

Since

the MB includes the anterior portion of the SIIT-containing raphe system,
which numerous lesion and pharmacological experiments (cf. Jouvet, 1972b)
indicate is vital for sleep, facilitation of PB-sleep might be attributed to
the augmented MB 5IIT levels.

This effect would have to be balanced somewhat

by the decreased hypothalamic 5IIT which would tend to counter sleep (vide
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infra regarding reduced SHT and depression).

There are no significant dif-

ferences for SHT from control at 1200, 1800 or 2400 hours for brain stem,
which contains the posterior portion of the raphe system.
An examination of the time-course of rectal temperatures in treated

animals reveals a pattern that is in essence similar to that of the control.
This would tend to eliminate temperature changes as a factor for the significant increase in PB-sleep at 1200 hours.

At 2400 hours, rectal temperature

is significantly lower in AMPr-treated animals than controls (at 55 and 65
minutes) 0.43 and 0.49°C. lower, respectively) but such small differences in
body temperature are not likely to be effective in prolonging PB-sleep at
2400 hours.
The effects of AMPT on PB-binding to serum proteins or the PB-metabolizing enzyme are probably minor.

AMPT was administered 4 hours prior to

PB) which probably is insufficient time to alter the PB-metabolizing enzyme
system (Nair, personal conununication).

Danon and Sapira (1972) reported that

L-tyrosine is not boµnd to albumin, but AMPT was not studied.

Notwithstanding

its inhibitory effect, there is some indication that AMPT itself can be hydroxylated to alpha-methyl DOPA and subsequently form alpha-methyl DA and
alpha-methyl NE (Maitre, 1965).

Danon and Sapira (1972) did find that alpha-

methyl DOPA was bound to the same extent as DOPA.

Moore~

al. (1967)

reported a number of toxic effects after AMPr, but which do not appear until
20-48 hours after administration.

These effects include hypothermia (b.0°C.

lower than controls)) lethargy, and weight loss.

AMPT-treated animals have

higher blood glucose levels within 2 hours after injection, which return to
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normal 24 hours later.

An interesting aspect of the AMPT-sleep pattern is

its similarity to the bimodal circadian plasma glucose pattern obtained by
Frideman and Walker (1969).

They explained the nature of their pattern on

the basis of a diurnal rhythm for the initial glucose peak and a feeding
rhythm for the second peak.

Lawson~

al. (1951) demonstrated that glucose

was effective in restoring sleep to animals awakening from drug-induced sleep.
Finally, one cannot help but think that the possibility exists for the displacement of PB from plasma by several substances entering the plasma concomitantly with AMPT itself or its metabolites and dietary constituents.
C.

Drugs Affecting the 5IIT System
1.

p-Chlorophenylalanine
pCPA treatment significantly prolongs PB-sleep above controls

at all experimental time points.

Furthermore, the 24-hour pattern of sleep

duration is circadian, with a peak at 1200-1800 hours (Figs. 13-17

).

This

compound produces a significant reduction of 5IIT levels at each point of
measurement during the 24-hour period (16/16).

Several concomitant reductions

in DA levels occur during the light phase, viz., 29.1% decrease in MB DA
(P < 0.05) at 1200 hours, 24.2% decrease in CN DA (P < 0.05) at 1200 hours
and a 72.7% decrease in hypothalamic DA (P < 0.005) at 1800 hours.
MB 5IIT exhibits a maximum at 2400 hours in the dark phase, with
significant differences between this peak and 0600, 1200 and 1800 hours.
Hypothalamic NE is minimal at 1800 hours, differing significantly from 0600,
1200 and 2400 hours.

CN NE and hypothalamic DA are also minimal at 1800
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hours, differing significantly from the values at 0600 and 1200 hours.

CN

DA is maximal at 1800 hours, differing significantly from 0600 and 1200 hours
levels.

Hypothalamic 5HT exhibits a trough at 0600 hours (SHT concentrations

reduced to zero) and a peak at 1200 hours, with significant differences between
the trough and the other three time points and the peak and the 2400 value.
CN SHT levels are minimal at 1200 hours and maximal at 2400 hours, during
the dark phase.

Brain stem DA is minimal at 0600 hours, while brain stem

SHT is maximal at 1200 hours.
The amine patterns after pCPA exhibit diurnal variations, which, in
general are at their normal levels for CAs and reduced for SHT.

The extent

of depletion is great, i.e., in 12/16 measurements it is greater than 85%.
MB SHT is depleted to the smallest extent (40.4%) at 2400 hours, when the
prolongation of sleep by PB is least.

The depletion of hypothalamic SHT at

1200 hours (66.9%) or CN SHT at 1800 hours (74.5%) occurs when the augmentation of PB-sleep is maximal.

In the pCPA-depleted state, brain stem and

hypothalamic 5HT are at their peak levels, at 1200 hours, although these
tissues are at 13.2% and 33.1% of their respective control levels.

The fact

that the sleep pattern, although shifted to an augmented level, still maintains a 24-hour variation, reflecting the normal pattern would suggest that
the relative, rather than absolute 5HT values play a role in the modulation
of sleep.

Superimposed upon this effect is the general depressant activity

of PB itself.

The brain stem contains most of the 5HT-containing raphe

system, which is important in normal sleep (cf. Jouvet, 1972b).

The con-

comitant reduction in CN NE and hypothalamic NE and DA are factors that might
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facilitate PB sleep.

Many studies suggest that NE and DA are important for

waking (cf. Marczynski, 1967; Marley and Stephenson, 1972; Jouvet, 1972b).
In view of several reports of the insomnic effect of pCPA (Delorme
et al., 1966a;Koella et al., 1968;

Mouret~

al., 1968;

Pujol~

al., 1971),

one would not have expected the prolongation of sleep obtained in the present
studies.

In pCPA-induced sleep changes, both REM and SWS are decreased.

Dement et al. (1972) reported in the cat, that the early effect of pCPA is
an increase in REM sleep for the first 24-48 hours (no dosage is given).
is followed by a reduction in REM and SWS after the third day.

This

The prolonged

deprivation of REM and SWS over the three-day period in which pCPA was administered could explain the enhanced effect of PB seen in these studies, as
a rebound phenomenon.

The circadian variation in the prolongation might then

be a reflection of the variation of the CA present, as well as a change in
relative, rather than absolute levels of SHT.
Central depression can occur with reduced 5Hr levels.

Shaw et al.

(1967) and Pare et al. (1969) demonstrated that 5Hr levels were significantly
lower in the brain stem of depressed subjects.
that 5HIAA was also reduced in such cases.

Bourne et al. (1968) found

These findings, together with

others (vide supra) seem to indicate that depression can occur whenever 5Hr
levels deviate from a specific optimal range of values.
Whether binding of pCPA to plasma proteins is involved in this augmentation of PB-sleep is not certain, since it is not known if pCPA

bin~s

significantly to plasma proteins, although phenylalanine does not (Danon and
Sapira, 1972).

However, pCPA is fairly slowly cleared from the plasma.

Koe
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and Weissman (1966) reported that 3 days were required for a single dose of
pCPA (316 mg/kg, IP), to fall to one-half its maximum plasma level.

With such

a slow clearance, the consecutive administration of pCPA would result in its
accumulation in the plasma.
pCPA affects the rectal temperature only slightly under the conditions
of these experiments, compared to controls.

Occasional changes, in the

direction of hyperthermia compared to controls, occurred (at 0600 hours, at
95-105 minutes, 1.11 and l.27°C.; and 1200 hours, at 65 minutes, 0.88°C).
These changes would very likely mitigate against prolonged sleep.
2.

Tryptophan
TP prolongs PB-sleep significantly over controls at each of the

experimental times (Table 4

), but the only significant difference between

the TP groups is between the 1800 and 2400 hours values.

TP significantly

elevates 5HT at 0600 hours in the MB and hypothalamus and at 1800 hours in
the hypothalamus.

Amine concentrations decrease in the following areas:

hypothalamic NE levels at 0600 hours; in the MB,

brain~

and l!Ypothalamic

DA and CN NE at 1200 hours; in Ma.NE at 1800 hours; and hypothalamic DA levels
at 2400 hours.

TP, a secondary precursor of 5HT, was given to elevate brain

5HT, which it did in only 4/16 instances, perhaps because the time interval
and dose schedule used was insufficient.

The use of 5HTP to increase central

SHT has been criticized because of the widespread distribution of the decarboxylating enzyme leads to formation of SHT in CNS areas in which it is not
normally present (Moir and Eccleston, 1968).

Exogenous TP follows the phy-

siological uptake pathways, which involve hydroxylation of TP at intra-
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neuronal sites and uptake into the CNS SHI stores.

Exogenous SHIP is taken

up by the brain. and decarboxylated in the cytoplasm, and subsequently and
quite readily attacked by MAO.
MB and hypothalamic SHI concentrations peak at 1800 hours and are
greater than levels at 0600, 1200 and 2400 hours.

Brain stem NE is maximal

at 1800 hours and CN DA is maximal at 1800-2400 hours.
the hypothalamus (1800 hours) and

brain~

The elevated SHI in

(2400 hours) and decreased brain

stem and CN DA at 1200 hours might be expected to favor sedation.
brain stem DA and CN NE levels are minimal at 1200 hours.

MB and

Reduced levels of

NE and DA at 1200 hours might be expected to reduce their alerting effects
and facilitate depression by PB.

It should be pointed out that the results

favoring sleep that were obtained at 1200-1800 hours occur during the period
of normal sleep in these animals.
Several clinical studies have reported that TP ingestion by humans
has a facilitatory effect on sleep (Wyatt£! al., 1970b; Hartman et al., 197lb).
Wyatt et al. (1970b) found increased total and NREM sleep and decreased REM
sleep.

Pretreatment with a decarboxylase inhibitor enhanced the sedative

effect, while reducing the unpleasant side effects.

However, these

investi-

gators concluded that TP does not act through a SHI mechanism, since SHIP
increases REM sleep, but TP did not.

They further report that TP still has

the same effects in pCPA-treated patients, in which the conversion of TP to
SHI is inhibited.

Hartman et al. (197lb)found that TP reduced sleep latency

and slightly increased total sleep time, which was dose-dependent.

They also

reported that similar doses of L-histidine or L-tyrosine did not have these
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effects.
As seen in Figs. 47, 49 and Tables 19, 21, TP markedly lowers body
temperature from control levels, from the onset of sleep, throughout the
period of measurement.

For example 5 minutes after the onset of sleep

temperature fell 3.81°C. (from 38.48 in controls to 34.67°C.) at 0600 hours
and 3.75°C. (from 37.92 in controls to 34.70°C.) at 1800 hours.

As pointed

out earlier, the reduction of body temperature results in prolongation of
PB-sleep, by decreasing its rate of metabolism.

These changes in body tem-

perature are of such magnitude that they might readily contribute to the enhancement of sleep.
The binding of TP to serum albumin might also contribute to prolongation of PB-sleep.

McManemy and Oncley (1958) and McManemy et al. (1961)

reported in fasting humans and
is bound to albumin.

respectively, that 75% of plasma L-TP

This binding is stereospecific and pH dependent, in-

volving the indole ring.
cantly.

~vitro,

However, tryptamine and 5HT are not bound signifi-

The large dose of TP utilized (500 mg/kg, IP) could raise plasma TP

levels significantly to displace PB and enhance its actions.
3.

Melatonin
Two doses of melatonin (M25 and M50) were used in the hypnotic

study but only the lower dose was used for the brain amine determinations.
The M25 dose prolongs PB-sleep significantly at 1200, 1800 and 2400 hours,
with a peak at 1200 hours and a trough at 2400 hours.

The M50 dose prolongs

PB-sleep significantly at each experimental time, but shifted the peak to
0600 hours and the trough to 1800 hours.

M has behavioral and EEG hyper-

262

synchronizing effects (Marczynski et al., 1964; Arutyunyan
Hishikawa et al., 1969).

Barchas

~al.

~al.,

1964;

(1967) demonstrated in mice that

M (25 mg/kg, IP) prolonged HB sleeping time by 50%.

Arutyunyan

~al.

found that M prolonged chloral hydrate- and hexenal-induced sleep.

(1964)

The

present study is the first report of a diurnal pattern for this enhanced
hypnotic effect of M.

The peak effect of the M25 dose occurs in the light

phase) when rats normally sleep.
The M25 dose had relatively little effect on brain amines.
hours the effects of increasing 5lIT and decreasing DA in the
which is prolonged at this time.

~

At 0600

favor sleep,

At 1200 hours, the decrease of brain stem

5HT favors waking, while reduced hypothalamic DA favors sleep.

Prolonged PB-

sleep is the effect at this time, indicating that the overall effect of these
amine changes is a facilitation of sleep.

The primary CN amine, DA, is

reduced significantly at 1800 hours, when PB-sleep is prolonged.

Since the

CN is involved with motor activity, the reduced DA level might reflect the
inactivity of animals at this time.

At 2400 hours the amines changes are not

significant and PB-sleep is less prolonged.
same direction as those obtained by

These amine results are in the

Anton-Tay~

al. (1968), who, in the female

rat, found elevations of MB 51IT,. 1 and 2 hours after a considerably lower dose
of M, as well as increased hypothalamic 5I:IT at 1 hour and reduced cortical
5I:IT at 20 and 60 minutes.
areas.

There were no significant changes in NE in these

The sites of the prominent amines changes are the same as those

have been shown to selectively concentrate
and Wurtman, 1969).

3

H-M

(Noble~

~vhich

al., 1967; Anton-Tay
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The M25 dose had no significant effects on body temperature effects
of PB, except for a reduction at 75-85 minutes in the 1200 hours group
(Table19-2~

Figs .47-50

).

Barchas

~

al. (1967) found that M (25 mg/kg) had

no effect on body temperature in rabbits, while Arytyunyan et al. (1967)
reported that in mice, dose of M (50-100 mg/kg, SC) lower body temperature
2-3°C.

Hypothermia obtained with M in the present study is probably a factor

in the prolongation of PB-sleep.
The effect of the M50 dose paradoxically is reversed, with a maximum
at 0600 hours in the dark and a minimum at 1800 hours, but PB-sleep is prolonged to the same extent as the M25 dose at 1200 and 1800 hours.
results are subject to several possible interpretations.

The M50

Doubling the M dose

does not result in a uniform enhancement of PB-sleep over the M25-treated
groups.

The increased prolongation at 0600 and 2400 hours with M50(motor

·and metabolic) occurs in the dark phase, suggests that there might be a relationship to the greater activity of the animals at these times.

Doubling

the M dose might produce brain monoamine changes favoring longer sleep.
Because M is structurally similar to 5HT it might displace 5HT from its
active site, and to a greater extent with the M50 than the M25 dose.

3H-M

selectively concentrated in the MB and hypothalamus (Anton-Tay and Wurtman,
1969).

Greater effects on these areas, which normally contain significant

amounts of 5HT, would favor the depressant actions of Mand 5HT.

The extent

of M-hypothermia might be greater for the M50, when the animals normal temperature is high, resulting in a greater fall when combined
a slower rate of PB metabolism.

with PB, to yield

Finally, with the M50 dose toxic effects
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might be more prominent during the active period.
4.

5HTP and 5HT-related Compounds
5HTP significantly prolonged PB-sleeping time over controls at

1200 and 2400 hours (Figs. 13-17 , Table 5 ) , although there is an increase
at 0600 hours that is of borderline significance.

This bimodal pattern is

similar to that obtained with AMPT, in which there is prolongation during the
normal sleep period (1200 hours) and at 2400 hours, when rats are active.

In

a limited study of the brain amines after 5HTP, at 1200 hours, SHI was elevated
in MB, hypothalamus and to a lesser extent in the CN.
increase in MB, CN and

brain~

DA, as well as CN NE.

There was a concomitent

A metabolite of DA

might be involved in the enhanced PB-sleep after SHTP (vide supra).

Because

SHI plays an important role in the production of sleep (Jouvet, 1972b) the
increase in SHI produced in many brain areas by SHIP might be expected to prolong PB sleep throughout the 24 hour period.

The question to be asked then is

why was there no prolongation at 1800 hours?
The SHTP temperature pattern at 1200 hours is significantly lower than
control (between S-95 minutes, P < 0.001), with absolute differences ranging
between 1.62 - 3.22°C. (Table 20 , Fig.

48

).

Significant decreases occur

at 1800 hours at the lS, 2S and 6S minutes measurements (each, P < O.OS).
There are also significant differences between SHIP-treated and control groups
at 2400 hours, at 2S-55 minutes (each, P < 0.001) and at 6S-7S minutes (each,
P < O.OS).

The absolute reductions in body temperature are less than at 1200

hours, ranging from 0.88 - l.08°C.

There are no significant differences

between temperatures for SHIP-treated and control groups at 0600 hours and

2fi5

most of the measurements at 1800 hours.

The prolongation of PB-sleep at 1200

and 2400 hours could be explained in part, on the basis of reduced body temperatures at these times.

Barofsky and Feldstein (1970) found that 5HTP (50-

200 mg/kg, IP) produced hypothermia.
formation of

11

They attributed this effect to the

tryptophols" (tryptophol, 5-methoxytryptophol and 5-hydroxy-

tryptophol), which can lower body temperature in a dose-dependent manner.
Pretreatment with a MAO inhibitor prevented the 5HTP-induced hypothermia,
suggesting that the "tryptophol" metabolite, rather than 5HT, is the active
hypothermic agent.

Feldstein et al. (1970) and Taborsky (1971) reported that

5-hydroxytryptophol and 5-methoxytryptophol induce sleep as well.
The effects of several 5HT-related compounds were tested for their
ability to prolong PB-sleep in mice.

5HIAA and 5-methoxy indoleacetic acid

were without significant effect, while 5-methoxytryptamine and N-acetyl-5HT
were active.

Rectal temperatures were not determined, but it is probable

that these compounds share some of the hypothermic properties of the tryptophols.

These studies indicate that the activity of metabolites should be

considered in any analysis of the effects of biogenic amines.
D·

Drugs Affecting the Histamine System
l·

Histidine
Hd significantly prolonged PB-sleep over controls in the following

instances:

HdlOO dose at 0600, 1200 and 2400 hours; Hd500 dose at 1800 hours;

and at the HdlOOO dose at the four experimental time points (Table 6
18-22 ).

, Figs.

PB-sleep is reduced significantly with the Hd500 dose at 2400 hours.
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PB-sleep in the Rd-pretreated groups follows a circadian pattern, with peaks
at 1200 hours (HdlOO) and at 1800 hours (HdSOO and HdlOOO), during the normal
sleep period for rats.

Monnier and Hatt (1969) reported that H activates the

CNS reflexly when administered systemically and by a direct action on the
reticulo-thalamic activating systems after intraventricular injection.

In-

ferentially, Friedman and Walker (1969) suggested a waking effect of H as
the result of finding that H concentrations in the CN are maximal during the
normal waking period of rats.

The results of the present study do not support

such a role for H in PB-sleep, although H might be active in the sleep-wakefullness cycle of physiological sleep.
Although brain H levels were not measured in the present study there
is abundant evidence to show that Hd elevates H in the brain (Taylor and
Snyder, 1972; Schwartz£.!. al., 1972).

Taylor and Snyder (1972) found in the

mouse, that H was significantly elevated in the hypothalamus, MB-thalamushippocampus, cortex, striatum, medulla-pons and cerebellum, one hour after
Hd (1000 mg/kg, IP).

PB (60 mg/kg, IP) alone, one hour prior to determina-

tion, produced a significant elevation (26%) of whole mouse brain H.
After HdSOO, DA in the brain stem decreases and hypothalamic DA
increases at 0600 hours, while MB SHT is elevated.
SHT is reduced.
SHT.

At 1200 hours, brain stem

At 2400 hours there are elevations in MB DA and hypothalamic

At 1800 hours, when the peak prolongation of PB-sleep occurs, with the

HdSOO and HdlOOO doses, there are no significant changes in the levels of any
of the amines studied, in any of the brain parts examined, suggesting that
these amine changes are of minor importance in the prolongation of PB-sleep.
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The changes that do occur at other times tend to balance out.

Taylor and

Snyder (1972) found no significant alterations in whole mouse brain NE, DA
or acidic and neutral indoles, one hour after Hd (1000 mg/kg, IP) but did
find a significant decrease (35%) in 5HT.
There is no simple explanation forthcoming for the significant decrease in sleep at 2400 hours compared to control, produced with the Hd 500
dose.
There are no significant alterations in body temperature at 0600 and
1200 hours of rats pretreated with HdlOO (Tables 19, 20, Figs. 47, 48).

Un-

fortunately this aspect of the study is incomplete, but the formation if H
from Hd, might be expected to produce hypothermia according to the findings
of Packman et al. (1953).
ventricular,
~al.

1~10

Shaw (1971) reported that in mice, H (intra-

ugm) or 125 mg/kg H (SC) produced hypothermia.

Packman

(1953) obtained hypothermia in rats, with several doses of H (SC).
The prolongation of PB-sleep by Hd appears to be unrelated to changes

in levels of CNS monoamines studied.

Displacement of PB binding to serum

proteins is probably not involved because Hd does not bind to proteins to a
significant extent (McManemy

~al.,

1961).

The effects might be due to a

direct depressant effect of H, which prolong PB-sleep in a pattern following
the normal sleep cycle of the rat.

Phillis

~al.

(1968) described depressant

effects of iontophoretic H on cortical neurones, which could be antagonized
by antihistamines.

The greater depression at 0600 hours by the HdlOOO as

compared to Hd500 dose could be explained by the higher levels of H produced.
Although they found that iontophoretic methyl H had similar effects on
cortical neurons as H, Taylorand Snyder (1972) showed no significant trans-

,
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formation of
brain.

3
3
3
H-methyl H from H-histamine formed from H-histidine in rat

This argues against H metabolites being responsible for some of these

effects.

The overall result of increasing Hin many brain areas by Hd pre-

treatment would probably favor depression, facilitating the action of PB.
Several investigators have reported that the H levels in neonatal
rat brain are five times higher than in adults (Pearce and Scharnberg, 1969;
Ronnberg and Schwartz, 1969).

Snyder (1972) found that telencephalon and

diencephalon H exhibit a peak 5-10 days after birth, with a decline to adult
levels by day 17.

The increased H might be related to the maturing CNS,

since high H levels occur at times of rapid neuronal growth.

However, this

elevated CNS H might also be related to the increased amount of time new-born
animals sleep, if H has the depressant effects mentioned above.
2.

Decaborane
DB significantly prolonged PB sleep.

The pattern is relatively

flat, indicating that a ceiling effect has been reached.

DB was used to

deplete brain H, but also affected levels of NE, DA and 5HT.

NE concentrations

are significantly depleted in almost all tissues and at all experimental times
(14/16).

The extent of depletion in the hypothalamus (76.3 - 78.7%) is

greater than that in the MB (58.1 - 61.1%) or
Merritt~

(54.8 - 65.6%).

al. (1964) reported that rat brain NE was depleted 63%,

24 hours after DB (15 mg/kg, IP).
9/16 cases.

brain~

In this study 5HT is also depleted in

Both of these amines· are involved in central temperature regu-

lation (Bligh and Cottle, 1966;

Myers and Yaksh, 1969).

Their depletion

might be expected to disrupt mechanisms involved in heat production and loss.
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DB inhibits decarboxylase activity, in vivo and in vitro, but also
increases the rate of release of amines (Merritt and Sulkowski, 1967).
decarboxylase inhibition accounts for the depletion of NE and 5HT.

The

Medina

et al. (1969) demonstrated that DB (15 mg/kg, IP) depleted whole rat brain
H maximally 24 hours after injection, by inhibiting Hd decarboxylase.
depleted about 60%, suggesting other, resistant pools of H exist.

H was

The de-

pletion of H, by DB, might be expected to increase circulating H significantly, with a resultant H-induced vasodilatation which would further the
heat loss (vide supra discussion of H-induced hypothemia; Packman et al.,
1953).
The elevated DA in the MB at 0600 and 1800 hours and at 0600 hours
in the hypothalamus might be expected to favor a waking effect.
2400 hours DA is reduced in the brain stem.
are also reduced.

At 0600 and

Brain stem 5HT concentrations

The H-depleting effects of DB fit with the arousal actions

of H described earlier, in that the decrease in the levels of an alerting substance would tend to facilitate sleep.

Sleep after Hd is augmented, partly

because high concentrations of H exert a depressant effect.

Hd pretreatment

has fewer effects on other brain monoamines, while DB produced many, which
contribute to the overall prolongation of PB-sleep obtained.

A more specific

H-depletor might better reveal the exact involvement of H in sleep.

NE-

depleting actions of DB favor sleep, as do the effects interfering with temperature regulation.
Since DB inhibits decarboxylating enzymes, it might also inhibit the
liver oxidizing enzyme system, responsible for metabolizing PB.

Administra-

tion of DB 24 hours prior to PB would allow sufficient time for enzyme inhi-
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bition to occur, which would result in a reduced PB metabolism and therefore
a longer duration of sleep.
3.

Diphenhydramine
DPH significantly prolonged PB-sleep at all times examined and

did so in a circadian manner (Table 6, Figs. 18-21).

The effect is minimal

at 1800 hours, and maximal at 2400-0600 hours.

DPH was used because in its

clinical use it frequently produces sedation.

The maximum effect on PB-sleep

occurs during the dark phase,unlike in the PB pattern, in which the peak
occurs at 1200 hours, during the sleep period of rats.

Clearly, the pattern

does not follow that of sedatives, which produces longer sleep duration
during the normal sleep period of animals.
DPH effects on amine levels are not striking (Table 16, Fig. 41).
The increase of MB SHT at 0600 hours favors enhanced sleep because this amine
has a significant function in the raphe system.

The reduction in hypotha-

lamic NE also contributed to this effect.

This period corresponds to a time

of maximal enhancement of PB-sleep by DPH.

The elevation of CN SHT at 1200

hours is the only significant amine change at a time which also favors sleep.
However, SHT is of secondary importance in the CN.
duration is prolonged to an intermediate extent.

At 1200 hours, DPH-sleep
The lowering of MB NE at

1800 hours would favor enhanced sleep, which does occur at 1800 hours,
although at this time DPH prolongs PB-sleep to the least extent.

There are

no significant amine changes at 2400 hours, although the prolongation of PBsleep returns to its maximal level.
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The effect of antihistamines (beyond antagonizing H) are numerous and
depend on structural features of molecular types.
a dual central action:

Most antihistamines have

the initial depression seen at therapeutic doses

shifts to EEG activation and seizures, if the dose is increased sufficiently.
Douglas (1970) states that there is not yet a clear-cut explanation of the
diverse actions of antihistamines, but a partial explanation might involve
their anticholinergic effects or direct antagonism of CNS H.
Green and Erickson (1964) reported that DPH (SO mg/kg, oral, one hour
prior to sacrifice) reduces whole rat brain H.

DPH (lS mg/kg, SC, 2 hours

prior to sacrifice) increases guinea pig brain stem and cerebellum H (Green
and Erickson, 1967).

In whole mouse brain, Taylor and Snyder (1972) found

no change in H, 4 hours after DPH (20 mg/kg, IP).

Boissier et al. (1970)

reported that DPH (SO mg/kg, IP, one hour prior to sacrifice) did not alter
H levels in whole rat brain or in several rat brain areas, including hypothalamus, CN and thalamus.
Winter (1948) demonstrated in mice, the prolongation of HB (100 mg/kg,
IP) or PB (SO mg/kg, IP) sleep, by DPH and other antihistamines (10 mg/kg,
IP).

No explanation of mechanism involved was given, except for citing its

clinical sedative side effects.

The results of the present study clearly

corroborate this observation, but extend it by demonstrating that this prolongation varies significantly with the time of day.
There are several other factors which could influence the duration of
PB-sleep after DPH.

The antihistamine might prolong sleep by blocking the

alerting activity of H in the CNS, reported by Monnier and Hatt (1969) or
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Friedman and Walker (1969).
~hich

DPH has anticholinergic effects (Douglas, 1970),

could antagonize central ACh, which, according to Friedman and Walker

(1972) is maximal in the rat when these animals are in an alert state.

Anta-

gonizing ACh at times when it is normally maximal (i.e., 2400-0600 hours)
might account for the longer duration of PB-sleep, because of the association
of ACh with states of central excitation.

Packman et

~·

(1953) reported that

in mice, DPH produced significant ·and maximal depression of body temperature
one hour after its administration.

Such a hypothermia could facilitate the

prolongation of PB-sleep.
Antihistamines also affect neural transmission and neuromuscular
function.

Abdel-Aziz and Bakry (1973) reported that DPH blocked transmission

in a rat phrenic nerve-diaphragm preparation and reduced the action of ACh on
the frog rectus muscle.

This blocking action might delay the recovery of the

righting reflex in PB-treated animals.

A local anesthetic effect for anti-

histamines was also reported by Douglas (1970).
The basis of the circadian differences in PB-sleep with DPH might be
due to its monoamine changes, as well as the multiple effects just described,
interpreted according to the continuum in the development of catalepsy by
sedative drugs elaborated by Winters et al. (1967; 1972).

Faingold and Berry

(1972) demonstrated that IV infusion of DPH in cats (3.0 mg/kg/minute) initially produced synchronized cortical activity, followed by an abrupt change
to a desynchronized pattern approximately 5 minutes prior to the cortical
seizure.

The dose required to produce a seizure was 37 mg/kg.

The dose

utilized in the present study (SO mg/kg) is greater than that required for
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seizure in the cat, although in the cat administration was IV and differences
in species sensitivity must be considered.

The use of PB in this study could

obscure the later desynchronizing phase.
E.

Gamma-butyrolactone
GBL (350 mg/kg, IP) produced a maximum duration of sleep at 1800 hours

and a minimum at 0600 hours (Table 17, Fig. 44, 45), a pattern similar to that
for PB-treated animals, in which the peak duration of sleep occurs during the
normal sleep phase for rats.

Significant increases over control for 5HT

levels occur in the MB at 1200 and 1800 hours and in the brain stem at 1200
hours.

These areas contain the raphe system.

Significant elevations in CN

DA at 1200 hours and hypothalamic DA at 1800 hours, and CN DA at 1800 and
2400 hours (with borderline significance:

P about 0.05) favor waking although

the possibility of structurally-related depressant amines cannot be discounted.
A balance between these effects must exist, since the GBL pattern follows both
normal and PB-sleep in a facilitory manner.
Winters !:.!:_ !!._. (1967; 1972) have criticized designating the effects of
GBL (or GHB) as "sleep".
gression of effects:

They found that GHB produced the following pro-

hypersynchrony, spiking with polyphasic bursts (7-15

Hz) and periods of electrical silence and hypersynchronous high frequency
generalized seizures.

They claim that this is a "catatonic" state, or a

"generalized non-convulsive epilepsy or seizure".

They cite several other

drugs used for anesthesia, which follow this GHB continuum, including ether,
alpha-chlorolose and phencyclidine.

The present study demonstrates a diurnal
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pattern for GEL-induced sleep which is similar to that of PB.

At this dose

the hypersynchronizing effects described by Winters and coworkers might
predominate and induce sleep, while facilitating normal sleep.

If this is

not the case, and the results of GBL administration is to produce catatonia,
the present data would indicate that such a catatonia follows a circadian
pattern.
Roth and Suhr (1970) found that GBL (3 x 500 mg/kg, IP for three hours)
significantly elevated whole rat brain DA and SHT, without any altering brain
NE.

(The results of the present study are similar although a considerably

lower dose was used).

They found that GBL (or GHB) specifically blocks DA

release without affecting synthesis, but did not elucidate the mechanism of
its CNS depressant action.

They did find a good correlation between the

sedative action and the increase in brain DA.

Bustos~

al. (1972) indicated

that the blockade of DA release is probably due to the reduced impulse flow
in the nigro-neostriatal pathway, but did not elaborate on how this might
affect sleep.

In the present study brain DA levels increased only infre-

quently, therefore it cannot be directly related to the circadian pattern
for the duration of GBL-induced sleep.

Giarman and Schmidt (1963) reported

that GBL increased ACh in whole mouse brain and rat MB and brain stem.
Since microinjection of ACh into several areas of the RF results in behavioral and EEG sleep

(Courville~

al., 1962; vide supra), this effect

of GBL on brain ACh might be related to its depressant actions.
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Anticholinesterases
Physostigmine in mice increases PB-sleep significantly only at 2400

hours (Table 7

, Fig. 23 ).

The pattern is flat.

Neostigmine significantly

prolongs PB-sleep at 0600, 1200 and 2400 hours, while significance is borderline at 1800 hours.
2400 hours.

The pattern has a peak at 0600 hours and a trough at

Since neostigmine is a quaternary compound and does not cross

the BBB, it must exert its effects peripherally by some indirect mechanism.
Neostigmine inhibits cholinesterase, resulting in increased ACh at
cholinergic sites.

Its effects at the neuromuscular junction, spinal cord

and ganglia are based on a combination of its cholinesterase inhibition and
direct effects, which can result in muscle paralysis.

Friedman and Walker

(1972) demonstrated that rat MB and CN ACh levels were maximal at 2400 hours
(and minimal for MB at 1200 hours and at 1800 hours for CN).

They found that

in mice, the neostigmine toxicity pattern, which was maximal at 0600 hours,
and minimal at 1800 hours resembles the pattern of the duration of PB-sleep
in mice after neostigmine.

The LDSO of neostigmine ranged from 0.23 - 0.36

mg/kg (IP) during the 24-hour period.

The dose utilized in the present study

(0.30 mg/kg, IP) is in the middle of this circadian LDSO range.

The peak

prolongation of PB-sleep at 0600 hours might be due to an interaction of PB
with the toxic effects of neostigmine at various pharmacological sites.
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VI. SUMMARY

This study was undertaken in order toclarigy the influence of some

rNS amines on the narcosis produced by a classic hypnotic agent, pentobarbital and to a lesser extent, by another type of soporific agent, gammabutyrolactone (GBL). It was prompted by a number of earlier investigations,
including those from our laboratory, which reported significant variations
over a 24-hour period in the duration of drug-induced sleep, in the concentrations of biogenic amines in whole brain and portions of the brain.

This

study required a consideration of the normal circadian fluctuation of biogenic
amines in various brain regions and the effects of pretreatment with various
precursors, depletors, inhibitors of synthesis or metabolism, and other drugs
related to biogenic amines, with respect to the duration of drug-induced sleep.
An attempt to correlate alterations in brain amine levels in several brain
areas with sleep duration seemed warranted.

Since any drug or compound

capable of changing body temperature presumably could alter the time-coursP
of PB-sleep by influencing such activities as metabolism, an examination of
temperature effects was also undertaken.
The experimental animals (adult male rats and mice) were adapted under
stable laboratory conditions to an automatically-timed light-dark cycle
(0800-2000 hours light) for at least three weeks prior to use.

The onset and

duration of sleep, measured by the loss and recovery of the righting reflex,
were determined every six hours ( at 0600, 1200, 1800 and 2400 boars), after
IP doses of PB (50mg/kg) or GBL (350mg/kg).

Pretreatment regimens were

institlied at a sufficient time prior to the administration of the hypnotic
so that the levels of the amine(s) under examination might be changed,

Pre-
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treated and vehicle-injected control animals were used to determine alterations
in sleeping timeo

Similarly treated animals, sacrificed midway through the

previously-determined sleep period were used for the spectrophotofluorometric
determinations of biogenic amine levels in the midbrain, hypothalamus, caudate
nucleus and brain stem.

The duration of sleep in control rats after PB,

50mg/kg, IP, ranged from a low of 101.3 + 8.9 minutes at 2400 hours during the
dark phase of the illumination cycle, to 119.5 .±. 9. 7 minutes, at _1200 hours,
during the light phase.

Peak and trough values are significantly different

(P < 0.01) and correlate inversely with rectal temperature, which peaks at
2400 hours, when these nocturnal animals are most active and troughs at 1200
hours, when they are quiescent.

As a generalization, a majority of the treat-

ment regimens resulted in some prolongation of PB-sleep.

The following types

of modified PB sleeping patterns were obtained with the pretreatment regimens
used:
Type I:

a normal diurnal or circadian pattern, in which the peak occurs

during the usual sleeping period.

In rats and mice this is during the light

phase of the illumination cycle.
Type II:

a relatively flat pattern indicating that the system was

responding maximally to a particular treatment.
Type III:

a relatively flat pattern in which one point departs signif-

icantly from the overall trendo
Type IV:

an inverted diurnal or circadian pattern, in which peak effects

are observed during the dark phase of the illumination cycle.
Type V:

a bimodal or ultradian pattern in which a peak and trough occur

in the light as well as in the dark phase of the illumination cycle.
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Treatments significantly prolonging PB-sleep in a Type I circadian
fashion include pcPA (a 5HT depletor), histidine (a precursor of histamine)
and melatonin (a naturally-occurring derivative of 5HT)o
pcPA administered in lOOmg/kg doses 72, 48 and 24 hours prior to PB
significantly prolonged PB-sleep at every experimental time point (P< 0.001).
The increases ranged from 19.5% at 0600 hours to 49.8% at l&QQ. hours.
peak duration at

~

hours differs significantly from the trough at

The
~

hours (P < 0.01).
Histidine was administered IP one hour prior to PB at three different
dose levels.

At lOOmg/kg, histidine significantly prolonged sleep from 1506

to 22.1% at 0600, 1200 and ~hours, but not at 1800 hours.

At 500mg/kg,

PB-sleep increased significantly at 1800 hours by 47 .6% (P <0.001), but
decreased significantly at 2400 hours by 13.4% (P<0.05).

At lOOOmg/kg, PB-

sleep is significantly prolonged over the entire 24-hour period, from a low
of 13.1% at 2400 hours to a high of 54.1% at 1800 hours.
Melatonin, given concomitantly with PB potentiates sleep in a dose-dependent manner.

Sl~ep

is significantly prolonged (from P

< 0.05 to <..0.001) by

50mgjkg at every time point and at every time point except ~hours with
25mg/kg.

Sleep is prolonged by 20.0 to 30o4% at the lower dose and by 29 0 5

to 66.6% at the higher dose.

There is a shift of the peak effect with 25mg/kg

from 1200 hours to 0600 hours with 5 Gng/kg.

The pattern with the M50 dose

therefore must be categorized as a Type IV PB-sleep pattern.
Highly significant potentiation of PB-sleep (P<0.001) was achieved
after pretreatment with DOPA-pargyline (a precursor amine plus a MAO!) and
decaborane (an inhibitor of histam,ine synthesis).

These patterns were Type
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II.

DL-DOPA (500mg/kg, IP) and pargyline (6,0mg/kg, IP) administered one hour

and 30 minutes, respectively, prior to PB, increased the duration of sleep
from 103% at 0600 hours to 146.3% at 2400 hours.

Decaborane (15,0mg/kg, IP)

administered 24 hours before PB prolonged sleep at the subsequent 24-hour
period from 69.1% at 1200 hours to 114.8% at 2400 hours.
Type III PB-sleep patterns were obtained with tryptophan (a secondary
precursor of 5HT) and 5HTP (the immediate precursor of 5HT).

Tryptophan (500

mg/kg, IP) administered one hour prior to PB, potentiated sleep significantly
(P

< 0.001)

from 32.0% at 1200 hours to 59.1% at 2400 hours.

significantly lower at 2400 hours than at 1800 hours (P

Sleeping time was

< 0.05).

After 5HTP

(lOOmg/kg, IP) administered one hour before PB, sleep was significantly prolonged (except for the measurement at 1800 hours) over control at 0600
(P(0.05), 1200 (P(0.001), and 2400 (P<0.001) hours from 13.7 to 34.7%.

The

duration of sleep at 1800 hours was significantly lower than at 1200 hours
(P( O. 01).
A Type V bimodal sleep pattern was obtained after pretreatment with AMPT

(200mg/kg, administered IP 4 hours before PB).

The two significant peaks of

19.8% and 75% above control occurred at 1200 (P<0.05) and 2400 (P<0.001)
hours, respectively.

The two troughs at 0600 and 1800 hours were not signif-

icantly different from controls.
I>iphenhydramine (50mg/kg, administered one hour prior to PB) exhibited a
Type IV pattern with the peak occurring in the dark phase of the illumination
cycle.

The significant increases in sleep (P< 0,001 at each time point)

ranged from 62.7% at 1800 hours to 178.1% at 2400 hours.
differed significantly from each other.

Peak and trough
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A tertiary anticholinesterase, physostigmine and a quaternary anticholinesterase, neostigmine were examined in mice for their effects on PB-sleep.
Both were administered at a dose of 0~3mgjkg, IP, one hour prior to PB (50mg/
kg 1 IP).

The duration of sleep in control mice ranged from 26.3 ±. 18.3 min-

utes at 2400 hours to 41.7 ±. 26.0 minutes at 1800 hours.

A diurnal rhythm

was not obtained in these controls because of the variability of the data, although there is the suggestion of a peak at !§QQ. hours.

Phys•stigmine pro-

longed sleep at each time point but only at 2400 hours is an increase of 71.8%
significant (P <0.05).

On the other hand, neostigmine prolongs sleep signif-

icantly at each time point {except at 1800 hours, where significance is borderline) from 67 .6% (P <0.01) at 1200 hours to 105.2% (P ( 0.001) at 0600 hours.

-

--

fhe effect on sleep of compounds structurally-related to 5HT were administered to mice at a dose of 20mg/kg, IP, one hour prior to PB at a single
time point (1500 hours), favorable to eliciting a hypnotic effect.

Signif-

icant prolongation of sleep occurred with 5-methoxytryptamine (74.6%;P<0.02)
and N-acetyl-5HT ( 105.4% ;P < 0.025).

5HIM and 5-methoxyindole acetic acid

were without signifieant effect.
The duration of sleep produced in rats by 350mg/kg, IP, of gamma-butyrolactone varies with the time of day it is administered.

It ranges from 68.2

±. 9.3 minutes at 0600 hours to ll0.3 ±. 16.3 minutes at 1800 hours.

The dif-

ference between peak and trough is statistically significant (P < 0.05).
Pretreatment with histidine 100 and 500mg/kg produced augmented sleep only at

,!&QQ_ hours, with the higher dose.

The difference was significant at P

< 0.05.
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Pretreatment with DOPA-pargyline significantly elevated DA levels in
various brain parts above control throughout the 24-hour period, in 15/16
instances.

On the other hand, NE levels were elevated in only 4/16 instances

(in CN at 0600, 1800 and 2400 hours; in the brain stem at 0600 hours), while
5HT decreased in 2/16 instances (in the brain stem at 1800 and 2400 hours).
In 9 of 12 amine patterns a fluctuating pattern was obtained over the 24-hour
period of measurement.

The remaining 3 amine patterns, viz., MB-5HT, CN DA

and brain stem NE, were unvarying.

The fall in rectal temperature after PB

is significantly reduced by DOPA-pargyline pretreatment.

Prolongation of

sleep with DOPA-pargyline correlates best with the increase in DA levels.
The possibility that DA might displace PB bound to plasma proteins or that DA
is converted to a metabolite exerting a hypnotic effect is considered in
attempting to explain the augmentation of PB-sleep by this regimen.
AMPT significantly reduced brain NE (13.6 to 62.2%) and DA (43.9 to 86.3%)
levels in 14/16 and 8/16 instances, respectively, during the 24-hour period
of examination. 5HT rose significantly in 3/14, fell in 1/14 and was
unchanged in 10/14 instances.
le\els of NE and DA.
diurnal rhythms,

Sleep correlates best with the decreased

Of 12 amine patterns, 5 are unvarying and 7 display

Temperature reductions after AMPT exhibit minimal differ-

ences from PB alone and do not appear to account for the increased duration of
slPPp.

Similarly, the effects of AMPT on the protein binding of PB are pro-

bably minor.
pCPA significantly decreased 5HT levels in all tissues throughout the 24hour period (16/16 instances), from 40,4 to 97.0%, with only minor changes in
CA levels.

Body temperature reduction is probably of minor significance in

the prolongation of PB-sleep.

The effect of pCPA on the protein

bindin~

of
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PB is unknown, but the cumulative effect could be significant.

The prolong-

ation Gf sleep correlates in this case with the widespread depletion of 5HTo
8 of 12 amine patterns fluctuate during the 24-hour period.
TP increased 5HT in 4/16 instances (40o5 to 69.2%), decreased NE in 3/16
(15.7 to 48.5%) and decreased DA in 4/16 instances (29o3 to 81.0%), suggesting that the amine changes were not of major importance in lengthening sleep.
However, the significant increase in hypothalamic 5HT with a concomitant fall
in MB NE at .!§Q.Q. hours might explain the peak effect in sleep seen at that
time.

Of 12 amine patterns, 10 show significant variation throughout the 24-

hour period.

Two other factors undoubtedly contribute to TP-augmented PB-

sleep, viz., the probable displacement of bound PB because TP is significantly
bound to plasma protein and the marked hypothermic effect TP produces.

Within

five minutes of the onset of PB sleep, rectal temperature was significantly
lower than control by almost 4°C.

This difference was maintained for more

than two hours and was greater at 1800 than 0600 hours.
The amine effects with M were studied only at the M25 dose.

Only 5/48

amine levels changed from control significantly (four decreases, MB DA (43.9%),
CN DA (11.8%), brain stem 5HT (46.3%) and hypothalamic DA (76.1%); 1 increase,
MB 5HT (76.3%)).

Temperature effects of this dose are minor and displacement

of protein bound PB is improbable.

This suggests that the effect might be due

to a direct depressant action.
Although Hd500 significantly prolonged PB-sleep at 1800 hours, no significant changes in the levels of the amines studied occurred in any of the
brain parts examined, suggesting that neither NE, DA nor 5HT play a significant role in Hd-proiongation of PB-sleepo
significantly from control.

Only 6 of 48 amine levels changed

Four increased and two decreased at times when

2H3

sleep was not significantly different from controls.

Binding and PB dis-

placement does not seem to be involved in facilitated PB-sleep, since Hd does
not bind to plasma to any extent.

Two possibilitess to explain the effect

observed include a direct depressant effect of the elevated histamine generated by Hd and/or histamine hypothermia.

Temperature studies in the rat were

limited to the HdlOO dose and were not striking.

7 of 12 amine patterns after

Hd500 exhibited diurnal variation during the 24-hour period.
DB, a histamine depletor, markedly reduces NE levels in 14/16 instances
from 54.8 to 78.7%, an action favoring sleep.

(Depletion of NE was consist-

ently greater in the hypothalamus than in MB and brain stem.)
depleted in 9/16 instances by 29.0 to 78.7%.
in 7/16 cases.

5HT was

lso

On the other hand, DA increased

The latter two amine changes, it can be argued, favor waking.

However, 5HT levels normally are inversely related to NE levels.
relationship is altered sleeping time is extended.

When this

The rise in DA levels is

probably not sufficient to overcome the loss of functional NE.

Furthermore,

the conversion of DA to a soporific metabolite cannot be discounted.
and 5HT are involved in heat production and loss.

Both NE

The profound hypothermia

produced by DB might reflect the reduced levels of these amines and their
involvement in temperature regulation.

Additionally, vasodilatation resulting

from the mobilization of histamine by DB could contribute to heat loss and
reduced metabolic activity.

The degree of amine mobilization by DB suggests

that it could raise the level of circulating amines and thus could interfere
with PB binding. 11 of 12 amines exhibit significant diurnal variaiions after
DB.
The very significant prolonged Type IV PB-sleep patter after DPH does

r
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not appear to reflect brain amine changes to any extent.

Only 2/16 5HT values,

2/16 NE and no DA values were significantly different from controls.

HoweYer,

8 of 12 amine patterns display diurnal changes (These are detailed in Figs. 4243, Table 16 and Appendix B.)

The DPH-augmented PB-sleep and its inverted diurn-

al pattern can be explained on the basis of some of the following diverse pharmacological and toxic actions of antihistamines:
alerting effects of histamine,
abolic activity,

1) antagonism of the CNS

2) hypothermia, especially during maximal met-

3) local anesthetic, anticholinergic and neuromuscular-

blocking.actions, 4) time-related change in sensitivity to the toxic actions,
which include, sedation and cortical seizure activity leading to catalepsy.
There is no evidence available to suggest that DPH is bound to any extent by
plasma proteins.
The few significant amine changes after GBL (6/48) occur during the light
phase, the normal sleeping time MB 5HT increases 77.8 and 64.0% respectinly,

--

at 1200 and 1800 hours, while brain stem 5HT increased 50,0% at 1200 hours.

--

--

CN DA at 1200 hours and hypothalamic DA at 1800 hours increased 41.3 and 128%
respectively.
2400 hours).

The only decrease occurring is in hypothalamic NE (20.4% at
These data in essence corroborate the findings of Roth and Suhr

(1970) obtained in whole rat brain, with a considerably higher dose.
correlated sedative effects of GBL with the increased DA levels.

They

The effect

of 5HT might supersede any other amine, since the 5HT increases occur in the
raphe system, where according to Jouvet (1972b) sleep centers are located.

The

possibility that what is termed "GBL-sleep" is really a state of catatonia has
lwen suggested by WintPrs et !!.!_. (1972).
follows a circadian pattern.

If this is true, then this catatonia
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The question concerning the relationship of biogenic amine background
to the hypnotic effect of PB can be answered in the following manner:
PB sleep is augmented by raising brain levels of DA or by reducing 5HT levels
or by decreasing NE levels or by combination of these effects.

The amine

changes and sleep effects in general display a variety of diurnal or
circadian patterns, when measured over periods of 24 hours.

The probability

that other amines must participate in these effects is inferred from data
obtained with compounds that mobilize acetylcholine and histamine.
factors influencing the duration of PB-sleep include:

Other

hypothermic effects of

compounds, (a possible alteration of the protein binding of the hypnotic) and
a direct depressant effect of the compounds themselves.
follows the normal circadian sleep pattern of rats.

GBL "sleep"

Amine changes are not

extPnsive, but when normal sleep is expected GBL increases DA, and 5HT
levels and decreases NE levels.
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Appendix A:
1.

Drugs, Chemicals and Equipment

Dru.gs
N-acetyl-5-hydro:x:ytryptamine (Sigma)
I

L-alpha-methyl-E-tyrosine (Merck)
DL-.E=,chlorophenylalanine (Sigma)
Decaborane (Alpha Inorganics)
Diphenhydram.ine HCl (Sigma)
DL-DOPA (DL-394-dihydro:x:yphenylalanine; K & K)
Gamma-butyrolactone (Eastman)
L-histidine (Sigma)
5-hydro:x:yindoleacetic acid (Sigma)
Melatonin (Sigma)
5-metho:x:yindoleacetic acid (Sigma)
5-metho:x:ytryptam.ine
Neostigm.ine methylsulfate (Roche)
Pargyline (Abbott)
Pentobarbital sodium (Abbott)
L-tryptophan (Sigma)
Physostigmine salicylate (Merck)
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2.

Chemicals
Acetic acid (Baker)
Alumina (Grade I, Woelm)
Boric acid (Baker)
Disodium. EDTA (Fisher)
n-heptanol (Eastman, Sigma)
Iodine (Baker)
Perchloric acid (Baker)
Potassium carbonate (Fisher)
Potassium iodide (Fisher)
Potassium phosphate, monobasic (Mallinkrodt)
Sodium chloride (Fisher)
Sodium phosphate, monobasic (Merck)
Sodium phosphate, dibasic (Merck)
Sodium sulfite (Baker)
Ninhydrin (Pfanstiehl)
Tricine (Calbiochem)
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3.

Equipment
Aminco-Bowman Spectrophotof luorometer
Beckman, Model 72 pH Meter, with electrode #39030
Christian Becker, Model EA-1 Torsion Balance
Eberbach, 2-speed shaker
IEC centrifuge (Model K)
Hythermco oven
Precision Scientific beating bath (Model 83)
Scientific Products Deluxe Mixer

(vortex)

Yellow Springs Telethermometer (with probes 401 and 403)
Harvard decapitator
Paragon 24-hour timer(Model 4000-0)
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Appendix B:

1.

Analyses of Amine patterns

Drugs affecting the NE and DA systems
a.

DOPA-parg;yline(Figures 28-29, Table 9)
Analyses of the 12 24-hour amine patterns in DOPA-pargyline

treated animals reveals that 9 are circadian.

At 1200 hours, the M!!, NE peak

is significantly different from the values obtained at 0600 (P <0.02) and
2400 hours (P

< 0.025).

MB DA maxima occur at 1800-2400 hours, while minima

are at 0600-1200 hours.

The concentration of MB DA at 11!.QQ hours differs

significantly from that at 0600 and 1200 hours (each at a P

< 0.001).

level at g!QQ. hours also differs significantly from that at 0600 (P
and 1200 hours (P .( 0.01).

The DA

< 0.02)

CN NE concentrations exhibit a trough at 0600

hours, which differs significantly from ~and 1800 hours levels (each at
P<0.05). CN 5HT exhibits peak concentrations at 1200 hours, which differs
significantly from ~hours (P <0.02) and 2400 hours (P < 0.05) values.
5HT concentrations at ~and 11!.QQ hours also differ significantly (P< 0.05).
Brain

~

DA levels peak at 11!.QQ hours, differing significantly from 0600

and 1200 hours values, at

.P< 0.01. DA levels at 0600 and g!QQ. hours also

differ significantly (P<0.05).

Brain stem 5HT levels reach a maximum at

--·

1200 hours, which differs significantly from the values at 1800 hours (P

<0

0

025)

and 2400 hours (P< 0.005) •. Hypothalamic DA levels peak at 1800 hours, which
is significantly different from the levels at 0600 (P < 0.001), ~ (P < 0.001)
and 2400 hours (P < 0.02).
following points:
0.05).

There are also significant differences between the

0600 vs. ~hours (P <0.005), 0600 vs. g!QQ. hours (P (

Hypothalamic 5HT levels exhibit a peak at 1800 hours and a trough at
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0600 hours, which differ significantly (P<0.05).

The trou~h at 0600 hours

also differs significantly from ~ and 2400 (both P
b.

< O. 01).

Alpha-methyl-£-tyrosine (Table 10, Figs. 30, 31)
In AMPT-treated animals, 9 of 12 amine patterns exhibit diurnal

fluctuations.

MB DA exhibits a significant difference between levels at 1200

and 2400 hours (P< 0.02; Fig. 31).

The MB 5HT pattern has a peak at 1200

hours, which differs significantly (P

<o. 01),

from the trough at 1800 hours.

The peak also differs significantly from the values at 0600 hours (P<0.001)
and 2400 hours (P < O. 02).

The trough at 1800 hours also differs significantly

from values at 0600 hours (P

< 0. 01).

differ significantly (P< 0.05).

CN NE levels at 0600 and 1200 hours

The values of CN 5HT exhibit a minimum at

2400 hours, which differs significantly from those at 0600 (P < O. 02) and
1200 hours (P < 0. 005).

The maximum brain stem NE concentration at 0600 hours

------

differs significantly from the values at 1800 and 2400 hours (both P< 0.0!5).
~i~nifican~<'

is bord<'rline at 1200 hours.

Brain stem DA
-----

levels exhibit a

minimum at 2100 hours, that differs significantly from the values at 1200
hours (P<0.02) and 1800 hours (P(0.01).

The minimum brain stem 5HT concen-

--- ---

tration at 2400 hours differs significantly from that at 0690 hours (P
and 1200 hours (P <0.01).

< 0,001)

Hypothalamic DA levels at 0600 and 1800 hours

differ significantly (P<0.02).

2.

Drugs Affecting the Serotonin System
a.

£-Chlorophenylalanine (Table 11, Figs. 32,33)
The aminP patterns of pCPA-treated animals exhibit circadian

fluctuation i11

!)

of 12 instances.

MB 5HT levels in pCPA-treated animals

2!11

exhibit

a maximum at 2400 hours, which differs significantly from the levels

at .Q2QQ. hours (P

<0.005),

1200 hours (P

< 0.005)

and 1800 hours

(P

< 0.001).

CN NE decreases to a minimum at 1:§.QQ hours, which differs significantly from
the values obtained at 0600 hours (P
hours (P

< 0.025).

< 0.05),

1200 hours (P

< 0.005)

and ~

CN DA exhibits a peak at 1800 hours, which differs signif-

icantly from the concent:rations at 0600 ho.urs (P< 0.025), 1200 hours (P< 0.001)
and 2400 hours (P

< 0.005).

CN 5HT is maximal at ~hours, differing signif-

icantly from the value at 1200 hours (P

< 0.001).

The value at 1,gQQ hours

differs significantly from that at 1800 hours (P< 0.01).
Brain

~DA

is minimal at .Q2QQ. hours, and differs significantly from

the value at 1200' hours (P < 0.05).

Brain ~NE is maximal at 2§.QQ hours,

differing significantly from the values at !&QQ. hours (P about 0.05) and 1800
hours (P < 0.01).

Hypothalamic NE has a trough at 1800 hours, which differs

significantly from the values at 2§.QQ hours (P < 0.05), !,g_QQ hours (P < 0.02)
and 2400 hours (P

< 0.005).

The hypothalamic DA levels trough at 1800 hours

and differ significantly from those at 0600 hours (P
(P < 0.01).

< 0.005)

and 1200 hours

The peak value of hypothalamic 5HT at ~hours, differs signif-

icantly from that at~ hours (P <0.,02) and ~hours (P

< 0.05).

The 5HT

value at 0600 hours also differs significantly from that at 1800 hours (P

<

0.01) and 2400 hours (P< 0.001).

b.

Tryptophan(Figures 34-35, Table 12)
TP (500mg/kg, IP) treated animals exhibited circadian flucfoations

of 24-hour amine levels in 10 of 12 cases.

The pattern of MB DA in treated

animals exhibits a minimum concentration at 1200 hours, which differs significantly from the values at ~ and 2400 hours (both P

< o. 01).

MB 5HT has a
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peak at
0.025).

!§QQ hours and trough at

~hours.

These differ significantly (P<

The peak at .!§.QQ hours also differs significantly from the values at

1200 (P<0.02) and~ hours (P<0.01).

CN NE exhibits a minimal concen-

tration at 1200 hours, which differs significantly from the value at 2400
hours (P<0.01).

CN DA concentration is minimal at .Q2.QQ.hours, and differs

significantly from the peak level at 1800 hours (P < 0.001).

CN 5HT levels

describe a similar pattern with a trough at Q2QQ. hours, that differs significantly from the 2400 hours values (P < 0.05).
maximal at

~

The brain stem NE pattern

is

hours, and differs significantly from the values at 1200 hours

(P<0.02) and 2400 hours (P<0.05).

The brain~ DA pattern has a trough

at 1200 hours, which differs significantly from the concentrations at 0600,
1800 and 2400 hours (all P <0.001).

The minimum brain stem 5HT levels at 0600

hours differs significantly from that at 1200 hours (P<0.01).

Hypothalamic

DA levels are minimal at giQQ. hours, and differ significantly from the value
at 1200 hours (P<0.005).

Hypothalamic 5HT exhibits peak levels at !§.QQ.hours

and trough values at Q&QQ hours, which differ significantly from each other
(P

< O. 005). The peak value also differs significantly from that at

1200 and

2400 hours (both P< 0.001}.

c.

Melatonin{Figures 36-37, Table 13)
In M-treated animals, amine patterns fluctuated in a diurnal

manner in 8 out of 12 instances.

The pattern of

~DA

has a minimam at Q2QQ_

hours, that differs significantly from the peak concentration at 1800 hours
(P

< 0.001).

MB 5HT levels are maximal at g_QQ-~ hours.

The value of 5HT

at Q2QQ. hours differs significantly from that at 1200 (P < 0.05) and 1800 hours
(P

< O. 005)

and the value at g!Q.Q. hours also differs significantly from 1200
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and 1800 hours (each at P<0.01).

CN NE is minimal at 1200 hours and is sig-

nificantly lower than the value at 1800 hours (P<0.005).

CN 5HT concentra-

tion also exhibits a minimum at 1200 hours, which differs significantly from
the levels at 0600 hours (P

< 0.01), .!§QQ.

hours (P < 0.02) and ~ hours

(P < 0.05).
Brain

~DA

levels are maximal at 0600 hours, and significantly higher

than the minimum level at 2400 hours (P
~ ~

< 0.01).

The peak concentration of

5HT at 1800 hours is significantly different from levels at 1200

and 2400 hours (both P

< 0.005).

Hypothalamic DA levels exhibit a maximum at

2400 hours and a minimum at .!_gQQ hours, which differ significantly from each
other (P < 0.005).

The trough value at .!_gQQ hours also differs significantly

from the levels at

.Q2QQ.

hours (P < 0.001) and 1800 hours (P

< 0.05).

Hypothalamic

5HT concentrations are maximal at .Q2QQ.-.!,g,QQ hours and minimal at t..!QQ_ hours.
The trough differs significantly from

.Q2QQ.

(P < 0.01) and 1200 hours (P

< 0.001).

There is also a significant difference between the levels at 1200 and 1800
hours (P
3.

< O. 005).
Drugs Affecting the Histamine System
a.

L-Histidin~Figures 38-39, Table 14)
Amine levels after Hd500 were altered in a cirdadian manner in 7

of 12 instances.

The 24-hour pattern of M!!_NE levels reaches a maximum at

g.±QQ hours and differs significantly from the levels at .Q2QQ. hours (P< 0.05).
~DA

levels are minimal at .!§QQ. hours and maximal at 2400 hours, and differ

significantly from each other (P< 0.001).

The trough value at .!§QQ. hours is

significantly lower than that at 1200 hours (P

<0.01),

while the peak level at

~ hours differs significantly from that at .!_gQQ hours (P

< 0.025).

CN NE
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concentration exhibits a peak at

Q2Q.Q.

hours, which is significantly greater

than the values obtained at 1200 hours (P < 0.005), ~ (P
hours (P<0.01).

and 2400

Brain stem DA and 5HT levels differ significantly between

Q2.QQ_ and 2400 hours (P < 0.05).

The difference in brain stem DA levels

between 0600 and 1200 hours is significant (P < 0.05).
thalamic

< 0.001)

The difference in ~

NE levels between 0600 and 2400 hours is also significant (P < O. 05).

Hypothalamic DA levels are maximal at

Q2Q.Q.

hours and differ significantly from

1200 hours (P< 0.005) and 1800 hours (P< 0.001).

b.

Decaborane(Figures 40-41, Table 15)
DB-treated animals had brain amine patterns that showed diurnal

fluctuations for 11 of 12 instances.

MB NE levels exhibit a minimum at 2400

hours, which differs significantly from levels at 0600 and ~ hours (both
P< 0.01).

MB DA is maximal at

Q2Q.Q.

hours, differing significantly from the

values at 1200 hours (P < 0.005), !§QQ hours (P

< 0.05) and

2400 hours (P< 0.01).

MB 5HT concentration is maximal at 1200 hours, and differs significantly from
that at 1800 and 240.0 hours (both p< 0.005).

The 5HT value at 2400 hours also

differs significantly from that at 1800 hours (P < 0.05).

CN NE concentrations

-

are minimal at g.±QQ hours and differs significantly from the value obtained
at 1800 hours (P

0.05).

The pattern of CN DA exhibits a minimum at 0600

hours, which differs significantly from the values obtained at 1200, 1800 and
~

hours (each at P < 0.001).

CN 5HT levels are minimal at g!QQ. hours, and

differ significantly from the level at ,!g.QQ hours.

The 5HT values at

~

1§.QQ hours differ significantly (P <0.001).

The

~~DA

pattern has a minimum at ,!g.QQ hours, which differs

significantly from the values at 0600 hours (P< 0.05), 1800 hours (P< 0.01)

and

295

and ?400 hours (P <0.001).

Brain stem levels of 5HT are maximal at 1200 hours

and differ significantly from the values obtained at~ hours (P<0.025),
1800 hours (P

< O. 05) and 2400 hours (P <.:, 0. 02).

Hypothalamic NE levels reach

a minimum at 2400 hours, differing significantly from that at 1200 hours
(P\0.025) and 1800 hours (P<0.01).

Hypothalamic DA concentrations are

maximal at 0600 hours, differing significantly from the values at 1200, 1800
and 2400 hours (each at P< 0.001).

Hypothalamic 5HT is minimal at 2400 hours,

differing significantly from the values at 0600 hours (P <\ 0.005) and 1200
hours (P

<0. 02).

The maximum at 0600 hours differs significantly from that

at 1200 and 1800 hours (each at P<0.005).
c.

piphenhydramine (Table 16, Figs. 42, 43)
DPH-treated animals had brain amines patterns that showed diurnal

variations in 8 of 12 instances.

The 24-hour pattern of MB NE has a minimum

at ,?400 hours, which differs significantly from the values at 0600 hours (P

<.

'

0.005) and 1800 hours (P < 0.001) (cf. Fig. 43).

MB DA concentrations are also

minimal at 2400 hours, and differs significantly from the levels at 0600
(P

< 0.001),

1200 (P< 0.02) and 1800 hours (P

< 0.005).

There is also a signif-

icant difference between MB DA levels at 0600 and 1200 hours (P < 0. 05).

CN

DA concentrations are maximal at 1200 hours, and differ significantly from
0600 (P <0.001), 1800 (P<0.001) and 2400 hours (P<0.02).

CN 5HT levels are

minimal at 0600 hours, and differ significantly from 1200 and 1800 hours
values (each at P <0.001).

There is a significant difference between ~

~NE levels at 1800 and 2400 hours (P<0.005).

Brain stem DA
-----

content is

minimal at 2100 hours, and differs significantly from that at 1200 (P
and 1800 hours (P<\O.Of>).

< 0.01)

Hypothalamic:_ NE rpaches a minimum at 2400 hours,
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which is significantly lower than the values at 0600 and 1800 hours (both
0.001).

Pz

Hypothalamic 5HT levels peak at 1200 hours and differ significantly

from values at Q2.Q.Q., 1800 and 2400 hours (each at P ( 0.01).
4.

Gamma-butyrolactone(Figures 44-45, Table 17)
a.

Saline controls
The 24-hour patterns for the monoamine levels in the brains of

controls exhibited a number of significant diurnal fluctuations.

The pattern

of MB 5H.T has a peak at 2400 hours and a trough at 1800 hours (Fig. 44 ).

-

-

The

trough at 1800 hours does not differ significantly from the value at 1200
hours.

The peak value at 2400 hours differs significantly from the values at

0600 (P < 0.05), 1200 (P

< 0~005)

and 1800 hours (P < 0.005).

There are also

significant differences between the concentrations at 0600 hours and that at
1200 hours (P < 0.01) and 1800 hours (P

< 0.02).

Brain stem NE has a peak

value at 2400 hours, which differs significantly from the values at 1200 hours
(P

< 0.01) and 1800 hours (P< 0.005). The pattern for brain stem DA is

bimodal~

with peaks at 0600 and 1800 hours, which differ significantly from each other
(P < 0.01).

The primary peak at QQQQ_ hours is significantly greater than the

value at 2400 hours (P < 0.01).

The secondary peak at 1800 hours differs

significantly from the DA concentrations at 1200 hours (P < 0.005) and g!Q.Q_
boll.rs (P< 0.005).

The hypothalamic NE pattern has a peak value at 2400 hours,

which differs significantly from that at Q2QQ. hours (P < 0.01), but not from the
values at the other times.

Hypothalamic DA exhibits a diurnal pattern, with a

peak at 1200 hours and trough at Q2QQ. hours,wwhich differ significantly (P
0.02).

<

The DA concentration at 2400 hours differs significantly from the val-

ues at Q2QQ. hours (P < 0.05) and ,!,g_QQ hours (P < 0.05).

There is a significant

2H7

difference between the hypothalamic 5HT at 1200 and 2400 hours (P<0.02), but
not the other values.
b.

GBL-treated(Figure 45, Table 17)
The MB 5HT pattern for the GBL-treated animals exhibits a peak

at

~

hours, which differs significantly from the values obtained at 0600

hours (P< 0.02), !,g_QQ hours (P<0.005) and 1800 hours (P< 0.005)(Fig. 45 ).
The value at ~ hours differs significantly from that at 1800 hours (P <
0.005).

The difference between the concentrations of CN NE at

hours is of borderline significance (O.l>P>0.05).

Q§.QQ

and 1200

The CN 5HT pattern

exhibits circadian fluctuations, with a maximum at 1800 hours and a minimum
at 0600 hours, which differ significantly (P< 0.05).

There is borderline

significance for the difference between the values at 0600 and 1200 hours
( 0.1> P > 0.05).

The brain stem DA pattern for GBL-treated animals is bimodal,

with peaks at 0600 and 1800 hours.

The minimum DA value at 1200 hours differs

significantly from,concentrations at 0600 hours (P
0.005) and g±QQ. hours (P< 0.05).

0.02), ~hours (P<

The brain stem 5HT pattern is diurnal, with

a peak at 1200 hours that differs significantly (P<0.02) from the trough at
0600 hours.

The trough also differs significantly from the values at 1800

hours (P < 0.005) and giQ.Q_ hours (P < 0.01).

Hypothalamic DA concentrations ex-

hibit a peak at 1800 hours that differs significantly from 0600 and 2400 hours
values (each P<0.02).

The peak hypothalamic 5HT concentration at 2400 hours

differs significantly from the Talues at 1200 and 1800 hours (both P < 0 05).
0

L. .
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Appendix C:
1.

Additional amine studies

Pentobarbital at the point of awakening
The concentrations of NE, DA and 5HT in the MB, CN, brain stem and

hypothalamus were determined at 0600, 1200 9 1800 and 2400 hours at the time
of awakening from PB-sleep (50m.g/kg, IP; 'Table 23 1 Fig. 51 )
significantly during the 24-hour period.

0

MB DA varies

The minimal concentration at 2400

hours is significantly less than that at 0600 hours (P<0.05), 1200 hours
(P.C 0.01) and 1800 hours (P< 0.025).
at 2400 hours and minimal at

hours, differs significantly in the follow-

.Q&Q.Q. vs 1800 hours (P < 0.05) and 1800 vs 2400 hours (P

ing comparisons:
Os05).

~

CN NE concentrations, which are maximal

<.

Brain stem NE concentrations are maximal at g!Q.Q_ hours, and differ

significantly from the values at 0600 hours (P < Oo005), 1200 hours (P< 0.001)
and 1800 hours (P < 0.001).

The pattern of brain stem DA exhibits a clearcut

diurnal pattern with a minimum at 1800 hours and a maximum at 0600 hours.
The peak differs significantly from values obtained at 1200 hours (P < o. 05)
and 1800 hours (P<0.005), but not from those at 2400 hourso

The trough

differs significantly from the concentration at~ hours (P<0.01).
Brain

~

5HT concentrations exhibit a maximum at 2400 hours, which

differs significantly from those at 0600 hours (P< 0.001) and 1800 hours
(P< 0 0 005).

There is a significant difference between the 0600 and the 1800

hours values (:p< 0.01).

Hypothalamic NE has a minimal value at 1800 hours,

which differs significantly from that at ~hours (P < 0.025) and 2400
hours (P < 0.005).

Hypothalamic DA is maximal at g!Q.Q. hours and differs

significantly from the values at 0600 and 1800 hours (each P< o.05)o

~

thalamic 5HT concentrations during the 24-hour period are not significantly
different from each other.

Table 23: CNS concentrations of NE, DA and 5HT at the time of awakening
from PB (50mg/kg, IP)

MB NE
Hpth NE

0600

1200

-1800

2400

.85+.10

.87+.16

.78+.13

.87+.,10

(5)

(5)

(5)

(6)

2.21+.22

2.32+.73

1.80+.28

2.61+.34

CN NE

.29+.07

.26+.06

.16+.09

.,39+. 11

Stem NE

.99+.10

.87+.10

.93+.06

MBDA
Hpth DA.

(5)
(5)

(5)

.24+.07

(5)

(5)

(5)

(5)

.28+.07

(4)

.18+.07
6.48+.80

(5)

Stem DA.

.22+.07

(5)

MB 5HT

• 71+.12

(5)

(5)

(6)
.25+.05

(4)

.17+.08

(5)

CN DA

(6)

(6)

4.77+.74

(5)

.07+.02

(2)

4.72+1.42

(6)
.05+.02

(5)

(5)
.17+.04

(6)

.29+.07

(4)
5.14+1.67

(6)

.14+.05

(4)

.54+.25

.22+.04

CN 5HT

.32+.14

.23+.08

Stem 5HT

.28+.08

.59+.17

(4)

1.33+.16

.71+.30

(5)

.34+.13

(5)

(4)

.85+.15

Hpth 5HT

(5)

(6)

(5)

(6)

(3)

(5)

(6)

1.15+.24

(4)

Table indicates amine concentrations (ugm/gm) of NE, DA and 5HT
in the four areas indicated in Table 9, for animals receiving PB alone.
Animals were sacrificed at the time of awakening from PB. Values are
means ±.standard deviation, with the number of animals used in parentheses.
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Amine concentrations after 5Hl'P
CNS concentrations of NE, DA and 5HT were determined in animals

administered 5HTP (lOOmg/kg, IP) one hour before PB (50mg/kg, IP), at the
time of awakening from PB-sleep.

The determination was made at

~

hours,

a time in which this pretreatment increased PB-sleep significantly (to
144.0 .:!:. 15.4 minutes, P <0.001).

These results are summarized in the follow-

ing Table.
CN

Brain stem

Hypothalamus

.80+.01
(4)

.41+.12

.87+.02

1.91+.07

.33+.20

14.70+.88

.22+.09

.66+.25

MB

NE

DA

5HT

(3)

1.40+.20

(4)

(4)

(4)

(4)

(3)

.61+.16

.85+.20

(4)

(4)

(4)

(4)

1.46+.14
(4)

Values represent means .:!:. standard deviation, with the number of
animals used in parentheses.
In comparison to similarly treated controls, 5HT is significantly
elevated in all brain areas, except brain stem.

Brain DA was elevated in

all four areas, but there were no significant changes in NE levels.
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